



DHS SCIENCE AND TECHNOLOGY

Master Question List for COVID-19 (caused by SARS-CoV-2)

Weekly Report

09 June 2020

For comments or questions related to the contents of this document, please contact the DHS S&T Hazard Awareness & Characterization Technology Center at HACTechnologyCenter@hq.dhs.gov.



**Homeland
Security**

Science and Technology

DHS Science and Technology Directorate | MOBILIZING INNOVATION FOR A SECURE WORLD

CLEARED FOR PUBLIC RELEASE

FOREWORD

The Department of Homeland Security (DHS) is paying close attention to the evolving Coronavirus Infectious Disease (COVID-19) situation in order to protect our nation. DHS is working very closely with the Centers for Disease Control and Prevention (CDC), other federal agencies, and public health officials to implement public health control measures related to travelers and materials crossing our borders from the affected regions.

Based on the response to a similar product generated in 2014 in response to the Ebolavirus outbreak in West Africa, the DHS Science and Technology Directorate (DHS S&T) developed the following “master question list” that quickly summarizes what is known, what additional information is needed, and who may be working to address such fundamental questions as, “What is the infectious dose?” and “How long does the virus persist in the environment?” The Master Question List (MQL) is intended to quickly present the current state of available information to government decision makers in the operational response to COVID-19 and allow structured and scientifically guided discussions across the federal government without burdening them with the need to review scientific reports, and to prevent duplication of efforts by highlighting and coordinating research.

The information contained in the following table has been assembled and evaluated by experts from publicly available sources to include reports and articles found in scientific and technical journals, selected sources on the internet, and various media reports. It is intended to serve as a “quick reference” tool and should not be regarded as comprehensive source of information, nor as necessarily representing the official policies, either expressed or implied, of the DHS or the U.S. Government. DHS does not endorse any products or commercial services mentioned in this document. All sources of the information provided are cited so that individual users of this document may independently evaluate the source of that information and its suitability for any particular use. This document is a “living document” that will be updated as needed when new information becomes available.

The Department of Homeland Security Science and Technology Directorate is committed to providing access to our web pages for individuals with disabilities, both members of the public and federal employees. If the format of any elements or content within this document interferes with your ability to access the information, as defined in the Rehabilitation Act, please contact the Hazard Awareness & Characterization Technology Center for assistance by emailing HACTechnologyCenter@hq.dhs.gov. A member of our team will contact you within 5 business days. To enable us to respond in a manner most helpful to you, please indicate the nature of your accessibility problem, the preferred format in which to receive the material, the web address (<https://www.dhs.gov/publication/st-master-question-list-covid-19>) or name of the document of the material (Master Question List for COVID-19) with which you are having difficulty, and your contact information.

Table of Contents

Infectious Dose – How much agent will make a healthy individual ill?	3
<p>The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. SARS-CoV-2 is the cause of coronavirus disease 19 (COVID-19). Studies from other animal models are used as surrogates for humans.</p> <p>Identifying the infectious dose for humans by the various routes through which we become infected is critical to the effective development of computational models to predict risk, develop diagnostics and countermeasures, and effective decontamination strategies. Animal studies are a plausible surrogate.</p>	
Transmissibility – How does it spread from one host to another? How easily is it spread?	4
<p>SARS-CoV-2 is passed easily between humans, likely through close contact with relatively large droplets and possibly through smaller aerosolized particles.</p> <p>Individuals can transmit SARS-CoV-2 to others before they have symptoms.</p> <p>Undetected cases play a major role in transmission, and most cases are not reported.</p> <p>Individuals who have recovered clinically, but test positive, appear unable to transmit COVID-19.</p> <p>Identifying the contribution of asymptomatic or pre-symptomatic transmission is important for implementing control measures. Additionally, the relative contributions of different infection sources – fomites, droplets, aerosols, and potentially feces – are unknown.</p>	
Host Range – How many species does it infect? Can it transfer from species to species?	5
<p>SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the identity of the SARS-CoV-2 intermediate host is unknown.</p> <p>SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.</p> <p>To date, ferrets, mink, hamsters, cats, and primates have been shown to be susceptible to SARS-CoV-2 infection. It is unknown whether these animals can transmit infection to humans.</p> <p>Several animal models have been developed to recreate human-like illness, though to date they have been infected with high dose exposures. Lower dose studies may better replicate human disease acquisition.</p>	
Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?	6
<p>The majority of individuals develop symptoms within 14 days of exposure. For most people, it takes at least 2 days to develop symptoms, and on average symptoms develop 5 days after exposure. Incubating individuals can transmit disease for several days before symptom onset. Some individuals never develop symptoms but can still transmit disease.</p> <p>The incubation period is well-characterized. Patients may be infectious, however, for days before symptoms develop.</p>	
Clinical Presentation – What are the signs and symptoms of an infected person?	7
<p>Many COVID-19 cases are asymptomatic. Most symptomatic cases are mild, but severe disease can be found in any age group.⁶ Older individuals and those with underlying medical conditions are at higher risk of serious illness and death.</p> <p>The case fatality rate varies substantially by patient age and underlying comorbidities.</p> <p>Additional studies on vulnerable subpopulations are required.</p> <p>Children are susceptible to COVID-19,¹²⁴ though generally show milder^{83, 261} or no symptoms.</p> <p>The true case fatality rate is unknown, as the exact number of cases is uncertain. Testing priorities and case definitions vary by location. The proportion of asymptomatic infections is not known.</p>	
Protective Immunity – How long does the immune response provide protection from reinfection?	8
<p>Infected patients show productive immune responses, however more data is needed.</p> <p>Currently, there is no evidence that recovered patients can be reinfected with SARS-CoV-2.</p> <p>Understanding the duration of protective immunity is limited by small sample sizes. Animal models are plausible surrogates.</p> <p>Additional research to quantify the risk of reinfection after weeks, months, and years is needed.</p>	
Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?	9
<p>Diagnosis relies on identifying the genetic signature of the virus in patient nose, throat, or sputum samples. These tests are relatively accurate. Confirmed cases are still underreported.</p> <p>Validated serological (antibody) assays are being developed to help determine who has been exposed to SARS-CoV-2.</p> <p>Serological evidence of exposure does not indicate immunity.</p>	

In general, PCR tests appear to be sensitive and specific, though confirmation of symptoms via chest CT is recommended. The sensitivity and specificity of serological testing methods is variable, and additional work needs to be done to determine factors that affect test accuracy.

Medical Treatments – Are there effective treatments?.....10

Treatment for COVID-19 is primarily supportive care including ventilation if necessary.^{163, 273} Numerous clinical trials are ongoing. Several drugs show efficacy.

Remdesivir shows promise for reducing symptom duration in humans.³⁶

Hydroxychloroquine is associated with elevated risk of cardiac arrhythmias and provides limited to no clinical benefit at this point in time. Large, randomized clinical trial results are necessary.

Other pharmaceutical interventions are being investigated.

Additional information on treatment efficacy is required, particularly from randomized clinical trials.

Vaccines – Are there effective vaccines?.....11

Work is ongoing to develop a SARS-CoV-2 vaccine in human and animal trials. Early results are being released, but evidence should be considered preliminary until larger trials are completed.

Published results from randomized clinical trials (Phase I – III) are needed.

Non-pharmaceutical Interventions – Are public health control measures effective at reducing spread?.....12

Broad-scale control measures such as stay-at-home orders are effective at reducing movement and contact rates, and modeling shows evidence that they reduce transmission.

Research is needed to help plan for easing of restrictions.

As different US states have implemented differing control measures at various times, a comprehensive analysis of social distancing efficacy has not yet been conducted.

Environmental Stability – How long does the agent live in the environment?.....13

SARS-CoV-2 can persist on surfaces for at least 3 days and on the surface of a surgical mask for up to 7 days depending on conditions. If aerosolized intentionally, SARS-CoV-2 is stable for at least several hours. The seasonality of COVID-19 transmission is unknown. SARS-CoV-2 on surfaces is inactivated rapidly with sunlight.

Additional testing on SARS-CoV-2, as opposed to surrogate viruses, is needed to support initial estimates of stability.

Decontamination – What are effective methods to kill the agent in the environment?14

Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.

Methods for decontaminating N95 masks have been approved by the FDA under an Emergency Use Authorization (EUA).

Additional decontamination studies, particularly with regard to PPE and other items in short supply, are needed.

PPE – What PPE is effective, and who should be using it?15

The effectiveness of PPE for SARS-CoV-2 is currently unknown, and data from other related coronaviruses are used for guidance. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.

Most PPE recommendations have not been made on SARS-CoV-2 data, and comparative efficacy of different PPE for different tasks (e.g., intubation) is unknown. Identification of efficacious PPE for healthcare workers is critical due to their high rates of infection.

Forensics – Natural vs intentional use? Tests to be used for attribution.16

All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.

Identifying the intermediate species between bats and humans would aid in reducing potential spillover from a natural source. Wide sampling of bats, other wild animals, and humans is needed to address the origin of SARS-CoV-2.

Genomics – How does the disease agent compare to previous strains?17

Current evidence suggests that SARS-CoV-2 accumulates substitutions and mutations at a similar rate as other coronaviruses. Mutations and deletions in specific portions of the SARS-CoV-2 genome have not been linked to any changes in transmission or disease severity, though modeling work is attempting to identify possible changes.

Research linking genetic changes to differences in phenotype (e.g., transmissibility, virulence, progression in patients) is needed.

Forecasting – What forecasting models and methods exist?.....18

Forecasts differ in how they handle public health interventions such as shelter-in-place orders and tracking how methods change in the near future will be important for understanding limitations going forward.

SARS-CoV-2 (COVID-19)	Infectious Dose – How much agent will make a healthy individual ill?
<p>What do we know?</p>	<p>The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. SARS-CoV-2 is the cause of coronavirus disease 19 (COVID-19). Studies from other animal models are used as surrogates for humans.</p> <p><i>Non-human primates</i></p> <ul style="list-style-type: none"> • A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (10^6 TCID₅₀ total dose).³⁴⁸ Macaques did not exhibit clinical symptoms, but shed virus from the nose and throat.³⁴⁸ • Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75×10^6 PFU (SARS-CoV-2 delivered through several routes), while common marmosets developed mild infections when exposed to 1.0×10^6 PFU intranasally.²⁶⁰ • Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of approximately 700,000 PFU (10^6 TCID₅₀).¹²⁰ Rhesus macaques infected with 2,600,000 TCID₅₀ of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate disease observed in the majority of human cases.²⁹⁵ • African green monkeys developed symptoms consistent with severe human disease when exposed to 500,000 PFU of SARS-CoV-2 via the intranasal and intratracheal routes.⁴²⁶ <p><i>Rodents</i></p> <ul style="list-style-type: none"> • Golden Syrian hamsters exposed to 80,000 TCID₅₀ (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).³⁶⁸ • Golden Syrian hamsters infected with 100,000 PFU via the intranasal route closely resemble human respiratory infection. Uninfected hamsters in close contact with infected hamsters show symptoms within 4 days of exposure.⁷⁹ • Mice genetically modified to express the human ACE2 receptor (transgenic hACE2 mice) were inoculated intranasally with 100,000 TCID₅₀ (~70,000 PFU), and all mice developed pathological symptoms consistent with COVID-19.³¹ • Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID₅₀/minute) to between 900 and 1080 TCID₅₀ (~630-756 PFU). All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID₅₀, ~504 PFU).³² Key methodological details (e.g., particle size, quantification of actual aerosol dose) are missing from the study's report. • Transgenic (hACE2) mice exposed intranasally to 400,000 PFU of SARS-CoV-2 develop clinical and pathological symptoms seen in humans.³⁷⁸ <p><i>Other animal models</i></p> <ul style="list-style-type: none"> • Ferrets infected with 316,000 TCID₅₀²⁰⁹ or 600,000 TCID₅₀³⁴¹ of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.^{209, 341} Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.²⁰⁹ In one study, direct contact was required to transfer infection between ferrets,²⁰⁹ however, transmission without direct contact was found in another study.³⁴¹ • In a ferret study, 1 in 6 individuals exposed to 10^2 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to $>10^4$ PFU became infected.³⁵⁴ • Domestic cats exposed to 100,000 PFU of SARS-CoV-2 via the intranasal route developed severe pathological symptoms including lesions in the nose, throat, and lungs.³⁶⁶ In a separate study, infected cats showed no clinical signs, but were able to shed virus and transmit to other cats.⁴⁶ <p><i>Related Coronaviruses</i></p> <ul style="list-style-type: none"> • The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).^{116, 118} • Genetically modified mice expressing DPP4 exposed intranasally to doses of Middle East respiratory syndrome coronavirus (MERS-CoV) between 100 and 500,000 PFU show signs of infection. Infection with higher doses result in severe syndromes.^{14, 101, 237, 460}
<p>What do we need to know?</p>	<p>Identifying the infectious dose for humans by the various routes through which we become infected is critical to the effective development of computational models to predict risk, develop diagnostics and countermeasures, and effective decontamination strategies. Animal studies are a plausible surrogate.</p> <ul style="list-style-type: none"> • Human infectious dose by aerosol, surface contact (fomite), fecal-oral routes, and other potential routes of exposure • Most appropriate animal model(s) to estimate the human infectious dose for SARS-CoV-2

SARS-CoV-2 (COVID-19)	Transmissibility – How does it spread from one host to another? How easily is it spread?
<p>What do we know?</p>	<p>SARS-CoV-2 is passed easily between humans, likely through close contact with relatively large droplets and possibly through smaller aerosolized particles.</p> <ul style="list-style-type: none"> • Pandemic COVID-19 has caused 7,145,847 infections and 407,067 deaths¹⁹⁶ in at least 188 countries and territories (as of 6/9/2020).^{69, 361, 420} In the US there are 1,961,187 confirmed COVID-19 cases across all 50 US states, with 111,007 deaths (as of 6/9/2020).¹⁹⁶ • Initial high-quality estimates of human transmissibility (R_0) range from 2.2 to 3.1.^{270, 318, 344, 432, 459} Based on contact tracing of 1,058 cases in Hong Kong, the number of cases linked to superspreading events (1 person infects >6-8 people) for COVID-19 is estimated to be similar to other pathogens.¹¹ • SARS-CoV-2 is believed to spread through close contact and droplet transmission,⁷³ with fomite transmission likely¹⁹⁹ and close-contact aerosol transmission plausible^{52, 162} but unconfirmed.⁴¹⁸ • SARS-CoV-2 replicates in the upper respiratory tract,¹⁷⁶ and infectious virus is detectable in throat and lung tissue for at least 8 days.⁴²³ Studies of autopsied lung tissue¹⁷⁶ and clinical studies of COVID-19 patients³¹⁴ support aspiration as a means by which SARS-CoV-2 reaches the deep lung. SARS-CoV-2 RNA has been found in semen from both clinically symptomatic and recovered cases,²³⁶ however, the infectiousness and the possibility of sexual transmission is unknown. Infectious SARS-CoV-2 has been cultured from patient feces.⁴³⁶ • Contamination of patient rooms with aerosolized SARS-CoV-2 in the human respirable range (0.25-2.5 μm) indicates the potential for airborne transmission.²⁵⁵ Viral RNA was detected up to 4 meters from ICU patient beds.¹⁶⁴ To date infectious virus has not been isolated from aerosol samples.³⁵⁸ • SARS-CoV-2 may be spread by conversation and exhalation.^{9, 235, 358, 373} A preliminary study in China detailing a restaurant-associated outbreak supports transmission via aerosol.²⁴⁴ • Experimentally infected ferrets were able to transmit SARS-CoV-2 to other ferrets by both direct contact (another ferret in same enclosure) as well as through the air (ferrets in an adjacent enclosure, separated by 10 cm).³⁴¹ Similar results have been documented in transgenic mice.³² • Evidence suggests that SARS-CoV-2 is not transmitted to infants during birth.^{85, 90, 93, 360, 444, 448} <p>Individuals can transmit SARS-CoV-2 to others before they have symptoms.</p> <ul style="list-style-type: none"> • Individuals may be infectious for 1-3 days prior to symptom onset,⁴⁰⁸ and culturable virus has been found in individuals up to 6 days prior to symptom onset.²⁴ Pre-symptomatic^{44, 372, 376, 462} or asymptomatic^{29, 181, 264} patients can transmit SARS-CoV-2. At least 12% of all cases are estimated to be due to asymptomatic transmission.¹²⁶ It has been estimated that 23%,²⁵² 44%,¹⁷¹ or as much as 56%⁶⁵ of infections may be caused by pre-symptomatic transmission. Individuals are most infectious before symptoms began and within 5 days of symptom onset,⁹² and pre-symptomatic individuals contribute to environmental contamination.¹⁹⁷ • In China, it is estimated that infected individuals transmit COVID-19 to between 11.2%⁴² and 16.3%²⁴¹ of household contacts, though even more may lack symptoms.²⁶⁴ In New York, 38% of household contacts of infected patients became infected, with the proportion increasing with age (20% for contacts <5 years old, 55% for >65 years old).³⁴⁹ On a cruise ship, 59% of individuals on board tested positive for COVID-19, though the initial number infected was unknown.¹⁸⁹ <p>Undetected cases play a major role in transmission, and most cases are not reported.</p> <ul style="list-style-type: none"> • Models suggest up to 86% of early COVID-19 cases in China were undetected, and these infections were the source for 79% of reported cases.²⁴⁰ • Models estimate that the true number of cases may be approximately 11 times greater than the reported number of cases in the UK,⁴⁴⁵ and 5 to 10 times greater than the reported number of cases in the US.^{200, 353} Preliminary estimates of the case reporting rate vary widely among countries, from roughly 1 reported case for every 3 actual cases (in Germany), to 1 in 149 (in China).²¹⁵ <p>Individuals who have recovered clinically, but test positive, appear unable to transmit COVID-19.</p> <ul style="list-style-type: none"> • Epidemiological investigations by the Korean CDC suggest that individuals who have clinically recovered from COVID-19, but later show PCR positive tests, are not infectious.²⁰⁷
<p>What do we need to know?</p>	<p>Identifying the contribution of asymptomatic or pre-symptomatic transmission is important for implementing control measures. Additionally, the relative contributions of different infection sources – fomites, droplets, aerosols, and potentially feces – are unknown.</p> <ul style="list-style-type: none"> • Capability of SARS-CoV-2 to be transmitted by contact with fomites (phones, doorknobs, surfaces, clothing, etc.) – see also Experimental Stability • Is sexual transmission possible?

SARS-CoV-2 (COVID-19)	Host Range – How many species does it infect? Can it transfer from species to species?
<p>What do we know?</p>	<p>SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the identity of the SARS-CoV-2 intermediate host is unknown.</p> <ul style="list-style-type: none"> • Early genomic analysis indicates similarity to SARS-CoV-1,⁴⁶⁶ with a suggested bat origin.^{103, 466} • Positive samples from the South China Seafood Market strongly suggests a wildlife source,⁷⁵ though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.^{35, 104, 438, 449} • Analysis of SARS-CoV-2 genomes suggests that a non-bat intermediate species is responsible for the beginning of the outbreak.³⁴⁷ The identity of the intermediate host remains unknown.^{243, 247, 249} • Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago.²²⁴ <p>SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.</p> <ul style="list-style-type: none"> • Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1,⁴²⁸ potentially explaining its high transmissibility. The same work suggests that differences between SARS-CoV-2 and SARS-CoV-1 Spike proteins may limit the therapeutic ability of SARS antibody treatments.⁴²⁸ • Modeling of SARS-CoV-2 Spike and ACE2 proteins suggests that SARS-CoV-2 can bind and infect human, bat, civet, monkey and swine cells.⁴⁰⁰ Host range predictions based on structural modeling, however, are difficult,¹⁴⁶ and additional animal studies are needed to better define the host range. • In vitro experiments suggest a broad host range for SARS-CoV-2, with more than 44 potential animal hosts, based on viral binding to species-specific ACE2 orthologs.²⁵³ The host range is predicted to be limited primarily to mammals. • Genetic and protein analysis of primates suggests that African and Asian primates are likely more susceptible to SARS-CoV-2, while South and Central American primates are likely less susceptible.²⁸³ Identifying the SARS-CoV-2 host range is important for identifying animal reservoirs. • Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.²⁸⁴ <p>To date, ferrets, mink, hamsters, cats, and primates have been shown to be susceptible to SARS-CoV-2 infection. It is unknown whether these animals can transmit infection to humans.</p> <ul style="list-style-type: none"> • Animal model studies suggest that Golden Syrian hamsters, primates, and ferrets may be susceptible to infection.^{79, 209} In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.² It is thought that an infected mink has transmitted SARS-CoV-2 to a human.²¹⁷ Golden Syrian hamsters are able to infect other hamsters via direct contact and close quarters aerosol transmission.³⁶⁸ • Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route³⁶⁶ or a combination of routes¹⁶⁵), and can transmit the virus to other cats via droplet or short-distance aerosol.³⁶⁶ Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies⁴⁶ but exhibited no clinical symptoms.^{366, 369} • Wild cats (tigers)⁴⁰⁷ can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.^{271, 456} Two cases have been confirmed of pet domestic cats infected with SARS-CoV-2.⁶⁸ • Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, all via intranasal route).³⁶⁶ There is currently no evidence that SARS-CoV-2 infects livestock,¹⁸⁷ though modeling suggests sheep, cows, pigs, and goats may be susceptible to infection by SARS-CoV-2.²²³ • Pigs and chickens were not susceptible to SARS-CoV-2 infection when exposed to an intranasal dose of 10⁵ TCID₅₀ (~70,000 PFU), confirmed by lack of positive swab and tissue samples.¹⁴⁷ Fruit bats and ferrets were susceptible to this same exposure.¹⁴⁷
<p>What do we need to know?</p>	<p>Several animal models have been developed to recreate human-like illness, though to date they have been infected with high dose exposures. Lower dose studies may better replicate human disease acquisition.</p> <ul style="list-style-type: none"> • What is the intermediate host(s)? • Can infected animals transmit to humans (e.g., pet cats to humans)? • Can SARS-CoV-2 circulate in animal reservoir populations, potentially leading to future spillover events?

SARS-CoV-2 (COVID-19)	Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?
<p>What do we know?</p>	<p>The majority of individuals develop symptoms within 14 days of exposure. For most people, it takes at least 2 days to develop symptoms, and on average symptoms develop 5 days after exposure. Incubating individuals can transmit disease for several days before symptom onset. Some individuals never develop symptoms but can still transmit disease.</p> <ul style="list-style-type: none"> • The best current estimate of the COVID-19 incubation period is 5.1 days, with 99% of individuals exhibiting symptoms within 14 days of exposure.²³⁰ Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.²³⁰ • Individuals can test positive for COVID-19 even if they lack clinical symptoms.^{29, 78, 163, 382, 462} • Individuals can be infectious while asymptomatic,^{73, 350, 382, 462} and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.^{24, 208, 469} • Peak infectiousness may be during the incubation period, one day before symptoms develop.¹⁷¹ Infectious virus has been cultured in patients up to 6 days before the development of symptoms.²⁴ • Infectious period is unknown, but possibly up to 10-14 days.^{8, 240, 361} • Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.¹⁷⁹ • On average, there are approximately 4¹²⁶ to 7.5²³⁹ days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval). Based on data from 339 transmission chains in China, the mean serial interval is 5.29 days.¹²⁵ • Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).²⁶² • Most hospitalized individuals are admitted within 8-14 days of symptom onset.⁴⁶⁴
<p>What do we need to know?</p>	<p>The incubation period is well-characterized. Patients may be infectious, however, for days before symptoms develop.</p> <ul style="list-style-type: none"> • What is the average infectious period during which individuals can transmit the disease?

SARS-CoV-2 (COVID-19)	Clinical Presentation – What are the signs and symptoms of an infected person?
<p>What do we know?</p>	<p>Many COVID-19 cases are asymptomatic. Most symptomatic cases are mild, but severe disease can be found in any age group.⁶ Older individuals and those with underlying medical conditions are at higher risk of serious illness and death.</p> <ul style="list-style-type: none"> • Approximately 18-31% of patients are asymptomatic throughout the course of their infection.^{291, 301, 387} These estimates are based on studies that minimize the likelihood of including pre-symptomatic patients, which can obscure asymptomatic rates.²⁴ • The majority of symptomatic COVID-19 cases are mild (81%, n=44,000 cases).³⁸² Initial COVID-19 symptoms include fever (87.9% overall, but only 44-52% present with fever initially),^{22, 163} cough (67.7%),¹⁶³ fatigue, shortness of breath, headache, and reduced lymphocyte count.^{74, 82, 180} Chills, muscle pain, headache, sore throat, and loss of taste or smell⁴⁴² are also possible COVID-19 symptoms.⁷⁴ The prevalence of GI symptoms varies.¹⁴⁹ Neurological symptoms such as agitation and confusion may present with COVID-19,¹⁷² may be more common in severe cases,¹¹⁰ and neurological involvement can be seen on autopsy.³⁹⁸ Ocular issues⁴³⁴ and skin lesions may also be symptoms of COVID-19.⁴⁷ • Complications include acute respiratory distress syndrome (ARDS, 17-29% of hospitalized patients, leading to death in 4-15% of cases),^{89, 180, 402} pneumonia,³¹³ cardiac injury (20%),³⁶⁷ secondary infection, kidney damage,^{23, 374} arrhythmia, sepsis, and shock.^{163, 180, 402, 464} Most deaths are caused by respiratory failure or respiratory failure combined with heart damage.³⁵¹ A number of immunological indicators may help identify potentially severe cases.^{27, 129, 170, 182, 326, 377} • Approximately 15% of hospitalized patients are classified as severe,^{163, 382} and approximately 5% of patients are admitted to the ICU.^{163, 382} Patient deterioration can be rapid.¹⁵⁹ The survival rate of patients requiring mechanical ventilation varies widely (e.g., 35%,¹⁸⁶ 70%,²⁵ 75.5%³⁴²). • Recent evidence suggests that SARS-CoV-2 may attack blood vessels in the lung, leading to clotting complications and ARDS.^{10, 396} Clotting issues may be associated with severely ill COVID-19 patients²¹¹ and those with ARDS.¹¹⁰ COVID-19 patients should be monitored for possible thrombosis.²³³ • COVID-19 patients undergoing unrelated surgical procedures have high levels of postoperative complications and mortality.²⁹⁸ <p>The case fatality rate varies substantially by patient age and underlying comorbidities.</p> <ul style="list-style-type: none"> • Cardiovascular disease, hypertension,⁴⁵⁵ diabetes, and respiratory conditions all increase the CFR.^{382, 464} Hypertension and obesity are common in the US¹⁴⁹ and contribute to mortality.^{23, 316} • Individuals >60 are at higher risk of death, and the CFR for individuals >85 is between 10 and 27%.^{382, 464} In a small study, men exhibited more severe symptoms and died at higher rates than women.¹⁹⁸ The effect of comorbidities on the likelihood of severe symptoms is higher for men.²⁸⁵ • Deaths due to COVID-19 are underreported. In New York City, up to 5,293 (22%) of period-specific excess deaths are unexplained and could be related to the pandemic.³⁰⁶ More work is needed. <p>Additional studies on vulnerable subpopulations are required.</p> <ul style="list-style-type: none"> • Black, Asian, and Minority Ethnic (BAME) populations acquire SARS-CoV-2 infection at higher rates than other groups³¹² and are disproportionately represented in hospitalized populations.^{149, 327} African American communities contribute disproportionately to the number of deaths in the US.²⁸⁹ • Pregnant women appear to develop severe symptoms at the same rate as the general population,^{88, 204, 452} and current reports suggest no increase in risk of pre-term birth.⁴⁴³ Severe symptoms in pregnant women may be associated with underlying conditions such as obesity.²⁵⁶ Most studies of COVID-19 in pregnancy represent women in later stages of pregnancy. <p>Children are susceptible to COVID-19,¹²⁴ though generally show milder^{83, 261} or no symptoms.</p> <ul style="list-style-type: none"> • Between 21-28% of children may be asymptomatic.^{261, 319, 329} Most symptomatic children present with mild or moderate symptoms,³¹⁹ with few exhibiting severe or clinical illness.⁴³¹ • Severe symptoms in children are possible²⁵¹ and more likely in those with complex medical histories³⁶² or underlying conditions such as obesity.⁴⁵¹ Infant deaths have been recorded.^{54, 261} • Early reports indicate the possibility of rare hyperinflammatory syndromes or shock in children (termed Pediatric Multi-System Inflammatory Syndrome)¹⁵⁶ linked to COVID-19 infection.³⁴⁵ The WHO⁴¹⁹ and US CDC¹⁹⁵ have issued case definitions for this condition.
<p>What do we need to know?</p>	<p>The true case fatality rate is unknown, as the exact number of cases is uncertain. Testing priorities and case definitions vary by location. The proportion of asymptomatic infections is not known.</p> <ul style="list-style-type: none"> • How long does it take for infected individuals to recover outside of a healthcare setting? • What proportion of infected individuals are asymptomatic? Does this vary by age, location, or comorbidities?

SARS-CoV-2 (COVID-19)	Protective Immunity – How long does the immune response provide protection from reinfection?
<p>What do we know?</p>	<p>Infected patients show productive immune responses, however more data is needed.</p> <ul style="list-style-type: none"> • In a limited study (n=9), hospitalized patients shed high levels of infectious virus for 7 days via the nasal-pharyngeal route, 50% of patients produced antibodies within 7 days, and all patients produced antibodies by 14 days. Antibody production did not correlate with lower viral load.⁴²³ • In a larger study (n=175), most patients developed neutralizing antibodies within 10-15 days after disease onset. Elderly patients had significantly higher neutralizing antibody titers than younger patients.⁴³⁰ In a separate study, elderly patients also showed higher viral loads than younger patients.³⁸⁶ • In a study of 285 COVID-19 patients, 100% developed antiviral immunoglobulin-G within 19 days of symptom onset.²⁵⁷ The neutralizing ability of these antibodies was not tested.²⁵⁷ In a smaller in vitro study (n=23 patients), levels of antibodies (immunoglobulins M and G) were positively correlated with SARS-CoV-2 neutralizing ability.³⁸⁶ In a smaller study of 44 patients, plasma from 91% demonstrated SARS-CoV-2 neutralizing ability, appearing roughly 8 days after symptom onset.³⁷⁹ • In a small study (n=26 mild cases), researchers found prolonged persistence of SARS-CoV-2 antibodies and SARS-CoV-2 RNA for up to 50 days.⁴⁰¹ • Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.^{59, 433} More data are needed. • A small subset of COVID-19 patients in China (8%) did not develop a serological response to infection, though the potential for reinfection in these patients is unknown.⁴³⁰ Similarly, between 16.7% (for IgG) and 51.7% (for IgM) of patients in a separate study did not exhibit any immune response, in terms of production of those two types of antibodies.³⁸⁰ • In a study of 221 COVID-19 patients, levels of two types of antibodies (IgM and IgG) were not associated with the severity of symptoms.¹⁷⁸ However, in a smaller study, patients with severe disease showed stronger antibody responses than those with non-severe symptoms.³⁸⁶ • The early recovery phase of COVID-19 patients is characterized by inflammatory immune response,⁴¹⁰ suggesting the potential for adverse reactions after clinical improvement. • Two studies identified key components of the adaptive immune system (CD4⁺ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.^{50, 160} These studies also identified Spike protein responses in CD4⁺ T cells of ~30-40% of unexposed patients,¹⁶⁰ suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.^{50, 160} The degree of protection provided by cross-reactivity is currently unknown. <p>Currently, there is no evidence that recovered patients can be reinfected with SARS-CoV-2.</p> <ul style="list-style-type: none"> • Two studies suggest limited reinfection potential in macaques. In the first, two experimentally infected macaques were not capable of being reinfected 28 days after their primary infection resolved.³⁰ In the second, rhesus macaques exposed to different doses of SARS-CoV-2 via the intranasal and intratracheal routes (10⁴ – 10⁶ PFU) developed pathological infection and were protected upon secondary challenge 35 days after initial exposure (little to no clinical symptoms, large reduction in viral titer compared to initial infection).⁸¹ Longer-term research and work in humans still needs to be conducted.⁸¹ • Ferrets infected with 10²-10⁴ PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms such as lethargy and ruffled fur.³⁵⁴ Cats exposed to SARS-CoV-2 after initial recovery did not shed virus, suggesting some protective effect of primary infection.⁴⁶ • According to the WHO, there is no evidence of re-infection with SARS-CoV-2 after recovery.²²⁹ • Patients can test positive via PCR for up to 37 days after symptoms appear,⁴⁶⁴ and after recovery and hospital discharge.²²⁵ The ability of these individuals to infect others is unknown. <p>The strength and duration of any immunity after initial COVID-19 infection is unknown.^{17, 415}</p>
<p>What do we need to know?</p>	<p>Understanding the duration of protective immunity is limited by small sample sizes. Animal models are plausible surrogates. Additional research to quantify the risk of reinfection after weeks, months, and years is needed.</p> <ul style="list-style-type: none"> • How long does the immune response last? Is there evidence of waning immunity? • Can humans become reinfected? • How does the patient immune response vary by age or disease severity? • How do different components of the immune response contribute to long-term protection?

SARS-CoV-2 (COVID-19)	Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?
<p>What do we know?</p>	<p>Diagnosis relies on identifying the genetic signature of the virus in patient nose, throat, or sputum samples. These tests are relatively accurate. Confirmed cases are still underreported.</p> <ul style="list-style-type: none"> • The US CDC has expanded testing criteria to include symptomatic patients at clinician discretion.³³ • PCR protocols and primers have been widely shared internationally,^{66, 106, 239, 365, 414, 421} PCR-based diagnostic assays are unable to differentiate between active and inactive virus. • A combination of pharyngeal (throat) RT-PCR and chest tomography is the most effective diagnostic criteria (correctly diagnoses 91.9% of infections).³³⁹ A single throat swab detects 78.2% of infections, and duplicate tests identify 86.2% of infections.³³⁹ PCR tests using saliva are at least as effective as those using nasopharyngeal swabs,^{86, 435} and may be useful for at-home sampling. • Nasal and pharyngeal swabs may be less effective as diagnostic specimens than sputum and bronchoalveolar lavage fluid,⁴⁰⁴ although evidence is mixed.⁴²³ Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.⁴⁶¹ Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.⁵⁵ • The timing of diagnostic PCR tests impacts results. The false-negative rate for RT PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.²¹⁹ • The FDA issued an Emergency Use Authorization for an antigen-based diagnostic assay, limited to use in certified laboratories (clinical laboratory improvement amendments, CLIA).¹³¹ • The FDA released an Emergency Use Authorization enabling laboratories to develop and use tests in-house for patient diagnosis.¹³⁶ Tests from the US CDC are available to states.^{66, 73} Multiple rapid or real-time test kits have been produced by universities and industry, including the Wuhan Institute of Virology,¹¹¹ BGI,⁴⁰ Cepheid,³⁹⁷ Abbot,¹³⁴ and Mesa Biotech.⁴³ Home tests are being developed; however, none are FDA approved, nor are they useable as a diagnostic.^{296-297, 317} • The US CDC is developing serological tests to determine what proportion of the population has been exposed to SARS-CoV-2.²⁰² • Artificial intelligence algorithms were able to improve the ability of radiologists to distinguish COVID-19 pneumonia from non-COVID-19 pneumonia on chest CT scans.²⁸ <p>Validated serological (antibody) assays are being developed to help determine who has been exposed to SARS-CoV-2. Serological evidence of exposure does not indicate immunity.</p> <ul style="list-style-type: none"> • Researchers found high specificity in a number of enzyme-linked immunosorbent assays (ELISA), though sample sizes for SARS-CoV-2 patients were small.³⁰⁵ Additional research has shown high variability in the ability of tests (ELISA and lateral flow assays) by different manufacturers to accurately detect positive and negative cases (sensitivity and specificity, respectively).^{228, 411} Lateral flow assays may be less reliable than ELISA.¹² The FDA has recommended against the use of several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.¹³³ Researchers have designed a standardized ELISA procedure for SARS-CoV-2 serology samples aimed at minimizing false positives and false negatives.²¹² • Serological studies show that the proportion of individuals exposed to SARS-CoV-2 remains low in locations affected by the pandemic early, such as Wuhan (3.2-3.8%)⁴⁴⁰ and Hong Kong (2.5-4.0%).³⁸⁵ In one German town, serological testing has been used to identify the percent of the population already exposed to SARS-CoV-2 (14%), which can assist in public health response planning.³³⁶ • Preliminary serological studies in Santa Clara and Los Angeles, California, estimated that 2.5-4.1% of the population has already been exposed to SARS-CoV-2 since the first confirmed cases in January,^{37, 272} which is between 28 and 85 times greater than official reports. There are issues, however, with non-random study populations,³⁷ as well as false positive rates of the diagnostic tests themselves.²⁷² The false positive rate of the diagnostic assay used may account for a substantial portion of the reported infections,³⁷ particularly if the true proportion of positive patients is low. • In New York, initial serological testing indicates that 13.9% of the population has been exposed to COVID-19, approximately 10 times greater than the number of reported cases.³
<p>What do we need to know?</p>	<p>In general, PCR tests appear to be sensitive and specific, though confirmation of symptoms via chest CT is recommended. The sensitivity and specificity of serological testing methods is variable, and additional work needs to be done to determine factors that affect test accuracy.</p> <ul style="list-style-type: none"> • How accurate are clinical diagnoses compared to genetic tests? • How many serological tests need to be done to obtain an accurate picture of underlying exposure?

SARS-CoV-2 (COVID-19)	Medical Treatments – Are there effective treatments?
<p>What do we know?</p>	<p>Treatment for COVID-19 is primarily supportive care including ventilation if necessary.^{163, 273} Numerous clinical trials are ongoing. Several drugs show efficacy.</p> <ul style="list-style-type: none"> • Two WHO-backed clinical trials (Solidarity and Discovery)²²⁰ include remdesivir, hydroxychloroquine and chloroquine, ritonavir/lopinavir, and ritonavir/lopinavir and interferon-beta.²²⁰ <p>Remdesivir shows promise for reducing symptom duration in humans.³⁶</p> <ul style="list-style-type: none"> • Remdesivir can reduce the duration of symptoms in infected individuals, from 15 days to 11 days on average (compared to controls).³⁶ Remdesivir received an Emergency Use Authorization from FDA.²⁹⁹ Five and ten-day courses of remdesivir showed similar effects in preliminary Phase III trial results, but were not compared to a control group.¹⁵⁷ • In a separate clinical trial of severe COVID-19 patients, the effects of remdesivir were inconclusive due to a limitation in the study sample size.⁴⁰⁵ This trial ended early, reducing its statistical power.⁴⁰⁵ <p>Hydroxychloroquine is associated with elevated risk of cardiac arrhythmias and provides limited to no clinical benefit at this point in time. Large, randomized clinical trial results are necessary.</p> <ul style="list-style-type: none"> • Preliminary results from the RECOVERY trial indicate no benefit of hydroxychloroquine in terms of reduced mortality when administered to hospitalized patients.¹⁷⁵ The trial has stopped administering hydroxychloroquine to new patients.¹⁷⁵ Other existing studies have found no benefit of hydroxychloroquine (with or without azithromycin)^{87, 152, 266-267, 381} as well as cardiac side effects^{39, 98, 154, 193, 268, 286} and elevated risk of mortality.²⁶⁶ Individuals taking hydroxychloroquine for autoimmune disorders were not protected from COVID-19,¹⁵³ though sample sizes were limited. Patients given hydroxychloroquine after exposure to COVID-19 developed illness at the same rate as untreated patients, indicating no protective benefit.⁴⁸ A large observational study showing elevated mortality in patients taking hydroxychloroquine was retracted due to lack of access to primary data.²⁸² • Initial results purporting benefits of hydroxychloroquine and azithromycin¹⁵¹ have been called into question by other researchers¹⁸⁴ and the journal’s publishing society.¹⁹¹ One small clinical trial (n=62) suggests that hydroxychloroquine can reduce recovery time compared to control group.⁹¹ Key details are missing from this preprint.⁹¹ A small retrospective study (n=48) found benefits to hydroxychloroquine, though details on patient study population selection were limited.⁴⁴⁶ <p>Other pharmaceutical interventions are being investigated.</p> <ul style="list-style-type: none"> • A randomized Phase II trial found that a triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin administered early in infection reduced symptom severity, viral shedding, and hospital stay time compared to patients taking lopinavir-ritonavir alone.¹⁸⁵ In a separate study, interferon beta-1a was associated with lower mortality in a small study, but was only tested in combination with other drugs such as lopinavir/ritonavir or hydroxychloroquine.¹¹⁵ • Limited, preliminary evidence from clinical trials supports the efficacy of favipiravir⁸⁴ (which has been approved to treat COVID-19 in China)¹ and intravenous immunoglobulin.⁶¹ • Early research found no efficacy from combination ritonavir and lopinavir.^{60, 245} • Phase II clinical trial results for the kinase inhibitor ruxolitinib showed few severe side effects and suggested benefits in terms of symptom duration and mortality.⁶² • Early results from a randomized clinical trial found that high doses of chloroquine diphosphate were associated with toxicity and lethality in severely ill patients.⁴⁵ Efficacy was not assessed.⁴⁵ • Small, observational studies have found benefits of tocilizumab^{371, 439} and sarilumab³⁸ in severe COVID-19 patients, and Phase II trial results show limited reductions in mortality.³²⁴ Potential benefits of immunosuppressants⁷ should be weighed against potential risks.³³² • The anticoagulant heparin is being used to mitigate risks of pulmonary embolism.¹²⁹ Systemic anticoagulant use was associated with reduced mortality rates in severely ill patients.³¹⁵ • Passive antibody therapy (convalescent serum)⁶³ is being given to patients,¹³⁵ appears safe,²⁰³ and several small trials suggest benefits from convalescent patient plasma for infected patients.^{250, 357, 363-364} Results from a randomized clinical trial showed no significant benefits of plasma therapy, though the trial may not have enrolled enough patients to assess statistical significance.²³⁸ • More work is needed to substantiate a reported link between androgen levels and disease severity in male patients.^{158, 293, 399}
<p>What do we need to know?</p>	<p>Additional information on treatment efficacy is required, particularly from randomized clinical trials.</p> <ul style="list-style-type: none"> • Do monoclonal antibodies exhibit any efficacy in human trials?

SARS-CoV-2 (COVID-19)	Vaccines – Are there effective vaccines?
<p>What do we know?</p>	<p>Work is ongoing to develop a SARS-CoV-2 vaccine in human and animal trials. Early results are being released, but evidence should be considered preliminary until larger trials are completed.</p> <ul style="list-style-type: none"> • Multiple entities are working to produce a SARS-CoV-2 vaccine (e.g., operation Warp Speed),¹⁸ including HHS/NIH/NIAID,^{173, 234} CEPI, Moderna Therapeutics, Pfizer,¹³⁰ Gilead Sciences,^{4-5, 300} Sanofi,⁴⁹ and Johnson and Johnson.²⁰¹ <p><i>Phase II Trials (initial testing for efficacy, continued testing for safety):</i></p> <ul style="list-style-type: none"> • China's CanSino is the first to complete Phase I safety trials of their adenovirus type5 vector based SARS-CoV-2 vaccine, Ad5-nCoV, and has advanced to Phase II human trials.²⁴⁶ • University of Oxford's ChAdOx1 candidate has begun Phase II/III human trials.³¹⁰ • Moderna is beginning its Phase II trial of mRNA-1273 with 600 participants.²⁷⁴ <p><i>Phase I Trials (initial testing for safety):</i></p> <ul style="list-style-type: none"> • Sinovac Biotech has reported that their inactivated virus vaccine shows protective effects in rhesus macaques, particularly at high doses.¹⁴⁸ The vaccine is currently in Phase I clinical trials.¹⁰² • Phase I trial results for the CanSino vaccine (Ad5-nCoV) showed few severe adverse reactions in humans within 28 days of follow-up (side effects included fever [sometimes severe], fatigue, headache, and muscle pain).⁴⁶⁷ Immune responses were found in most patients, peaking at 14 days for T-cells and 28 days for antibodies.⁴⁶⁷ Two doses were selected for human Phase II trials. Vaccine efficacy in humans is currently unknown.⁴⁶⁷ • Preliminary data from a Phase I trial of Moderna's mRNA-1273 candidate suggest that the vaccine is well-tolerated by human subjects, and induces an antibody response against SARS-CoV-2.²⁹² • Inovio had their IND approved by the FDA and have started their Phase I clinical trials on their DNA vaccine candidate INO-4800.³⁵⁵ • Shenzhen Geno-Immune Medical Institute is testing its aAPC²⁷⁹ and lentiviral²⁷⁷ vaccines in Phase I clinical trials. • BioNTech and Pfizer's BNT162 program is in Phase I/II clinical trial for four of its mRNA vaccine candidates.³²⁵ • The ChAdOx1 platform has shown protective efficacy in rhesus macaques in preclinical trials. Safety and efficacy still need to be determined in human trials.³⁹³ • The Beijing Institute of Biological Products/Wuhan Institute of Biological Products have initiated a Phase I trial of their inactivated vaccine candidate.⁴²² • Symvivo Corporation has received approval to begin a Phase I trial with their oral bacTRL-Spike vaccine candidate in Canada.²⁷⁵ • Novavax is testing a recombinant spike protein nanoparticle vaccine in Phase I trials.²⁷⁶ • Immunitor LLC is starting Phase I trials of a heat-inactivated vaccine derived from pooled patient plasma.²⁸¹ • Aivita Biomedical will begin a Phase Ib/II randomized double-blind clinical trial of 180 people, specifically healthcare workers and first responders. Their vaccine DC-ATA consists of autologous dendritic cells loaded with antigens from SARS-CoV-2.²⁷⁸ • Clover Biopharmaceuticals (with GSK, Dynavax) will begin a Phase I trial of their vaccine SCB-2019, a recombinant SARS-CoV-2 Trimeric S protein subunit vaccine.²⁸⁰ <p><i>Additional vaccine research</i></p> <ul style="list-style-type: none"> • Research has identified several DNA vaccine candidates that show protective efficacy in rhesus macaques, in terms of reduction in viral load compared to non-vaccinated controls, though animals exhibited mild clinical symptoms.⁴⁴⁷ Human trials with these candidates are needed. <p><i>Vaccine Production</i></p> <ul style="list-style-type: none"> • A number of initiatives have planned or begun production of COVID-19 vaccines, with the goal of producing hundreds of millions of doses by 2021. Production of vaccine candidates is occurring before efficacy trials are complete, though only those candidates with safe and effective trial results will be administered to humans.^{34, 166-169}
<p>What do we need to know?</p>	<p>Published results from randomized clinical trials (Phase I – III) are needed.</p> <ul style="list-style-type: none"> • Safety of candidate vaccines in humans and animals • Efficacy of candidate vaccines in humans and animals • Length of any vaccine-derived immunity • Evidence for vaccine-derived enhancement (immunopotential)

SARS-CoV-2 (COVID-19)	Non-pharmaceutical Interventions – Are public health control measures effective at reducing spread?
<p>What do we know?</p>	<p>Broad-scale control measures such as stay-at-home orders are effective at reducing movement and contact rates, and modeling shows evidence that they reduce transmission.</p> <ul style="list-style-type: none"> • Social distancing and other policies are estimated to have reduced COVID-19 spread by 44% in Hong Kong¹⁰⁹ and reduced spread throughout China^{214, 218, 222, 258, 269} and Italy.¹⁵⁰ Restrictive lockdowns in China are estimated to have reduced disease transmission within only a few days,⁴⁶⁸ in part, through reductions in an individual’s average number of contacts.⁴⁵³ • Modeling demonstrates that multifaceted restrictions and quarantines in China reduced the R_0 of SARS-CoV-2 from greater than 3 to less than 1 between January 23 and February 5.³¹¹ Additionally, movement restrictions and other control measures helped limit the amount of time where community transmission was possible (i.e., $R_0 > 1$).⁴⁵⁴ • A US county-level model found that shelter in place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.¹⁰⁷ School closures and cancellation of large gatherings had smaller effects.¹⁰⁷ Similarly, researchers found that a larger number of public health interventions in place was strongly associated with lower COVID-19 growth rates in the next week.²⁰⁵ • Mobility^{142, 227} and physical contact rates¹⁹⁴ decline after public health control measures are implemented. Modeling suggests that on their own, travel restrictions are ineffective at reducing COVID-19 spread and only delay peak prevalence by only a few days but do not limit epidemic size.¹⁶ • Models indicate that a combination of school closures, work restrictions, and other measures are required to effectively limit transmission.¹³⁹ School closures alone appear insufficient.^{192, 222} • Non-pharmaceutical interventions in China did not reduce transmission equally across all groups; transmission rates in younger individuals, particularly infants, as well as hospital workers continued to increase even while overall transmission rates declined.³¹¹ • Two modeling studies identified large reductions in transmission due to country lockdowns¹⁴⁴ and other social distancing measures,¹⁷⁷ with substantial variation in the efficacy of particular policies in different countries.^{144, 177} • Contact tracing to identify infected individuals reduces the amount of time infectious individuals can transmit disease in a population and increases the time between successive cases.⁴² Robust contact tracing and case finding may be needed to control COVID-19 in the US, but would require additional staff and resources to conduct effectively.⁴⁰⁶ In South Korea, early implementation of rapid contact tracing, testing, and quarantine of confirmed and suspected cases was able to reduce the transmission rate of COVID-19.³⁷⁶ Modeling studies suggest that contact tracing combined with high levels of testing may limit COVID-19 resurgence once initial social distancing policies are relaxed.^{15, 140} <p>Research is needed to help plan for easing of restrictions.</p> <ul style="list-style-type: none"> • Modeling suggests that 20-30 US states still have self-sustained COVID-19 transmission ($R_0 > 1$) as of 5/17/2020.³⁸⁹ The same work estimates that very few individuals have been infected overall (4.3% estimated prevalence), even in states with large case and fatality totals (e.g., 16.6% of New York residents).³⁸⁹ Relaxation of public health interventions is projected to increase cases and deaths.^{112, 389} • Modeling indicates that COVID-19 is likely to become endemic in the US population, with regular, periodic outbreaks, and that additional social or physical distancing measures may be required for several years to keep cases below critical care capacity in absence of a vaccine or effective therapeutic.²¹⁰ Results depend critically on the duration of immunity after exposure.²¹⁰ • Rolling interventions, whereby social distancing measures are put into place every few weeks, may keep healthcare demand below a critical point.⁴⁴⁵ • A modeling study using Chinese data suggests that carefully balancing control measures to maintain R_0 below 1 would be more efficient than allowing R_0 to increase above 1 at any point.²³¹ • The WHO has released guidelines on public health strategy,⁴¹³ and Johns Hopkins released a report outlining how to re-open certain categories of activities (e.g., schools, restaurants, events) while reducing COVID-19 risk.³⁴⁶
<p>What do we need to know?</p>	<p>As different US states have implemented differing control measures at various times, a comprehensive analysis of social distancing efficacy has not yet been conducted.</p> <ul style="list-style-type: none"> • What are plausible options for relaxing social distancing and other intervention measures without resulting in a resurgence of COVID-19 cases? • How is COVID-19 incidence changing in states that have begun easing movement and activity restrictions?

SARS-CoV-2 (COVID-19)	Environmental Stability – How long does the agent live in the environment?
<p>What do we know?</p>	<p>SARS-CoV-2 can persist on surfaces for at least 3 days and on the surface of a surgical mask for up to 7 days depending on conditions. If aerosolized intentionally, SARS-CoV-2 is stable for at least several hours. The seasonality of COVID-19 transmission is unknown. SARS-CoV-2 on surfaces is inactivated rapidly with sunlight.</p> <p><i>SARS-CoV-2 Data</i></p> <ul style="list-style-type: none"> • In simulated saliva on stainless steel surface, SARS-CoV-2 exhibits negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on the intensity of simulated UVB radiation levels.³³⁵ • SARS-CoV-2 can persist on plastic and metal surfaces between 3 days (21-23°C, 40% RH)³⁹¹ and 7 days (22°C, 65% RH). Infectious virus can be recovered from a surgical mask after 7 days (22°C, 65% RH).⁹⁷ • SARS-CoV-2 has an aerosol half-life of 2.7 hours (particles <5 µm, tested at 21-23°C and 65% RH).³⁹¹ • SARS-CoV-2 is susceptible to heat treatment (70°C) but can persist for at least two weeks at refrigerated temperatures (4°C).^{97, 334} • SARS-CoV-2 genetic material (RNA) was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days after cabins were vacated. The infectiousness of this material is not known.²⁹⁴ • In a preliminary study, SARS-CoV-2 stability was enhanced when present with bovine serum albumin, which is commonly used to represent sources of protein found in human sputum.³²⁰ • No strong evidence exists showing a reduction in transmission with seasonal increase in temperature and humidity.²⁶³ Modeling suggests that even accounting for potential reductions in transmission due to weather and behavioral changes, public health interventions will still need to be in effect to limit COVID-19 transmission.²⁸⁷ • The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel and ABS plastic) at varying temperature and relative humidity. This model estimates virus decay in the absence of exposure to direct sunlight.¹²² • A recent study determined that approximately 0.1-1% of initial SARS-CoV-2 inoculated on plastic, stainless steel, glass, ceramics, wood, latex gloves, cotton, paper, and surgical masks remained after 48 hours.²⁵⁴ Approximately 0.1% of SARS-CoV-2 remains in fecal matter after 6 hours.²⁵⁴ Approximately 0.1% of SARS-CoV-2 in human urine persists after 4-5 days.²⁵⁴ • RNA in clinical samples collected in viral transport medium is stable at 18-25°C or 2-8°C for up to 21 days without impacting real-time RT-PCR results.³⁷⁰ RNA in clinical samples is also stable at 4°C for up to 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL). Separately, storage of RNA in PBS at room-temperature (18-25°C) resulted in unstable sample concentrations.³²² <p><i>Surrogate Coronavirus data:</i></p> <ul style="list-style-type: none"> • Studies suggest that other coronaviruses can survive on non-porous surfaces up to 9-10 days (MHV, SARS-CoV),^{64, 80} and porous surfaces for up to 3-5 days (SARS-CoV)¹²⁸ in air conditioned environments (20-25°C, 40-50% RH). • Coronavirus survival tends to be higher at lower temperatures and lower relative humidity (RH),^{64, 80, 331, 392} though infectious virus can persist on surfaces for several days in typical office or hospital conditions.³⁹² • SARS can persist with trace infectivity for up to 28 days at refrigerated temperatures (4°C) on surfaces.⁶⁴ • One hour after aerosolization approximately 63% of airborne MERS virus remained viable in a simulated office environment (25°C, 75% RH).³²⁸ • Porous hospital materials, including paper and cotton cloth, maintain infectious SARS-CoV for a shorter time than non-porous material.²²¹
<p>What do we need to know?</p>	<p>Additional testing on SARS-CoV-2, as opposed to surrogate viruses, is needed to support initial estimates of stability.</p> <ul style="list-style-type: none"> • Particle size distribution (e.g., droplet, large droplet, and true aerosol distribution) • Duration of SARS-CoV-2 infectivity via fomites and surfaces (contact hazard) • Stability of SARS-CoV-2 on PPE (e.g., Tyvek, nitrile, etc.) • Evidence for seasonality in transmission, or other environmental impacts (UV, temperature, humidity)

SARS-CoV-2 (COVID-19)	Decontamination – What are effective methods to kill the agent in the environment?
<p>What do we know?</p>	<p>Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.</p> <p><i>SARS-CoV-2</i></p> <ul style="list-style-type: none"> • Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.²¹⁶ • Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.⁹⁶ • Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.³⁰⁷ • EPA has released a list of SARS-CoV-2 disinfectants, but solutions were not tested on SARS-CoV-2.¹³ <p><i>Other Coronaviruses</i></p> <ul style="list-style-type: none"> • Chlorine-based⁴¹⁷ and ethanol-based¹⁰⁵ solutions are recommended. • Heat treatment (56°C) is sufficient to kill coronaviruses,^{331, 463} though effectiveness depends partly on protein in the sample.³³¹ • 70% ethanol, 50% isopropanol, sodium hypochlorite (0.02% bleach), and UV radiation can inactivate several coronaviruses (MHV and CCV).³⁵⁶ • Ethanol-based biocides effectively disinfect coronaviruses dried on surfaces, including ethanol containing gels similar to hand sanitizer.^{183, 424} • Surface spray disinfectants such as Mikrobac, Dismozon, and Korsolex are effective at reducing infectivity of the closely related SARS-CoV-1 after 30 minutes of contact.³³⁰ • Coronaviruses may be resistant to heat inactivation for up to 7 days when stabilized in stool.³⁸³⁻³⁸⁴ • Coronaviruses are more stable in matrixes such as respiratory sputum.¹²⁷ <p>Methods for decontaminating N95 masks have been approved by the FDA under an Emergency Use Authorization (EUA).</p> <ul style="list-style-type: none"> • Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor): UV radiation, heating to 70°C, and vaporized hydrogen peroxide (VHP).¹⁴¹ Ethanol (70%) was associated with loss of physical integrity.¹⁴¹ • Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.³⁴³ Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.¹³¹ • The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals.⁵¹
<p>What do we need to know?</p>	<p>Additional decontamination studies, particularly with regard to PPE and other items in short supply, are needed.</p> <ul style="list-style-type: none"> • What is the minimal contact time for disinfectants? • Does contamination with human fluids/waste alter disinfectant efficacy profiles? • How effective is air filtration at reducing transmission in healthcare, airplanes, and public spaces? • Are landfills and wastewater treatment plants effective at inactivating SARS-CoV-2? • Is heat or UV decontamination effective to clean N95 masks, respirators and other types of PPE for multi-use?

SARS-CoV-2 (COVID-19)	PPE – What PPE is effective, and who should be using it?
<p>What do we know?</p>	<p>The effectiveness of PPE for SARS-CoV-2 is currently unknown, and data from other related coronaviruses are used for guidance. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.</p> <ul style="list-style-type: none"> • Healthcare worker illnesses³⁸² demonstrates human-to-human transmission despite isolation, PPE, and infection control.³⁵⁹ Risk of transmission to healthcare workers is high, with up to 20% of healthcare workers in Lombardy, Italy becoming infected.³³⁸ Over 50% of US healthcare workers infected with COVID-19 report work in a healthcare setting as their single source of exposure.⁵⁶ • “Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).”⁷¹ WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.⁴¹⁶ Clothing and PPE that covers all skin may reduce exposure to pathogens.^{138, 409} • Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those dealing with possible aerosols.⁴¹⁷ Additional protection, such as a Powered Air Purifying Respirator (PAPR) with a full hood, should be considered for high-risk procedures (i.e., intubation, ventilation).⁵³ • Particular attention should be paid to the potential for transmission via exhaled air during supportive respiratory procedures.¹⁶² • KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.¹³² On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.¹³⁷ • A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply. The study used an experimental setup with aerosolized simulant, not human testing.³²¹ • Particular care should be taken with “duckbill” N95 respirators, which may fail fit tests after repeated doffing.¹¹⁹ Dome-shaped N95 respirators also failed fit tests after extended use.¹¹⁹ <p>Masks may be effective at slowing transmission.</p> <ul style="list-style-type: none"> • On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.⁷² The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.⁴¹² • A meta-analysis of SARS, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission.⁹⁹ N95 respirators were associated with a larger reduction in transmission risk compared to surgical face masks.⁹⁹ Physical distance (>1 or 2 meters) was also associated with lower transmission risk.⁹⁹ • In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.³⁰⁴ N95 respirators were associated with large reductions (up to 80%) in SARS-CoV-1 infections.³⁰⁴ • Surgical face masks, respirators and homemade face masks may prevent transmission of coronaviruses from infectious individuals (with or without symptoms) to other individuals.^{114, 232, 390} Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus (not SARS-CoV-2) expressed as aerosol particles (<5 μm) compared to not wearing a mask.²³² • The efficacy of homemade PPE, made with T-shirts, bandanas, or similar materials, is less than standard PPE, but may offer some protection if no other options are available.^{100, 113, 340} The filtering efficiency of homemade mask materials is variable. Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3μm,²¹³ while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).⁴⁰³
<p>What do we need to know?</p>	<p>Most PPE recommendations have not been made on SARS-CoV-2 data, and comparative efficacy of different PPE for different tasks (e.g., intubation) is unknown. Identification of efficacious PPE for healthcare workers is critical due to their high rates of infection.</p> <ul style="list-style-type: none"> • What is the importance of aerosol transmission (particles <5μm)? What is the effective distance of spread via droplet or aerosol? • How effective are barriers such as N95 respirators or surgical masks for SARS-CoV-2? • What is the appropriate PPE for first responders? Airport screeners? • What are proper procedures for reducing spread and transmission rates in medical facilities? • How effective are homemade masks at reducing SARS-CoV-2 transmission?

SARS-CoV-2 (COVID-19)	Forensics – Natural vs intentional use? Tests to be used for attribution.
<p>What do we know?</p>	<p>All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.</p> <ul style="list-style-type: none"> • Genomic analysis places SARS-CoV-2 into the beta-coronavirus clade, with close relationship to bat coronaviruses. The SARS-CoV-2 virus is distinct from SARS-CoV-1 and MERS viruses.¹²³ • Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by “recombination” with other circulating strains of coronavirus.^{19, 466} • Genomic data support at least two plausible origins of SARS-CoV-2: “(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.”¹⁹ Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates. • Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses,⁴²⁵ and data suggest that pangolins may be a natural host for beta-coronaviruses.^{247, 249} Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.⁴³⁷ Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.⁴⁵⁷ Additional research is needed. • There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.^{20, 242, 248, 457} These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor. Additional research is needed. • A novel bat coronavirus (RmYN02) has been identified in China with an insertion in the viral furin cleavage site. While distinct from the insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.⁴⁶⁵ • Additionally, “[...] SARS-CoV-2 is not derived from any previously used virus backbone,” reducing the likelihood of laboratory origination,¹⁹ and “[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.”¹⁹ • Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.¹¹⁷
<p>What do we need to know?</p>	<p>Identifying the intermediate species between bats and humans would aid in reducing potential spillover from a natural source. Wide sampling of bats, other wild animals, and humans is needed to address the origin of SARS-CoV-2.</p> <ul style="list-style-type: none"> • What tests for attribution exist for coronavirus emergence? • What is the identity of the intermediate species? • Are there closely related circulating coronaviruses in bats or other animals with the novel PRRA cleavage site found in SARS-CoV-2?


SARS-CoV-2 (COVID-19)	Genomics – How does the disease agent compare to previous strains?
<p>What do we know?</p>	<p>Current evidence suggests that SARS-CoV-2 accumulates substitutions and mutations at a similar rate as other coronaviruses. Mutations and deletions in specific portions of the SARS-CoV-2 genome have not been linked to any changes in transmission or disease severity, though modeling work is attempting to identify possible changes.</p> <ul style="list-style-type: none"> • There have been no documented cases of SARS-CoV-2 prior to December 2019. Preliminary genomic analyses, however, suggest that the first human cases of SARS-CoV-2 emerged between 10/19/2019 – 12/17/2019.^{21, 35, 333} • Analysis of more than 7,000 SARS-CoV-2 genome samples provides an estimated mutation rate of 6×10^{-4} nucleotides per genome per year.³⁹⁴ The same analysis estimates the emergence of SARS-CoV-2 in humans between October and December 2019.³⁹⁴ This aligns with the first known human cases in China in early December 2019, in Europe in late December 2019,¹²¹ and circulation in the US (Washington State) in February 2020.⁴²⁷ • Despite evidence of variation in the genome⁷⁷ and areas under positive selection,⁵⁷ there are no known associations between particular mutations and changes in transmission or virulence.⁵⁸ Thus, there is currently no evidence of distinct SARS-CoV-2 phenotypes at this time.^{265, 394} Research attempting to define clades or subgroups of SARS-CoV-2 based solely on genomic features has suffered from limited data⁴⁵⁰ and sampling bias.¹⁴⁵ • Analysis shows that no recurrent SARS-CoV-2 mutations are associated with increases in viral transmission, providing no evidence of distinct lineage with different rates of growth.³⁹⁵ • In 94 COVID-19 patients where both symptoms and genetic sequences of SARS-CoV-2 were known, there was no association between viral genotype and clinical severity.⁴⁵⁸ • SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).⁴²⁹ Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts,⁴²⁹ and that additional jumps into humans from reservoir species may occur. • Pangolin coronaviruses are closely related to both SARS-CoV-2 and closely related bat coronaviruses. Phylogenetic analysis suggests that SARS-CoV-2 is of bat origin, but is closely related to pangolin coronavirus.^{247, 249} • The SARS-CoV-2 Spike protein, which mediates entry into host cells and is the major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.²⁵⁹ The rest of the genome is more closely related to two separate bat²⁵⁹ and pangolin²⁴⁹ coronaviruses. • An analysis of SARS-CoV-2 sequences from Singapore has identified a large nucleotide (382 bp) deletion in ORF-8.³⁷⁵ In Arizona, researchers identified an 81-base pair deletion (removing 27 amino acids) in the ORF-7a protein, indicating that mutations can be detected by routine sentinel surveillance. The function of these deletions are unknown at this time.¹⁷⁴ • A recent report of virus mutations within patients needs more research.²⁰⁶ Additional analysis of data suggests the results may be due to experimental methods.^{155, 441} • Structural modeling suggests that observed changes in the genetic sequence of the SARS-CoV-2 Spike protein may enhance binding of the virus to human ACE2 receptors.³⁰⁸ More specifically, changes to two residues (Q493 and N501) are linked with improving the stability of the virus-receptor binding complex.³⁰⁸ Additionally, structural modeling identified several existing mutations that may enhance the stability of the receptor binding domain, potentially increasing binding efficacy.³⁰⁹ Infectivity assays are needed to validate the genotypic changes and possible phenotypic results identified in these studies. • A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).¹⁰⁸ • The US CDC is launching a national genomics consortium to assess SARS-CoV-2 genomic changes over time.⁶⁷
<p>What do we need to know?</p>	<p>Research linking genetic changes to differences in phenotype (e.g., transmissibility, virulence, progression in patients) is needed.</p> <ul style="list-style-type: none"> • Are there similar genomic differences in the progression of coronavirus strains from bat to intermediate species to human? • Are there different strains or clades of circulating virus? If so, do they differ in virulence? • What are the mutations in SARS-CoV-2 that allowed human infection and transmission?

SARS-CoV-2 (COVID-19)	Forecasting – What forecasting models and methods exist?
<p>What do we know?</p>	<p>There are many groups focused on forecasting cases, hospitalizations, or fatalities due to COVID-19. Each model has its own methods and goals, summarized in this section. An evaluation of model performance is beyond the scope of this document. Assumptions and limitations of each model are detailed at the linked reference.</p> <p><i>US CDC forecasting</i></p> <p>The US CDC is hosting an ongoing forecasting initiative, and provides ensemble forecasts based on the arithmetic mean of participating groups.⁷⁰</p> <ul style="list-style-type: none"> • Columbia University Model: Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.³⁵² • Imperial College London: Week-ahead forecasts of cases, deaths, and transmissibility (R_0) at the country-level. Transmissibility estimates used to forecast incidence based on Poisson renewal process.⁴¹ • Institute of Health Metrics and Evaluation (IHME): Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.¹⁸⁸ • Los Alamos National Laboratory: Forecasts of state-level cases and deaths based on statistical growth model fit to reported data. Implicitly accounts for effects of social distancing and other control measures.²²⁶ • Massachusetts Institute of Technology: Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths. Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).²⁹⁰ • Northeastern University: Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.³⁰² • Notre Dame University: Agent-based model forecasting cases and deaths for Midwest states. Includes effectiveness of control measures like social distancing.³²³ • University of California, Los Angeles: Mechanistic SIR model with statistical optimization to find best-fitting parameter values. Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.³⁸⁸ • University of Chicago: Age-structured SEIR model that accounts for asymptomatic individuals and the effectiveness of social distancing policies. Forecasts only for Illinois.⁹⁵ • University of Geneva: Country-level forecasts of cases, deaths, and transmissibility (R_0). Uses statistical models fit to reported data, not mechanistic models.¹⁴³ • University of Massachusetts, Amherst: Aggregation of state and national forecasts to create ensemble model.³³⁷ • University of Texas, Austin: Machine learning model aimed at identifying links between social distancing measures and changes in death rates. Forecasts fatalities at the state, metropolitan area, and national level. Cannot be used to make projections beyond initial infection wave.²⁸⁸ • Youyang Gu: Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values. Forecasts deaths and infections at the state and national level, including 60 non-US countries. Includes effects of public health control efforts.¹⁶¹ • Auquan: SEIR model used to forecast deaths and illnesses at the country and state level.²⁶ • CovidSim: SEIR model allowing users to simulate the effects of future intervention policies at the state and national level (US only).⁹⁴ <p><i>Other forecasting efforts:</i></p> <ul style="list-style-type: none"> • University of Georgia: Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., “nowcasts”). Available at the state and national level for the US.⁷⁶ • Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US. Relies in part on IHME forecasts.¹⁹⁰ • COVID Act Now: State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds). Fundamentally uses an SEIR model fit to observed data.³⁰³
<p>What do we need to know?</p>	<p>Forecasts differ in how they handle public health interventions such as shelter-in-place orders and tracking how methods change in the near future will be important for understanding limitations going forward.</p>

Table 1. Definitions of commonly-used acronyms

Acronym/Term	Definition	Description
ACE2	Angiotensin-converting enzyme 2	Acts as a receptor for SARS-CoV and SARS-CoV-2, allowing entry into human cells
Airborne transmission	Aerosolization of infectious particles	Aerosolized particles can spread for long distances (e.g., between hospital rooms via HVAC systems). Particles generally <5 μm.
ARDS	Acute respiratory distress syndrome	Leakage of fluid into the lungs which inhibits respiration and leads to death
Attack rate	Proportion of “at-risk” individuals who develop infection	Defined in terms of “at-risk” population such as schools or households, defines the proportion of individuals in those populations who become infected after contact with an infectious individual
CCV	Canine coronavirus	Canine coronavirus
CFR	Case Fatality Rate	Number of deaths divided by confirmed patients
CoV	Coronavirus	Virus typified by crown-like structures when viewed under electron microscope
COVID-19	Coronavirus disease 19	Official name for the disease caused by the SARS-CoV-2 virus.
Droplet transmission	Sneezing, coughing	Transmission via droplets requires relatively close contact (e.g., within 6 feet)
ELISA	Enzyme-linked immunosorbent assay	Method for serological testing of antibodies
Fomite	Inanimate vector of disease	Surfaces such as hospital beds, doorknobs, healthcare worker gowns, faucets, etc.
HCW	Healthcare worker	Doctors, nurses, technicians dealing with patients or samples
Incubation period	Time between infection and symptom onset	Time between infection and onset of symptoms typically establishes guidelines for isolating patients before transmission is possible
Infectious period	Length of time an individual can transmit infection to others	Reducing the infectious period is a key method of reducing overall transmission; hospitalization, isolation, and quarantine are all effective methods
Intranasal	Agent deposited into external nares of subject	Simulates inhalation exposure by depositing liquid solution of pathogen/virus into the nose of a test animal, where it is then taken up by the respiratory system.
MERS	Middle-East Respiratory Syndrome	Coronavirus with over 2,000 cases in regional outbreak since 2012
MHV	Mouse hepatitis virus	Coronavirus surrogate
Nosocomial	Healthcare- or hospital-associated infections	Characteristic of SARS and MERS outbreaks, lead to refinement of infection control procedures
PCR	Polymerase chain reaction	PCR (or real-time [RT] or quantitative [Q] PCR) is a method of increasing the amount of genetic material in a sample, which is then used for diagnostic testing to confirm the presence of SARS-CoV-2
PFU	Plaque forming unit	Measurement of the number of infectious virus particles as determined by plaque forming assay. A measurement of sample infectivity.
PPE	Personal protective equipment	Gowns, masks, gloves, and any other measures used to prevent spread between individuals
R ₀	Basic reproduction number	A measure of transmissibility. Specifically, the average number of new infections caused by a typical infectious individual in a wholly susceptible population.

Acronym/Term	Definition	Description
SARS	Severe Acute Respiratory Syndrome	Coronavirus with over 8,000 cases in global 2002-2003 outbreak
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2	Official name for the virus previously known as 2019-nCoV.
SEIR	Susceptible (S), exposed (E), infected (I), and resistant (R)	A type of modeling that incorporates the flow of people between the following states: susceptible (S), exposed (E), infected (I), and resistant (R), and is being used for SARS-CoV-2 forecasting
Serial interval	Length of time between symptom onset of successive cases in a transmission chain	The serial interval can be used to estimate R_0 , and is useful for estimating the rate of outbreak spread
SIR	Susceptible (S), infected (I), and resistant (R)	A type of modeling that incorporates the flow of people between the following states: susceptible (S), infected (I), and resistant (R), and is being used for SARS-CoV-2 forecasting
TCID ₅₀	50% Tissue Culture Infectious Dose	The number of infectious units which will infect 50% of tissue culture monolayers. A measurement of sample infectivity.
Transgenic	Genetically modified	In this case, animal models modified to be more susceptible to MERS and/or SARS by adding proteins or receptors necessary for infection



Literature Cited:

1. (U) China approves first anti-viral drug against coronavirus Covid-19. *Pharmaceutical Technology* 2020. <https://www.pharmaceutical-technology.com/news/china-approves-favilavir-covid-19/>
2. (U) Coronavirus diagnosed at mink farms in North Brabant. *NOS* 2020. <https://nos.nl/artikel/2331784-coronavirus-vastgesteld-bij-nertsenfokkerijen-in-noord-brabant.html>
3. (U) Coronavirus Survey Reveals 13.9% In New York Have COVID-19 Antibodies, Cuomo Says. *CBS* 2020. <https://newyork.cbslocal.com/2020/04/23/coronavirus-survey-reveals-13-9-percent-in-new-york-have-covid-19-antibodies-cuomo-says/>
4. (U) A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults 2020. <https://clinicaltrials.gov/ct2/show/NCT04280705>
5. (U) Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults 2020. <https://clinicaltrials.gov/ct2/show/record/NCT04283461?term=mrna-1273&draw=2&rank=1>
6. (U) Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. . *MMWR* 2020. https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm?s_cid=mm6912e2_w#suggestedcitation
7. (U) Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. Assistance Publique - Hôpitaux de Paris/Universities/INSERM-REACTing COVID-19 academic research collaboration: 2020. <https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19>
8. (U) [Wuhan Pneumonia] The Hospital Authority stated that 2 critically ill patients needed external life support treatment. <https://www.singtao.ca/4037242/2020-01-14/news-%E3%80%90%E6%AD%A6%E6%BC%A2%E8%82%BA%E7%82%8E%E3%80%91%E9%86%AB%E7%AE%A1%E5%B1%80%E6%8C%872%E5%90%8D%E9%87%8D%E7%97%87%E7%97%85%E6%82%A3%E9%9C%80%E9%AB%94%E5%A4%96%E7%94%9F%E5%91%BD%E6%94%AF%E6%8C%81%E6%B2%BB%E7%99%82/?variant=zh-hk>.
9. (U) AAAS, You may be able to spread coronavirus just by breathing, new report finds. *Science* 2 April, 2020. <https://www.sciencemag.org/news/2020/04/you-may-be-able-to-spread-coronavirus-just-breathing-new-report-finds>
10. (U) Ackermann, M.; Verleden, S. E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; Li, W. W.; Li, V. W.; Mentzer, S. J.; Jonigk, D., Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *New England Journal of Medicine* 2020. <https://www.nejm.org/doi/full/10.1056/NEJMoa2015432>
11. (U) Adam, D.; Wu, P.; Wong, J.; Lau, E.; Tsang, T.; Cauchemez, S.; Leung, G.; Cowling, B., Clustering and superspreading potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Hong Kong. 2020.
12. (U) Adams, E. R.; Anand, R.; Andersson, M. I.; Auckland, K.; Baillie, J. K.; Barnes, E.; Bell, J.; Berry, T.; Bibi, S.; Carroll, M.; Chinnakannan, S.; Clutterbuck, E.; Cornall, R. J.; Crook, D. W.; De Silva, T.; Dejnirattisai, W.; Dingle, K. E.; Dold, C.; Eyre, D. W.; Farmer, H.; Hoosdally, S. J.; Hunter, A.; Jeffrey, K.; Klenerman, P.; Knight, J.; Knowles, C.; Kwok, A. J.; Leuschner, U.; Liu, C.; Lopez-Camacho, C.; Matthews, P. C.; McGivern, H.; Mentzer, A. J.; Milton, J.; Mongkolsapaya, J.; Moore, S. C.; Oliveira, M. S.; Pereira, F.; Peto, T.; Ploeg, R. J.; Pollard, A.; Prince, T.; Roberts, D. J.; Rudkin, J. K.; Sreaton, G. R.; Semple, M. G.; Skelly, D. T.; Smith, E. N.; Staves, J.; Stuart, D.; Supasa, P.; Surik, T.; Tsang, P.; Turtle, L.; Walker, A. S.; Wang, B.; Washington, C.; Watkins, N.; Whitehouse, J.; Beer, S.; Levin, R.; Espinosa, A.; Georgiou, D.; Martinez Garrido, J. C.; Thraves, H.; Perez Lopez, E.; del Rocio Fernandez Mendoza, M.; Sobrino Diaz, A. J.; Sanchez, V., Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays.

medRxiv **2020**, 2020.04.15.20066407.

<https://www.medrxiv.org/content/medrxiv/early/2020/04/20/2020.04.15.20066407.full.pdf>

13. (U) Agency, U. S. E. P., EPA's Registered Antimicrobial Products for Use Against Novel Coronavirus SARS-CoV-2, the Cause of COVID-19. <https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2>.

14. (U) Agrawal, A. S.; Garron, T.; Tao, X.; Peng, B. H.; Wakamiya, M.; Chan, T. S.; Couch, R. B.; Tseng, C. T., Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. *J Virol* **2015**, *89* (7), 3659-70.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403411/pdf/zjv3659.pdf>

15. (U) Aleta, A.; Martin-Corral, D.; Pastore y Piontti, A.; Ajelli, M.; Litvinova, M.; Chinazzi, M.; Dean, N.; Halloran, M. E.; Longini, I.; Merler, S.; Pentland, A.; Vespignani, A.; Moro, E.; Moreno, Y., Modeling the impact of social distancing, testing, contact tracing and household quarantine on second-wave scenarios of the COVID-19 epidemic. *Preprint* **2020**. https://www.mobs-lab.org/uploads/6/7/8/7/6787877/tracing_main_may4.pdf

https://www.mobs-lab.org/uploads/6/7/8/7/6787877/tracing_main_may4.pdf

16. (U) Aleta, A.; Moreno, Y., Evaluation of the potential incidence of COVID-19 and effectiveness of containment measures in Spain: a data-driven approach. *BMC Medicine* **2020**, *18* (1), 157.

<https://doi.org/10.1186/s12916-020-01619-5>

17. (U) Altmann, D. M.; Douek, D. C.; Boyton, R. J., What policy makers need to know about COVID-19 protective immunity. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30985-5](https://doi.org/10.1016/S0140-6736(20)30985-5)

18. (U) Amanat, F.; Krammer, F., SARS-CoV-2 vaccines: status report. *Journal of Immunology* **2020**, *Early View*. <https://marlin-prod.literatumonline.com/pb-assets/journals/research/immunity/SARS-CoV-2%20vaccines%20status%20report.pdf>

<https://marlin-prod.literatumonline.com/pb-assets/journals/research/immunity/SARS-CoV-2%20vaccines%20status%20report.pdf>

19. (U) Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0820-9>

20. (U) Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**, *26* (4), 450-452. <https://doi.org/10.1038/s41591-020-0820-9>

21. (U) Anderson, K., Estimates of the clock and TMRCA for 2019-nCoV based on 27 genomes.

<http://virological.org/t/clock-and-tmrca-based-on-27-genomes/347> (accessed 01/26/2020).

22. (U) Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F. X.; Chong, M.; Lee, M., Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA* **2020**.

<https://doi.org/10.1001/jama.2020.4326>

23. (U) Argenziano, M. G.; Bruce, S. L.; Slater, C. L.; Tiao, J. R.; Baldwin, M. R.; Barr, R. G.; Chang, B. P.; Chau, K. H.; Choi, J. J.; Gavin, N.; Goyal, P.; Mills, A. M.; Patel, A. A.; Romney, M.-L. S.; Safford, M. M.; Schluger, N. W.; Sengupta, S.; Sobieszczyk, M. E.; Zucker, J. E.; Asadourian, P. A.; Bell, F. M.; Boyd, R.; Cohen, M. F.; Colquhoun, M. I.; Colville, L. A.; de Jonge, J. H.; Dershowitz, L. B.; Dey, S. A.; Eiseman, K. A.; Girvin, Z. P.; Goni, D. T.; Harb, A. A.; Herzik, N.; Householder, S.; Karaaslan, L. E.; Lee, H.; Lieberman, E.; Ling, A.; Lu, R.; Shou, A. Y.; Sisti, A. C.; Snow, Z. E.; Sperring, C. P.; Xiong, Y.; Zhou, H. W.; Natarajan, K.; Hripcsak, G.; Chen, R., Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series. *medRxiv* **2020**, 2020.04.20.20072116.

<https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.20.20072116.full.pdf>

24. (U) Arons, M. M.; Hatfield, K. M.; Reddy, S. C.; Kimball, A.; James, A.; Jacobs, J. R.; Taylor, J.; Spicer, K.; Bardossy, A. C.; Oakley, L. P.; Tanwar, S.; Dyal, J. W.; Harney, J.; Chisty, Z.; Bell, J. M.; Methner, M.; Paul, P.; Carlson, C. M.; McLaughlin, H. P.; Thornburg, N.; Tong, S.; Tamin, A.; Tao, Y.; Uehara, A.; Harcourt, J.; Clark, S.; Brostrom-Smith, C.; Page, L. C.; Kay, M.; Lewis, J.; Montgomery, P.; Stone, N. D.; Clark, T. A.; Honein, M. A.; Duchin, J. S.; Jernigan, J. A., Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *New England Journal of Medicine* **2020**.

<https://www.nejm.org/doi/full/10.1056/NEJMoa2008457>

25. (U) Auld, S.; Caridi-Scheible, M.; Blum, J. M.; Robichaux, C. J.; Kraft, C. S.; Jacob, J. T.; Jabaley, C. S.; Carpenter, D.; Kaplow, R.; Hernandez, A. C.; Adelman, M. W.; Martin, G. S.; Coopersmith, C. M.; Murphy, D. J., ICU and ventilator mortality among critically ill adults with COVID-19. *medRxiv* **2020**, 2020.04.23.20076737.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/26/2020.04.23.20076737.full.pdf>
26. (U) Auquan, COVID-19 Dashboard. <https://covid19-infection-model.auquan.com/>.
27. (U) Aziz, M.; Fatima, R.; Assaly, R., Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis. *J Med Virol* **2020**.
28. (U) Bai, H. X.; Wang, R.; Xiong, Z.; Hsieh, B.; Chang, K.; Halsey, K.; Tran, T. M. L.; Choi, J. W.; Wang, D. C.; Shi, L. B.; Mei, J.; Jiang, X. L.; Pan, I.; Zeng, Q. H.; Hu, P. F.; Li, Y. H.; Fu, F. X.; Huang, R. Y.; Sebros, R.; Yu, Q. Z.; Atalay, M. K.; Liao, W. H., AI Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Etiology on Chest CT. *Radiology* **2020**, 201491.
29. (U) Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D.-Y.; Chen, L.; Wang, M., Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*.
30. (U) Bao, L.; Deng, W.; Gao, H.; Xiao, C.; Liu, J.; Xue, J.; Lv, Q.; Liu, J.; Yu, P.; Xu, Y.; Qi, F.; Qu, Y.; Li, F.; Xiang, Z.; Yu, H.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Zhao, W.; Han, Y.; Zhao, L.; Liu, X.; Wei, Q.; Qin, C., Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. *bioRxiv* **2020**, 2020.03.13.990226.
<https://www.biorxiv.org/content/biorxiv/early/2020/03/14/2020.03.13.990226.full.pdf>
31. (U) Bao, L.; Deng, W.; Huang, B.; Gao, H.; Liu, J.; Ren, L.; Wei, Q.; Yu, P.; Xu, Y.; Qi, F.; Qu, Y.; Li, F.; Lv, Q.; Wang, W.; Xue, J.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Zhao, L.; Liu, P.; Zhao, L.; Ye, F.; Wang, H.; Zhou, W.; Zhu, N.; Zhen, W.; Yu, H.; Zhang, X.; Guo, L.; Chen, L.; Wang, C.; Wang, Y.; Wang, X.; Xiao, Y.; Sun, Q.; Liu, H.; Zhu, F.; Ma, C.; Yan, L.; Yang, M.; Han, J.; Xu, W.; Tan, W.; Peng, X.; Jin, Q.; Wu, G.; Qin, C., The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* **2020**.
32. (U) Bao, L.; Gao, H.; Deng, W.; Lv, Q.; Yu, H.; Liu, M.; Yu, P.; Liu, J.; Qu, Y.; Gong, S.; Lin, K.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Xue, J.; Song, Z.; Xiang, Z.; Wang, G.; Wang, S.; Liu, X.; Zhao, W.; Han, Y.; Wei, Q.; Qin, C., Transmission of SARS-CoV-2 via close contact and respiratory droplets among hACE2 mice. *The Journal of Infectious Diseases* **2020**. <https://doi.org/10.1093/infdis/jiaa281>
33. (U) BBC, Coronavirus: California declares emergency after death. *BBC* **2020**.
<https://www.bbc.com/news/world-us-canada-51740706>
34. (U) BBCNews, Coronavirus: AstraZeneca to begin making potential vaccine.
<https://www.bbc.com/news/business-52917118>.
35. (U) Bedford, T.; Neher, R., Genomic epidemiology of novel coronavirus (nCoV) using data from GISAID. <https://nextstrain.org/ncov>.
36. (U) Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C.; Hohmann, E.; Chu, H. Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R. W.; Dierberg, K.; Tapson, V.; Hsieh, L.; Patterson, T. F.; Paredes, R.; Sweeney, D. A.; Short, W. R.; Touloumi, G.; Lye, D. C.; Ohmagari, N.; Oh, M.-d.; Ruiz-Palacios, G. M.; Benfield, T.; Fätkenheuer, G.; Kortepeter, M. G.; Atmar, R. L.; Creech, C. B.; Lundgren, J.; Babiker, A. G.; Pett, S.; Neaton, J. D.; Burgess, T. H.; Bonnett, T.; Green, M.; Makowski, M.; Osinusi, A.; Nayak, S.; Lane, H. C., Remdesivir for the Treatment of Covid-19 — Preliminary Report. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2007764>
37. (U) Bendavid, E.; Mulaney, B.; Sood, N.; Shah, S.; Ling, E.; Bromley-Dulfano, R.; Lai, C.; Weissberg, Z.; Saavedra, R.; Tedrow, J.; Tversky, D.; Bogan, A.; Kupiec, T.; Eichner, D.; Gupta, R.; Ioannidis, J.; Bhattacharya, J., COVID-19 Antibody Seroprevalence in Santa Clara County, California. *medRxiv* **2020**, 2020.04.14.20062463.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/17/2020.04.14.20062463.full.pdf>

38. (U) Benucci, M.; Giannasi, G.; Cecchini, P.; Gobbi, F. L.; Damiani, A.; Grossi, V.; Infantino, M.; Manfredi, M., COVID-19 pneumonia treated with Sarilumab: a clinical series of eight patients. *J Med Virol* **2020**.
39. (U) Bessi re, F.; Rocchia, H.; Delini re, A.; Charri re, R.; Chevalier, P.; Argaud, L.; Cour, M., Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.1787>
40. (U) BGI, BGI Responds to Novel Coronavirus with Real-Time Detection Kits, Deploys Emergency Team to Wuhan. 2020. <https://www.bgi.com/global/company/news/bgi-responds-to-novel-coronavirus-with-real-time-detection-kits-deploys-emergency-team-to-wuhan/>
41. (U) Bhatia, S.; al., e., Short-term forecasts of COVID-19 deaths in multiple countries. <https://mrc-ide.github.io/covid19-short-term-forecasts/index.html#introduction>.
42. (U) Bi, Q.; Wu, Y.; Mei, S.; Ye, C.; Zou, X.; Zhang, Z.; Liu, X.; Wei, L.; Truelove, S. A.; Zhang, T.; Gao, W.; Cheng, C.; Tang, X.; Wu, X.; Wu, Y.; Sun, B.; Huang, S.; Sun, Y.; Zhang, J.; Ma, T.; Lessler, J.; Feng, T., Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* **2020**. [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30287-5/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30287-5/fulltext)
43. (U) Biotech, M., Mesa Biotech Receives Emergency Use Authorization from FDA for a 30 Minute Point of Care Molecular COVID-19 Test. Mesa Biotech: 2020. <https://www.mesabiotech.com/news/euacoronavirus>
44. (U) B hmer, M. M.; Buchholz, U.; Corman, V. M.; Hoch, M.; Katz, K.; Marosevic, D. V.; B hm, S.; Woudenberg, T.; Ackermann, N.; Konrad, R.; Eberle, U.; Treis, B.; Dangel, A.; Bengs, K.; Fingerle, V.; Berger, A.; H rmansdorfer, S.; Ippisch, S.; Wicklein, B.; Grahl, A.; P rtner, K.; Muller, N.; Zeitlmann, N.; Boender, T. S.; Cai, W.; Reich, A.; An der Heiden, M.; Rexroth, U.; Hamouda, O.; Schneider, J.; Veith, T.; M hlemann, B.; W lfel, R.; Antwerpen, M.; Walter, M.; Protzer, U.; Liebl, B.; Haas, W.; Sing, A.; Drosten, C.; Zapf, A., Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *The Lancet. Infectious diseases* **2020**, S1473-3099(20)30314-5. <https://pubmed.ncbi.nlm.nih.gov/32422201>
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228725/>
45. (U) Borba, M. G. S.; Val, F. F. A.; Sampaio, V. S.; Alexandre, M. A. A.; Melo, G. C.; Brito, M.; Mour o, M. P. G.; Brito-Sousa, J. D.; Ba a-da-Silva, D.; Guerra, M. V. F.; Hajjar, L. A.; Pinto, R. C.; Balieiro, A. A. S.; Pacheco, A. G. F.; Santos, J. D. O., Jr; Naveca, F. G.; Xavier, M. S.; Siqueira, A. M.; Schwarzbold, A.; Croda, J.; Nogueira, M. L.; Romero, G. A. S.; Bassat, Q.; Fontes, C. J.; Albuquerque, B. C.; Daniel-Ribeiro, C.-T.; Monteiro, W. M.; Lacerda, M. V. G.; Team, f. t. C.-. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Network Open* **2020**, 3 (4), e208857-e208857. <https://doi.org/10.1001/jamanetworkopen.2020.8857>
46. (U) Bosco-Lauth, A. M.; Hartwig, A. E.; Porter, S. M.; Gordy, P. W.; Nehring, M.; Byas, A. D.; VandeWoude, S.; Ragan, I. K.; Maison, R. M.; Bowen, R. A., Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats. *bioRxiv* **2020**, 2020.05.28.120998. <http://biorxiv.org/content/early/2020/05/29/2020.05.28.120998.abstract>
47. (U) Bouaziz, J.; Duong, T.; Jachiet, M.; Velter, C.; Lestang, P.; Cassius, C.; Arsouze, A.; Domergue Than Trong, E.; Bagot, M.; Begon, E.; Sulimovic, L.; Rybojad, M., Vascular skin symptoms in COVID-19: a french observational study. *Journal of the European Academy of Dermatology and Venereology n/a* (n/a). <https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16544>
48. (U) Boulware, D. R.; Pullen, M. F.; Bangdiwala, A. S.; Pastick, K. A.; Lofgren, S. M.; Okafor, E. C.; Skipper, C. P.; Nascene, A. A.; Nicol, M. R.; Abassi, M.; Engen, N. W.; Cheng, M. P.; LaBar, D.; Lother, S.

- A.; MacKenzie, L. J.; Drobot, G.; Marten, N.; Zarychanski, R.; Kelly, L. E.; Schwartz, I. S.; McDonald, E. G.; Rajasingham, R.; Lee, T. C.; Hullsiek, K. H., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMoa2016638>
49. (U) Branswell, H., Sanofi announces it will work with HHS to develop a coronavirus vaccine. Statnews, Ed. 2020. <https://www.statnews.com/2020/02/18/sanofi-announces-it-will-work-with-hhs-to-develop-coronavirus-vaccine/>
50. (U) Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Kurth, F.; Hippenstiel, S.; Dingeldey, M.; Kruse, B.; Fauchere, F.; Baysal, E.; Mangold, M.; Henze, L.; Lauster, R.; Mall, M.; Beyer, K.; Roehmel, J.; Schmitz, J.; Miltenyi, S.; Mueller, M. A.; Witzernath, M.; Suttorp, N.; Kern, F.; Reimer, U.; Wenschuh, H.; Drosten, C.; Corman, V. M.; Giesecke-Thiel, C.; Sander, L.-E.; Thiel, A., Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. *medRxiv* **2020**, 2020.04.17.20061440.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.17.20061440.full.pdf>
51. (U) Brennan, Z., FDA issues 2nd EUA for decontamination system for N95 masks. *Regulatory Focus* 2020. <https://www.raps.org/news-and-articles/news-articles/2020/4/fda-issues-2nd-eua-for-decontamination-system-for>
52. (U) Brosseau, L. M., COMMENTARY: COVID-19 transmission messages should hinge on science. <http://www.cidrap.umn.edu/news-perspective/2020/03/commentary-covid-19-transmission-messages-should-hinge-science>.
53. (U) Brosseau, L. M.; Jones, R., Commentary: Protecting health workers from airborne MERS-CoV - learning from SARS. <http://www.cidrap.umn.edu/news-perspective/2014/05/commentary-protecting-health-workers-airborne-mers-cov-learning-sars>.
54. (U) Bryner, J., First US infant death linked to COVID-19 reported in Illinois. *LiveScience* 2020. <https://www.livescience.com/us-infant-dies-coronavirus.html>
55. (U) Burbelo, P. D.; Riedo, F. X.; Morishima, C.; Rawlings, S.; Smith, D.; Das, S.; Strich, J. R.; Chertow, D. S.; Davey, R. T.; Cohen, J. I., Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients. *J Infect Dis* **2020**.
56. (U) Burrer, S. L.; de Perio, M. A.; Hughes, M. M.; Kuhar, D. T.; Luckhaupt, S. E.; McDaniel, C. J.; Porter, R. M.; Silk, B.; Stuckey, M. J.; Walters, M., Characteristics of health care personnel with COVID-19—United States, February 12–April 9, 2020. **2020**.
57. (U) Cagliani, R.; Forni, D.; Clerici, M.; Sironi, M., Computational inference of selection underlying the evolution of the novel coronavirus, SARS-CoV-2. *J Virol* **2020**.
58. (U) Cagliani, R.; Forni, D.; Clerici, M.; Sironi, M., Computational inference of selection underlying the evolution of the novel coronavirus, SARS-CoV-2. *Journal of Virology* **2020**, JVI.00411-20.
<https://jvi.asm.org/content/jvi/early/2020/03/27/JVI.00411-20.full.pdf>
59. (U) Callow, K.; Parry, H.; Sergeant, M.; Tyrrell, D., The time course of the immune response to experimental coronavirus infection of man. *Epidemiology & Infection* **1990**, 105 (2), 435-446.
60. (U) Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMoa2001282>
61. (U) Cao, W.; Liu, X.; Bai, T.; Fan, H.; Hong, K.; Song, H.; Han, Y.; Lin, L.; Ruan, L.; Li, T., High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. *Open Forum Infectious Diseases* **2020**. <https://doi.org/10.1093/ofid/ofaa102>

62. (U) Cao, Y.; Wei, J.; Zou, L.; Jiang, T.; Wang, G.; Chen, L.; Huang, L.; Meng, F.; Huang, L.; Wang, N.; Zhou, X.; Luo, H.; Mao, Z.; Chen, X.; Xie, J.; Liu, J.; Cheng, H.; Zhao, J.; Huang, G.; Wang, W.; Zhou, J., Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. *Journal of Allergy and Clinical Immunology* **2020**.
<http://www.sciencedirect.com/science/article/pii/S0091674920307387>
63. (U) Casadevall, A.; Pirofski, L.-a., The convalescent sera option for containing COVID-19. *The Journal of Clinical Investigation* **2020**, *130* (4). <https://doi.org/10.1172/JCI138003>
64. (U) Casanova, L. M.; Jeon, S.; Rutala, W. A.; Weber, D. J.; Sobsey, M. D., Effects of air temperature and relative humidity on coronavirus survival on surfaces. *Applied and environmental microbiology* **2010**, *76* (9), 2712-2717. <https://www.ncbi.nlm.nih.gov/pubmed/20228108>
65. (U) Casey, M.; Griffin, J.; McAloon, C. G.; Byrne, A. W.; Madden, J. M.; McEvoy, D.; Collins, A. B.; Hunt, K.; Barber, A.; Butler, F.; Lane, E. A.; O'Brien, K.; Wall, P.; Walsh, K. A.; More, S. J., Estimating pre-symptomatic transmission of COVID-19: a secondary analysis using published data. *medRxiv* **2020**, 2020.05.08.20094870.
<https://www.medrxiv.org/content/medrxiv/early/2020/05/11/2020.05.08.20094870.full.pdf>
66. (U) CDC, 2019 Novel Coronavirus RT-PCR Identification Protocols.
<https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html>.
67. (U) CDC, CDC launches national viral genomics consortium to better map SARS-CoV-2 transmission. Centers for Disease Control and Prevention: 2020. <https://www.cdc.gov/media/releases/2020/p0501-SARS-CoV-2-transmission-map.html>
68. (U) CDC, Confirmation of COVID-19 in Two Pet Cats in New York. Centers for Disease Control and Prevention: 2020. <https://www.cdc.gov/media/releases/2020/s0422-covid-19-cats-NYC.html>
69. (U) CDC, Confirmed 2019-nCoV Cases Globally. <https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html>.
70. (U) CDC, COVID-19 Forecasts. <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/forecasting-us.html>.
71. (U) CDC, Interim healthcare infection prevention and control recommendations for patients under investigation for 2019 novel coronavirus. <https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html>.
72. (U) CDC, Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. **2020**. <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html>
73. (U) CDC, Situation summary. <https://www.cdc.gov/coronavirus/2019-nCoV/summary.html>.
74. (U) CDC, Symptoms of Coronavirus. <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>.
75. (U) CDC, C., China's CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html (accessed 01/27/2020).
76. (U) CEID, Nowcasts for the US, states, and territories. <http://2019-coronavirus-tracker.com/nowcast.html>.
77. (U) Ceraolo, C.; Giorgi, F. M., Genomic variance of the 2019-nCoV coronavirus. *J Med Virol* **2020**, *92* (5), 522-528.
78. (U) Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.; Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; Yuen, K.-Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* **2020**. <https://www.sciencedirect.com/science/article/pii/S0140673620301549>

79. (U) Chan, J. F.; Zhang, A. J.; Yuan, S.; Poon, V. K.; Chan, C. C.; Lee, A. C.; Chan, W. M.; Fan, Z.; Tsoi, H. W.; Wen, L.; Liang, R.; Cao, J.; Chen, Y.; Tang, K.; Luo, C.; Cai, J. P.; Kok, K. H.; Chu, H.; Chan, K. H.; Sridhar, S.; Chen, Z.; Chen, H.; To, K. K.; Yuen, K. Y., Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clin Infect Dis* **2020**.
<https://www.ncbi.nlm.nih.gov/pubmed/32215622>
80. (U) Chan, K. H.; Peiris, J. S.; Lam, S. Y.; Poon, L. L.; Yuen, K. Y.; Seto, W. H., The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus. *Adv Virol* **2011**, *2011*, 734690.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265313/pdf/AV2011-734690.pdf>
81. (U) Chandrashekar, A.; Liu, J.; Martinot, A. J.; McMahan, K.; Mercado, N. B.; Peter, L.; Tostanoski, L. H.; Yu, J.; Maliga, Z.; Nekorchuk, M.; Busman-Sahay, K.; Terry, M.; Wrijil, L. M.; Ducat, S.; Martinez, D. R.; Atyeo, C.; Fischinger, S.; Burke, J. S.; Slein, M. D.; Pessaint, L.; Van Ry, A.; Greenhouse, J.; Taylor, T.; Blade, K.; Cook, A.; Finneyfrock, B.; Brown, R.; Teow, E.; Velasco, J.; Zahn, R.; Wegmann, F.; Abbink, P.; Bondzie, E. A.; Dagotto, G.; Gebre, M. S.; He, X.; Jacob-Dolan, C.; Kordana, N.; Li, Z.; Lifton, M. A.; Mahrokhian, S. H.; Maxfield, L. F.; Nityanandam, R.; Nkolola, J. P.; Schmidt, A. G.; Miller, A. D.; Baric, R. S.; Alter, G.; Sorger, P. K.; Estes, J. D.; Andersen, H.; Lewis, M. G.; Barouch, D. H., SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science* **2020**, eabc4776.
<https://science.sciencemag.org/content/sci/early/2020/05/19/science.abc4776.full.pdf>
82. (U) Changzheng, L. J. L., Experts in the medical treatment team: Wuhan's unexplained viral pneumonia patients can be controlled more. <https://www.cn-healthcare.com/article/20200110/content-528579.html>.
83. (U) Chen, C.; Cao, M.; Peng, L.; Guo, X.; Yang, F.; Wu, W.; Chen, L.; Yang, Y.; Liu, Y.; Wang, F., Coronavirus Disease-19 Among Children Outside Wuhan, China. *SSRN* **2020**.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546071
84. (U) Chen, C.; Huang, J.; Cheng, Z.; Wu, J.; Chen, S.; Zhang, Y.; Chen, B.; Lu, M.; Luo, Y.; Zhang, J.; Yin, P.; Wang, X., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. *medRxiv* **2020**, 2020.03.17.20037432.
<https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.17.20037432.full.pdf>
85. (U) Chen, H.; Guo, J.; Wang, C.; Luo, F.; Yu, X.; Zhang, W.; Li, J.; Zhao, D.; Xu, D.; Gong, Q., Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *The Lancet* **2020**, *395* (10226), 809-815.
86. (U) Chen, J. H.-K.; Yip, C. C.-Y.; Poon, R. W.-S.; Chan, K.-H.; Cheng, V. C.-C.; Hung, I. F.-N.; Chan, J. F.-W.; Yuen, K.-Y.; To, K. K.-W., Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. *Emerging Microbes & Infections* **2020**, 1-14.
<https://doi.org/10.1080/22221751.2020.1775133>
87. (U) CHEN Jun, L. D., LIU Li, LIU Ping, XU Qingnian, XIA Lu, LING Yun, HUANG Dan, SONG Shuli, ZHANG Dandan, QIAN Zhiping, LI Tao, SHEN Yinzong, LU Hongzhou, A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. *J Zhejiang Univ (Med Sci)* **2020**, *49* (2), 215-219.
<http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03>
88. (U) Chen, L.; Li, Q.; Zheng, D.; Jiang, H.; Wei, Y.; Zou, L.; Feng, L.; Xiong, G.; Sun, G.; Wang, H.; Zhao, Y.; Qiao, J., Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2009226>
89. (U) Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **2020**.
<https://www.ncbi.nlm.nih.gov/pubmed/32007143>

90. (U) Chen, Y.; Peng, H.; Wang, L.; Zhao, Y.; Zeng, L.; Gao, H.; Liu, Y., Infants Born to Mothers With a New Coronavirus (COVID-19). *Frontiers in Pediatrics* **2020**, *8* (104).
<https://www.frontiersin.org/article/10.3389/fped.2020.00104>
91. (U) Chen, Z.; Hu, J.; Zhang, Z.; Jiang, S.; Han, S.; Yan, D.; Zhuang, R.; Hu, B.; Zhang, Z., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv* **2020**, 2020.03.22.20040758.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/10/2020.03.22.20040758.full.pdf>
92. (U) Cheng, H.-Y.; Jian, S.-W.; Liu, D.-P.; Ng, T.-C.; Huang, W.-T.; Lin, H.-H.; Team, f. t. T. C.-O. I., Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Internal Medicine* **2020**.
<https://doi.org/10.1001/jamainternmed.2020.2020>
93. (U) Cheruiyot, I.; Henry, B. M.; Lippi, G., Is there evidence of intra-uterine vertical transmission potential of COVID-19 infection in samples tested by quantitative RT-PCR? *Eur J Obstet Gynecol Reprod Biol* **2020**.
94. (U) Chhatwal, J.; Ayer, T.; Linas, B. P. D., O. O.; Mueller, P.; Adey, M.; Ladd, M. A.; Xiao, J. Y. X., COVID-19. <https://www.covid19sim.org/>.
95. (U) Chicago, Forecasting for Illinois SARS-CoV-2 model.
https://github.com/cobeylab/covid_IL/tree/master/Forecasting.
96. (U) Chin, A.; Chu, J.; Perera, M.; Hui, K.; Yen, H.-L.; Chan, M.; Peiris, M.; Poon, L., Stability of SARS-CoV-2 in different environmental conditions. *medRxiv* **2020**, 2020.03.15.20036673.
<https://www.medrxiv.org/content/medrxiv/early/2020/03/27/2020.03.15.20036673.full.pdf>
97. (U) Chin, A. W. H.; Chu, J. T. S.; Perera, M. R. A.; Hui, K. P. Y.; Yen, H.-L.; Chan, M. C. W.; Peiris, M.; Poon, L. L. M., Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe*.
[https://doi.org/10.1016/S2666-5247\(20\)30003-3](https://doi.org/10.1016/S2666-5247(20)30003-3)
98. (U) Chong, V. H.; Chong, P. L.; Metussin, D.; Asli, R.; Momin, R. N.; Mani, B. I.; Abdullah, M. S., Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19. *J Med Virol* **2020**.
99. (U) Chu, D. K.; Akl, E. A.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H. J.; Chu, D. K.; Akl, E. A.; El-harakeh, A.; Bognanni, A.; Lotfi, T.; Loeb, M.; Hajizadeh, A.; Bak, A.; Izcovich, A.; Cuello-Garcia, C. A.; Chen, C.; Harris, D. J.; Borowiack, E.; Chamseddine, F.; Schünemann, F.; Morgano, G. P.; Muti Schünemann, G. E. U.; Chen, G.; Zhao, H.; Neumann, I.; Chan, J.; Khabisa, J.; Hneiny, L.; Harrison, L.; Smith, M.; Rizk, N.; Giorgi Rossi, P.; AbiHanna, P.; El-khoury, R.; Stalteri, R.; Baldeh, T.; Piggott, T.; Zhang, Y.; Saad, Z.; Khamis, A.; Reinap, M.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H. J., Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)31142-9](https://doi.org/10.1016/S0140-6736(20)31142-9)
100. (U) Chughtai, A. A.; Seale, H.; MacIntyre, C. R., Use of cloth masks in the practice of infection control—evidence and policy gaps. *Int J Infect Control* **2013**, *9* (3), doi: 10.3396/IJIC.v9i3.020.13.
101. (U) Cockrell, A. S.; Yount, B. L.; Scobey, T.; Jensen, K.; Douglas, M.; Beall, A.; Tang, X.-C.; Marasco, W. A.; Heise, M. T.; Baric, R. S., A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nature microbiology* **2016**, *2* (2), 1-11.
102. (U) Cohen, J., COVID-19 vaccine protects monkeys from new coronavirus, Chinese biotech reports. *Science* 2020. <https://www.sciencemag.org/news/2020/04/covid-19-vaccine-protects-monkeys-new-coronavirus-chinese-biotech-reports>
103. (U) Cohen, J., Mining coronavirus genomes for clues to the outbreak's origins. *Science* 2020.
<https://www.sciencemag.org/news/2020/01/mining-coronavirus-genomes-clues-outbreak-s-origins>

104. (U) Cohen, J., Wuhan seafood market may not be source of novel virus spreading globally. <https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally> (accessed 01/27/2020).
105. (U) Control, E. E. C. f. D. P. a., *Interim guidance for environmental cleaning in non-healthcare facilities exposed to SARS-CoV-2*; European Centre for Disease Prevention and Control: European Centre for Disease Prevention and Control, 2020. <https://www.ecdc.europa.eu/en/publications-data/interim-guidance-environmental-cleaning-non-healthcare-facilities-exposed-2019#no-link>
106. (U) Corman, V. M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D. K.; Bleicker, T.; Brunink, S.; Schneider, J.; Schmidt, M. L.; Mulders, D. G.; Haagmans, B. L.; van der Veer, B.; van den Brink, S.; Wijsman, L.; Goderski, G.; Romette, J. L.; Ellis, J.; Zambon, M.; Peiris, M.; Goossens, H.; Reusken, C.; Koopmans, M. P.; Drosten, C., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* **2020**, 25 (3). <https://www.ncbi.nlm.nih.gov/pubmed/31992387>
107. (U) Courtemanche, C.; Garuccio, J.; Le, A.; Pinkston, J.; Yelowitz, A., Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate. *Health Affairs* **2020**, 10.1377/hlthaff.2020.00608. <https://doi.org/10.1377/hlthaff.2020.00608>
108. (U) Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.; Decroly, E., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral research* **2020**, 176, 104742.
109. (U) Cowling, B. J.; Ali, S. T.; Ng, T. W. Y.; Tsang, T. K.; Li, J. C. M.; Fong, M. W.; Liao, Q.; Kwan, M. Y.; Lee, S. L.; Chiu, S. S.; Wu, J. T.; Wu, P.; Leung, G. M., Impact assessment of non-pharmaceutical interventions against COVID-19 and influenza in Hong Kong: an observational study. *medRxiv* **2020**, 2020.03.12.20034660. <https://www.medrxiv.org/content/medrxiv/early/2020/03/16/2020.03.12.20034660.full.pdf>
110. (U) Creel-Bulos, C.; Hockstein, M.; Amin, N.; Melhem, S.; Truong, A.; Sharifpour, M., Acute Cor Pulmonale in Critically Ill Patients with Covid-19. *New England Journal of Medicine* **2020**, e70. <https://www.nejm.org/doi/full/10.1056/NEJMc2010459>
111. (U) Daily, H., Wuhan Institute of Virology, Chinese Academy of Sciences and others have found that 3 drugs have a good inhibitory effect on new coronavirus. Chen, L., Ed. 2020. http://news.cnhubei.com/content/2020-01/28/content_12656365.html
112. (U) Dandekar, R.; Barbastathis, G., Neural Network aided quarantine control model estimation of global Covid-19 spread. *arXiv preprint arXiv:2004.02752* **2020**.
113. (U) Dato, V. M.; Hostler, D.; Hahn, M. E., Simple respiratory mask. *Emerg Infect Dis* **2006**, 12 (6), 1033-4. <https://www.ncbi.nlm.nih.gov/pubmed/16752475>
114. (U) Davies, A.; Thompson, K. A.; Giri, K.; Kafatos, G.; Walker, J.; Bennett, A., Testing the efficacy of homemade masks: would they protect in an influenza pandemic? *Disaster Med Public Health Prep* **2013**, 7 (4), 413-8. <https://www.ncbi.nlm.nih.gov/pubmed/24229526>
115. (U) Davoudi-Monfared, E.; Rahmani, H.; Khalili, H.; Hajiabdolbaghi, M.; Salehi, M.; Abbasian, L.; Kazemzadeh, H.; Yekaninejad, M. S., Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial. *medRxiv* **2020**, 2020.05.28.20116467. <https://www.medrxiv.org/content/medrxiv/early/2020/05/30/2020.05.28.20116467.full.pdf>
116. (U) De Albuquerque, N.; Baig, E.; Ma, X.; Zhang, J.; He, W.; Rowe, A.; Habal, M.; Liu, M.; Shalev, I.; Downey, G. P.; Gorczynski, R.; Butany, J.; Leibowitz, J.; Weiss, S. R.; McGilvray, I. D.; Phillips, M. J.; Fish, E. N.; Levy, G. A., Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. *J Virol* **2006**, 80 (21), 10382-94. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1641767/pdf/0747-06.pdf>
117. (U) de Haan, C. A. M.; Haijema, B. J.; Schellen, P.; Schreur, P. W.; te Lintelo, E.; Vennema, H.; Rottier, P. J. M., Cleavage of Group 1 Coronavirus Spike Proteins: How Furin Cleavage Is Traded Off

- against Heparan Sulfate Binding upon Cell Culture Adaptation. *Journal of Virology* **2008**, *82* (12), 6078-6083. <https://jvi.asm.org/content/jvi/82/12/6078.full.pdf>
118. (U) Dediego, M. L.; Pewe, L.; Alvarez, E.; Rejas, M. T.; Perlman, S.; Enjuanes, L., Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology* **2008**, *376* (2), 379-389. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810402/>
119. (U) Degesys, N. F.; Wang, R. C.; Kwan, E.; Fahimi, J.; Noble, J. A.; Raven, M. C., Correlation Between N95 Extended Use and Reuse and Fit Failure in an Emergency Department. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.9843>
120. (U) Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Liu, X.; Zhao, W.; Han, Y.; Qin, C., Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques. *bioRxiv* **2020**.
121. (U) Deslandes, A.; Berti, V.; Tandjaoui-Lambotte, Y.; Alloui, C.; Carbonnelle, E.; Zahar, J. R.; Briclher, S.; Cohen, Y., SARS-CoV-2 was already spreading in France in late December 2019. *International Journal of Antimicrobial Agents* **2020**, 106006. <http://www.sciencedirect.com/science/article/pii/S0924857920301643>
122. (U) DHS, Estimated Natural Decay of SARS-CoV-2 (virus that causes COVID-19) on surfaces under a range of temperatures and relative humidity. <https://www.dhs.gov/science-and-technology/sars-calculator>.
123. (U) Dong, N.; Yang, X.; Ye, L.; Chen, K.; Chan, E. W.-C.; Yang, M.; Chen, S., Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. *bioRxiv* **2020**, 2020.01.20.913368. <https://www.biorxiv.org/content/biorxiv/early/2020/01/22/2020.01.20.913368.full.pdf>
124. (U) Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S., Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. *Pediatrics* **2020**, e20200702. <https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.pdf>
125. (U) Du, Z.; Xu, x.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., COVID-19 serial interval estimates based on confirmed cases in public reports from 86 Chinese cities. *medRxiv* **2020**, 2020.04.23.20075796. <https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20075796.full.pdf>
126. (U) Du, Z.; Xu, X.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., The serial interval of COVID-19 from publicly reported confirmed cases. *medRxiv* **2020**, 2020.02.19.20025452. <https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.02.19.20025452.full.pdf>
127. (U) Duan, S.; Zhao, X.; Wen, R.; Huang, J.-j.; Pi, G.; Zhang, S.; Han, J.; Bi, S.; Ruan, L.; Dong, X.-p., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomedical and environmental sciences: BES* **2003**, *16* (3), 246-255.
128. (U) Duan, S. M.; Zhao, X. S.; Wen, R. F.; Huang, J. J.; Pi, G. H.; Zhang, S. X.; Han, J.; Bi, S. L.; Ruan, L.; Dong, X. P., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomed Environ Sci* **2003**, *16* (3), 246-55.
129. (U) Endeman, H.; van der Zee, P.; van Genderen, M. E.; van den Akker, J. P. C.; Gommers, D., Progressive respiratory failure in COVID-19: a hypothesis. *The Lancet Infectious Diseases* **2020**. [https://doi.org/10.1016/S1473-3099\(20\)30366-2](https://doi.org/10.1016/S1473-3099(20)30366-2)
130. (U) EuroTimes, Pfizer/BioNTech target April vaccine trial launch. *EuroTimes* **2020**. <https://www.eurotimes.org/pfizer-biontech-target-april-vaccine-trial-launch/>
131. (U) FDA, *Emergency Use Authorization*; Food and Drug Administration: 2020. <https://www.fda.gov/media/136529/download>

132. (U) FDA, FAQs on Shortages of Surgical Masks and Gowns. <https://www.fda.gov/medical-devices/personal-protective-equipment-infection-control/faqs-shortages-surgical-masks-and-gowns#kn95>.
133. (U) FDA, FAQs on Testing for SARS-CoV-2. <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-testing-sars-cov-2#nolonger>.
134. (U) FDA, *ID NOW COVID-19*; Food and Drug Administration: 2020. <https://www.fda.gov/media/136525/download>
135. (U) FDA, *Investigational COVID-19 Convalescent Plasma - Emergency INDs*; Food and Drug Administration: 2020. <https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-ind>
136. (U) FDA, Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency; Immediately in Effect Guidance for Industry and Food and Drug Administration Staff. 2020. <https://www.regulations.gov/docket?D=FDA-2020-D-0987>
137. (U) FDA, Respirator Models Removed from Appendix A. <https://www.fda.gov/media/137928/download> (accessed 05/15/2020).
138. (U) Feldman, O.; Meir, M.; Shavit, D.; Idelman, R.; Shavit, I., Exposure to a Surrogate Measure of Contamination From Simulated Patients by Emergency Department Personnel Wearing Personal Protective Equipment. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.6633>
139. (U) Ferguson, N.; Laydon, D.; Nedjati-Gilani, G.; Imai, N.; Ainslie, K.; Baguelin, M.; Bhatia, S.; Boonyasiri, A.; Cucunuba, Z.; Cuomo-Dannenburg, G.; Dighe, A.; Dorigatti, I.; Fu, H.; Gaythorpe, K.; Green, W.; Hamlet, A.; Hinsley, W.; Okell, L.; van Elsland, S.; Thompson, H.; Verity, R.; Volz, E.; Wang, H.; Wang, Y.; Walker, P.; Walters, C.; Winskill, P.; Whittaker, C.; Donnelly, C.; Riley, S.; Ghani, A., *Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand*; 2020. <https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf>
140. (U) Firth, J. A.; Hellewell, J.; Klepac, P.; Kissler, S. M.; Group, C. C.-W.; Kucharski, A. J.; Spurgin, L. G., Combining fine-scale social contact data with epidemic modelling reveals interactions between contact tracing, quarantine, testing and physical distancing for controlling COVID-19. *Preprint* **2020**. https://cmmid.github.io/topics/covid19/reports/2020_05_25_firth_et_al_manuscript.pdf
141. (U) Fischer, R.; Morris, D. H.; van Doremalen, N.; Sarchette, S.; Matson, J.; Bushmaker, T.; Yinda, C. K.; Seifert, S.; Gamble, A.; Williamson, B.; Judson, S.; de Wit, E.; Lloyd-Smith, J.; Munster, V., Assessment of N95 respirator decontamination and re-use for SARS-CoV-2. *medRxiv* **2020**, 2020.04.11.20062018. <https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.11.20062018.full.pdf>
142. (U) Fitzpatrick, J.; DeSalvo, K., Helping public health officials combat COVID-19. Google: 2020. <https://www.blog.google/technology/health/covid-19-community-mobility-reports?hl=en>
143. (U) Flahault, A.; Manetti, E.; Simonson, T.; Lee, G.; Choirat, C., COVID-19 Forecasting. https://renkulab.shinyapps.io/COVID-19-Epidemic-Forecasting/_w_e0463e1e/#shiny-tab-about.
144. (U) Flaxman, S.; Mishra, S.; Gandy, A.; Unwin, H. J. T.; Mellan, T. A.; Coupland, H.; Whittaker, C.; Zhu, H.; Berah, T.; Eaton, J. W.; Monod, M.; Perez-Guzman, P. N.; Schmit, N.; Cilloni, L.; Ainslie, K. E. C.; Baguelin, M.; Boonyasiri, A.; Boyd, O.; Cattarino, L.; Cooper, L. V.; Cucunubá, Z.; Cuomo-Dannenburg, G.; Dighe, A.; Djaafara, B.; Dorigatti, I.; van Elsland, S. L.; FitzJohn, R. G.; Gaythorpe, K. A. M.; Geidelberg, L.; Grassly, N. C.; Green, W. D.; Hallett, T.; Hamlet, A.; Hinsley, W.; Jeffrey, B.; Knock, E.; Laydon, D. J.; Nedjati-Gilani, G.; Nouvellet, P.; Parag, K. V.; Siveroni, I.; Thompson, H. A.; Verity, R.; Volz, E.; Walters, C. E.; Wang, H.; Wang, Y.; Watson, O. J.; Winskill, P.; Xi, X.; Walker, P. G. T.; Ghani, A. C.; Donnelly, C. A.; Riley, S. M.; Vollmer, M. A. C.; Ferguson, N. M.; Okell, L. C.; Bhatt, S.; Imperial College, C.-R. T., Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2405-7>

145. (U) Forster, P.; Forster, L.; Renfrew, C.; Forster, M., Phylogenetic network analysis of SARS-CoV-2 genomes. *Proceedings of the National Academy of Sciences* **2020**, *117* (17), 9241-9243.
<https://www.pnas.org/content/pnas/117/17/9241.full.pdf>
146. (U) Frank, H. K.; Enard, D.; Boyd, S. D., Exceptional diversity and selection pressure on SARS-CoV and SARS-CoV-2 host receptor in bats compared to other mammals. *bioRxiv* **2020**, 2020.04.20.051656.
<https://www.biorxiv.org/content/biorxiv/early/2020/04/20/2020.04.20.051656.full.pdf>
147. (U) Friedrich-Loeffler-Institute, Novel Coronavirus SARS-CoV-2: Fruit bats and ferrets are susceptible, pigs and chickens are not. <https://www.fli.de/en/press/press-releases/press-singleview/novel-coronavirus-sars-cov-2-fruit-bats-and-ferrets-are-susceptible-pigs-and-chickens-are-not/>.
148. (U) Gao, Q.; Bao, L.; Mao, H.; Wang, L.; Xu, K.; Yang, M.; Li, Y.; Zhu, L.; Wang, N.; Lv, Z.; Gao, H.; Ge, X.; Kan, B.; Hu, Y.; Liu, J.; Cai, F.; Jiang, D.; Yin, Y.; Qin, C.; Li, J.; Gong, X.; Lou, X.; Shi, W.; Wu, D.; Zhang, H.; Zhu, L.; Deng, W.; Li, Y.; Lu, J.; Li, C.; Wang, X.; Yin, W.; Zhang, Y.; Qin, C., Rapid development of an inactivated vaccine for SARS-CoV-2. *bioRxiv* **2020**, 2020.04.17.046375.
<https://www.biorxiv.org/content/biorxiv/early/2020/04/19/2020.04.17.046375.full.pdf>
149. (U) Garg, S., Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020**, *69*.
150. (U) Gatto, M.; Bertuzzo, E.; Mari, L.; Miccoli, S.; Carraro, L.; Casagrandi, R.; Rinaldo, A., Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures. *Proceedings of the National Academy of Sciences* **2020**, 202004978.
<https://www.pnas.org/content/pnas/early/2020/04/22/2004978117.full.pdf>
151. (U) Gautret, P.; Lagier, J.-C.; Parola, P.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V. E.; Dupont, H. T., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents* **2020**, 105949.
152. (U) Geleris, J.; Sun, Y.; Platt, J.; Zucker, J.; Baldwin, M.; Hripcsak, G.; Labella, A.; Manson, D.; Kubin, C.; Barr, R. G.; Sobieszczyk, M. E.; Schluger, N. W., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMoa2012410>
153. (U) Gendelman, O.; Amital, H.; Bragazzi, N. L.; Watad, A.; Chodick, G., Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. *Autoimmunity Reviews* **2020**, 102566.
<http://www.sciencedirect.com/science/article/pii/S1568997220301282>
154. (U) Gérard, A.; Romani, S.; Fresse, A.; Viard, D.; Parassol, N.; Granvullemin, A.; Chouchana, L.; Rocher, F.; Drici, M.-D., “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. *Therapies* **2020**.
<http://www.sciencedirect.com/science/article/pii/S0040595720300913>
155. (U) GitHub Inc., Reproducible analyses for rejecting rare genomic inversions in SARS-CoV-2. https://github.com/alexcrtschristoph/sars_cov_2_inversion (accessed 04 April).
156. (U) Godoy, M., Mystery Inflammatory Syndrome In Kids And Teens Likely Linked To COVID-19. *NPR* 2020. <https://www.npr.org/sections/health-shots/2020/05/07/851725443/mystery-inflammatory-syndrome-in-kids-and-teens-likely-linked-to-covid-19>
157. (U) Goldman, J. D.; Lye, D. C. B.; Hui, D. S.; Marks, K. M.; Bruno, R.; Montejano, R.; Spinner, C. D.; Galli, M.; Ahn, M. Y.; Nahass, R. G.; Chen, Y. S.; SenGupta, D.; Hyland, R. H.; Osinusi, A. O.; Cao, H.; Blair, C.; Wei, X.; Gaggar, A.; Brainard, D. M.; Towner, W. J.; Muñoz, J.; Mullane, K. M.; Marty, F. M.; Tashima,

- K. T.; Diaz, G.; Subramanian, A., Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *N Engl J Med* **2020**.
158. (U) Goren, A.; Vaño-Galván, S.; Wambier, C. G.; McCoy, J.; Gomez-Zubiaur, A.; Moreno-Arrones, O. M.; Shapiro, J.; Sinclair, R. D.; Gold, M. H.; Kovacevic, M.; Mesinkovska, N. A.; Goldust, M.; Washenik, K., A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain – A potential clue to the role of androgens in COVID-19 severity. *Journal of Cosmetic Dermatology n/a (n/a)*. <https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.13443>
159. (U) Goyal, P.; Choi, J. J.; Pinheiro, L. C.; Schenck, E. J.; Chen, R.; Jabri, A.; Satlin, M. J.; Campion, T. R.; Nahid, M.; Ringel, J. B.; Hoffman, K. L.; Alshak, M. N.; Li, H. A.; Wehmeyer, G. T.; Rajan, M.; Reshetnyak, E.; Hupert, N.; Horn, E. M.; Martinez, F. J.; Gulick, R. M.; Safford, M. M., Clinical Characteristics of Covid-19 in New York City. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2010419>
160. (U) Grifoni, A.; Weiskopf, D.; Ramirez, S. I.; Mateus, J.; Dan, J. M.; Moderbacher, C. R.; Rawlings, S. A.; Sutherland, A.; Premkumar, L.; Jadi, R. S., Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell* **1920**.
161. (U) Gu, Y., COVID-19 Projections Using Machine Learning. <https://covid19-projections.com/#view-projections>.
162. (U) Guan, L.; Zhou, L.; Zhang, J.; Peng, W.; Chen, R., More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. *European Respiratory Journal* **2020**, *55* (3), 2000352. <https://erj.ersjournals.com/content/erj/55/3/2000352.full.pdf>
163. (U) Guan, W.-j.; Ni, Z.-y.; Hu, Y.; Liang, W.-h.; Ou, C.-q.; He, J.-x.; Liu, L.; Shan, H.; Lei, C.-l.; Hui, D. S. C.; Du, B.; Li, L.-j.; Zeng, G.; Yuen, K.-Y.; Chen, R.-c.; Tang, C.-l.; Wang, T.; Chen, P.-y.; Xiang, J.; Li, S.-y.; Wang, J.-l.; Liang, Z.-j.; Peng, Y.-x.; Wei, L.; Liu, Y.; Hu, Y.-h.; Peng, P.; Wang, J.-m.; Liu, J.-y.; Chen, Z.; Li, G.; Zheng, Z.-j.; Qiu, S.-q.; Luo, J.; Ye, C.-j.; Zhu, S.-y.; Zhong, N.-s., Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine* **2020**, *382*, 1708-1720. https://www.nejm.org/doi/full/10.1056/NEJMoa2002032?query=recirc_artType_railA_article
164. (U) Guo, Z.; Wang, Z.; Zhang, S.; Li, X.; Li, L.; Li, C.; Cui, Y.; Fu, R.; Dong, Y.; Chi, X., Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. *Emerging infectious diseases* **2020**, *26* (7).
165. (U) Halfmann, P. J.; Hatta, M.; Chiba, S.; Maemura, T.; Fan, S.; Takeda, M.; Kinoshita, N.; Hattori, S. I.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Imai, M.; Kawaoka, Y., Transmission of SARS-CoV-2 in Domestic Cats. *N Engl J Med* **2020**.
166. (U) Hamilton, I. A., Bill Gates is funding new factories for potential coronavirus vaccines. <https://www.weforum.org/agenda/2020/04/bill-gates-7-potential-coronavirus-vaccines>.
167. (U) Hargreaves, B., Catalent takes on manufacture of J&J's coronavirus vaccine. <https://www.biopharma-reporter.com/Article/2020/04/30/Catalent-to-manufacture-Janssen-coronavirus-vaccine>.
168. (U) Hargreaves, B., Lonza and Moderna shoot for billion COVID-19 doses. <https://www.biopharma-reporter.com/Article/2020/05/05/Lonza-and-Moderna-partner-for-COVID-19-vaccine>.
169. (U) Hargreaves, B., Pfizer and BioNTech work to scale up COVID-19 vaccine production. <https://www.biopharma-reporter.com/Article/2020/05/11/Pfizer-scales-up-COVID-vaccine-production>.
170. (U) He, R.; Lu, Z.; Zhang, L.; Fan, T.; Xiong, R.; Shen, X.; Feng, H.; Meng, H.; Lin, W.; Jiang, W.; Geng, Q., The clinical course and its correlated immune status in COVID-19 pneumonia. *Journal of Clinical Virology* **2020**, *127*, 104361. <http://www.sciencedirect.com/science/article/pii/S1386653220301037>
171. (U) He, X.; Lau, E. H. Y.; Wu, P.; Deng, X.; Wang, J.; Hao, X.; Lau, Y. C.; Wong, J. Y.; Guan, Y.; Tan, X.; Mo, X.; Chen, Y.; Liao, B.; Chen, W.; Hu, F.; Zhang, Q.; Zhong, M.; Wu, Y.; Zhao, L.; Zhang, F.; Cowling, B.

- J.; Li, F.; Leung, G. M., Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0869-5>
172. (U) Helms, J.; Kremer, S.; Merdji, H.; Clere-Jehl, R.; Schenck, M.; Kummerlen, C.; Collange, O.; Boulay, C.; Fafi-Kremer, S.; Ohana, M.; Anheim, M.; Meziani, F., Neurologic Features in Severe SARS-CoV-2 Infection. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMc2008597>
173. (U) HHS, 2019-nCoV Update. 2020. https://www.hhs.gov/live/live-2/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmedia%2F2020%2Fa0128-hhs-coronavirus-update.html#11465
174. (U) Holland, L. A.; Kaelin, E. A.; Maqsood, R.; Estifanos, B.; Wu, L. I.; Varsani, A.; Halden, R. U.; Hogue, B. G.; Scotch, M.; Lim, E. S., An 81 base-pair deletion in SARS-CoV-2 ORF7a identified from sentinel surveillance in Arizona (Jan-Mar 2020). *medRxiv* **2020**, 2020.04.17.20069641.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.17.20069641.full.pdf>
175. (U) Horby, P.; Landray, M., No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial: 2020.
<https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19>
176. (U) Hou, Y. J.; Okuda, K.; Edwards, C. E.; Martinez, D. R.; Asakura, T.; Dinnon, K. H.; Kato, T.; Lee, R. E.; Yount, B. L.; Mascenik, T. M.; Chen, G.; Olivier, K. N.; Ghio, A.; Tse, L. V.; Leist, S. R.; Gralinski, L. E.; Schäfer, A.; Dang, H.; Gilmore, R.; Nakano, S.; Sun, L.; Fulcher, M. L.; Livraghi-Butrico, A.; Nicely, N. I.; Cameron, M.; Cameron, C.; Kelvin, D. J.; de Silva, A.; Margolis, D. M.; Markmann, A.; Bartelt, L.; Zumwalt, R.; Martinez, F. J.; Salvatore, S. P.; Borczuk, A.; Tata, P. R.; Sontake, V.; Kimple, A.; Jaspers, I.; O'Neal, W. K.; Randell, S. H.; Boucher, R. C.; Baric, R. S., SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. *Cell* **2020**.
<http://www.sciencedirect.com/science/article/pii/S0092867420306759>
177. (U) Hsiang, S.; Allen, D.; Annan-Phan, S.; Bell, K.; Bolliger, I.; Chong, T.; Druckenmiller, H.; Huang, L. Y.; Hultgren, A.; Krasovich, E.; Lau, P.; Lee, J.; Rolf, E.; Tseng, J.; Wu, T., The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2404-8>
178. (U) Hu, Q.; Cui, X.; Liu, X.; Peng, B.; Jiang, J.; Wang, X.; Li, Y.; Hu, W.; Ao, Z.; Duan, J.; Wang, X.; Zhu, L.; Guo, S.; Wu, G., The production of antibodies for SARS-CoV-2 and its clinical implication. *medRxiv* **2020**, 2020.04.20.20065953.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.20.20065953.full.pdf>
179. (U) Hu, Z.; Song, C.; Xu, C.; Jin, G.; Chen, Y.; Xu, X.; Ma, H.; Chen, W.; Lin, Y.; Zheng, Y.; Wang, J.; Hu, Z.; Yi, Y.; Shen, H., Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences* **2020**. <https://doi.org/10.1007/s11427-020-1661-4>
180. (U) Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* **2020**. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30183-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext)
181. (U) Huang, R.; Xia, J.; Chen, Y.; Shan, C.; Wu, C., A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. *The Lancet Infectious Diseases* **2020**, 20 (5), 534-535.
[https://doi.org/10.1016/S1473-3099\(20\)30147-X](https://doi.org/10.1016/S1473-3099(20)30147-X)
182. (U) Huang, Y.; Lyu, X.; Li, D.; Wang, Y.; Wang, L.; Zou, W.; Wei, Y.; Wu, X., A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19. *medRxiv* **2020**,

2020.04.18.20070656.

<https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.18.20070656.full.pdf>

183. (U) Hulkower, R. L.; Casanova, L. M.; Rutala, W. A.; Weber, D. J.; Sobsey, M. D., Inactivation of surrogate coronaviruses on hard surfaces by health care germicides. *American journal of infection control* **2011**, 39 (5), 401-407. <https://www.sciencedirect.com/science/article/pii/S0196655310009004>

184. (U) Hulme, O. J.; Wagenmakers, E.-J.; Damkier, P.; Madelung, C. F.; Siebner, H. R.; Helweg-Larsen, J.; Gronau, Q.; Benfield, T. L.; Madsen, K. H., A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19. *medRxiv* **2020**, 2020.03.31.20048777. <https://www.medrxiv.org/content/medrxiv/early/2020/04/28/2020.03.31.20048777.full.pdf>

185. (U) Hung, I. F.-N.; Lung, K.-C.; Tso, E. Y.-K.; Liu, R.; Chung, T. W.-H.; Chu, M.-Y.; Ng, Y.-Y.; Lo, J.; Chan, J.; Tam, A. R.; Shum, H.-P.; Chan, V.; Wu, A. K.-L.; Sin, K.-M.; Leung, W.-S.; Law, W.-L.; Lung, D. C.; Sin, S.; Yeung, P.; Yip, C. C.-Y.; Zhang, R. R.; Fung, A. Y.-F.; Yan, E. Y.-W.; Leung, K.-H.; Ip, J. D.; Chu, A. W.-H.; Chan, W.-M.; Ng, A. C.-K.; Lee, R.; Fung, K.; Yeung, A.; Wu, T.-C.; Chan, J. W.-M.; Yan, W.-W.; Chan, W.-M.; Chan, J. F.-W.; Lie, A. K.-W.; Tsang, O. T.-Y.; Cheng, V. C.-C.; Que, T.-L.; Lau, C.-S.; Chan, K.-H.; To, K. K.-W.; Yuen, K.-Y., Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31042-4](https://doi.org/10.1016/S0140-6736(20)31042-4)

186. (U) ICNARC, *ICNARC report on COVID-19 in critical care, 24 April 2020*; Intensive Care National Audit and Research Centre: 2020. <https://www.icnarc.org/DataServices/Attachments/Download/c5a62b13-6486-ea11-9125-00505601089b>

187. (U) IDEXX, Leading Veterinary Diagnostic Company Sees No COVID-19 Cases in Pets. IDEXX: 2020. <https://www.idexx.com/en/about-idexx/news/no-covid-19-cases-pets/>

188. (U) IHME, COVID-19 Projections. <https://covid19.healthdata.org/united-states-of-america>.

189. (U) Ing, A. J.; Cocks, C.; Green, J. P., COVID-19: in the footsteps of Ernest Shackleton. *Thorax* **2020**.

190. (U) IQ, H., COVID-19 Forecast for United States. <https://app.hospiq.com/covid19?region=>.

191. (U) ISAC, Statement on IJAA paper. International Society of Antimicrobial Chemotherapy: 2020. <https://www.isac.world/news-and-publications/official-isac-statement>

192. (U) Iwata, K.; Doi, A.; Miyakoshi, C., Was School Closure Effective in Mitigating Coronavirus Disease 2019 (COVID-19)? Time Series Analysis Using Bayesian Inference. **2020**.

193. (U) Jankelson, L.; Karam, G.; Becker, M. L.; Chinitz, L. A.; Tsai, M. C., QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. *Heart Rhythm* **2020**.

194. (U) Jarvis, C. I.; Van Zandvoort, K.; Gimma, A.; Prem, K.; Klepac, P.; Rubin, G. J.; Edmunds, W. J., Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. *BMC Med* **2020**, 18 (1), 124.

195. (U) Jenco, M., CDC details COVID-19-related inflammatory syndrome in children. *AAP News* 2020. <https://www.aappublications.org/news/2020/05/14/covid19inflammatory051420>

196. (U) JHU, Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE. <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>.

197. (U) Jiang, F.-C.; Jiang, X.-L.; Wang, Z.-G.; Meng, Z.-H.; Shao, S.-F.; Anderson, B. D.; Ma, M.-J., Detection of Severe Acute Respiratory Syndrome Coronavirus 2 RNA on Surfaces in Quarantine Rooms. *Emerging Infectious Diseases* **2020**, 26. https://wwwnc.cdc.gov/eid/article/26/9/20-1435_article

198. (U) Jin, J.-M.; Bai, P.; He, W.; Wu, F.; Liu, X.-F.; Han, D.-M.; Liu, S.; Yang, J.-K., Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Frontiers in Public Health* **2020**, 8 (152). <https://www.frontiersin.org/article/10.3389/fpubh.2020.00152>

199. (U) Jing, C.; Wenjie, S.; Jianping, H.; Michelle, G.; Jing, W.; Guiqing, H., Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. *Emerging Infectious Disease journal* **2020**, *26* (6). https://wwwnc.cdc.gov/eid/article/26/6/20-0412_article
200. (U) Johndrow, J. E.; Lum, K.; Ball, P., Estimating SARS-CoV-2-positive Americans using deaths-only data. *arXiv preprint arXiv:2004.02605* **2020**.
201. (U) Johnson, J. a., Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use. Johnson and Johnson: 2020. <https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use>
202. (U) Joseph, A., CDC developing serologic tests that could reveal full scope of U.S. coronavirus outbreak. *STAT* 2020. <https://www.statnews.com/2020/03/11/cdc-developing-serologic-tests-that-could-reveal-full-scope-of-u-s-coronavirus-outbreak/>
203. (U) Joyner, M.; Wright, R. S.; Fairweather, D.; Senefeld, J.; Bruno, K.; Klassen, S.; Carter, R.; Klompas, A.; Wiggins, C.; Shepherd, J. R.; Rea, R.; Whelan, E.; Clayburn, A.; Spiegel, M.; Johnson, P.; Lesser, E.; Baker, S.; Larson, K.; Ripoll Sanz, J.; Andersen, K.; Hodge, D.; Kunze, K.; Buras, M.; Vogt, M.; Herasevich, V.; Dennis, J.; Regimbal, R.; Bauer, P.; Blair, J.; van Buskirk, C.; Winters, J.; Stubbs, J.; Paneth, N.; Casadevall, A., Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. *medRxiv* **2020**, 2020.05.12.20099879. <https://www.medrxiv.org/content/medrxiv/early/2020/05/14/2020.05.12.20099879.full.pdf>
204. (U) Juan, J.; Gil, M. M.; Rong, Z.; Zhang, Y.; Yang, H.; Poon, L. C. Y., Effects of Coronavirus Disease 2019 (COVID-19) on Maternal, Perinatal and Neonatal Outcomes: a Systematic Review of 266 Pregnancies. *medRxiv* **2020**, 2020.05.02.20088484. <https://www.medrxiv.org/content/medrxiv/early/2020/05/06/2020.05.02.20088484.full.pdf>
205. (U) Jüni, P.; Rothenbühler, M.; Bobos, P.; Thorpe, K. E.; da Costa, B. R.; Fisman, D. N.; Slutsky, A. S.; Gesink, D., Impact of climate and public health interventions on the COVID-19 pandemic: A prospective cohort study. *Canadian Medical Association Journal* **2020**, cmaj.200920. <https://www.cmaj.ca/content/cmaj/early/2020/05/08/cmaj.200920.full.pdf>
206. (U) Karamitros, T.; Papadopoulou, G.; Bousali, M.; Mexias, A.; Tsiodras, S.; Mentis, A., SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies. *bioRxiv* **2020**, 2020.03.27.009480. <http://biorxiv.org/content/early/2020/03/28/2020.03.27.009480.abstract>
207. (U) KCDC, Findings from investigation and analysis of re-positive cases. Korean Centers for Disease Control and Prevention: 2020. <https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030>
208. (U) Kim, S. E.; Jeong, H. S.; Yu, Y.; Shin, S. U.; Kim, S.; Oh, T. H.; Kim, U. J.; Kang, S. J.; Jang, H. C.; Jung, S. I.; Park, K. H., Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients. *Int J Infect Dis* **2020**.
209. (U) Kim, Y.-I.; Kim, S.-G.; Kim, S.-M.; Kim, E.-H.; Park, S.-J.; Yu, K.-M.; Chang, J.-H.; Kim, E. J.; Lee, S.; Casel, M. A. B.; Um, J.; Song, M.-S.; Jeong, H. W.; Lai, V. D.; Kim, Y.; Chin, B. S.; Park, J.-S.; Chung, K.-H.; Foo, S.-S.; Poo, H.; Mo, I.-P.; Lee, O.-J.; Webby, R. J.; Jung, J. U.; Choi, Y. K., Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host & Microbe* **2020**. <http://www.sciencedirect.com/science/article/pii/S1931312820301876>
210. (U) Kissler, S. M.; Tedijanto, C.; Goldstein, E.; Grad, Y. H.; Lipsitch, M., Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science* **2020**, eabb5793. <https://science.sciencemag.org/content/sci/early/2020/04/14/science.abb5793.full.pdf>
211. (U) Klok, F.; Kruij, M.; van der Meer, N.; Arbous, M.; Gommers, D.; Kant, K.; Kaptein, F.; van Paassen, J.; Stals, M.; Huisman, M., Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research* **2020**.

212. (U) Klumpp-Thomas, C.; Kalish, H.; Drew, M.; Hunsberger, S.; Snead, K.; Fay, M. P.; Mehalko, J.; Shunmugavel, A.; Wall, V.; Frank, P.; Denson, J.-P.; Hong, M.; Gulten, G.; Messing, S.; Hicks, J.; Michael, S.; Gillette, W.; Hall, M. D.; Memoli, M.; Esposito, D.; Sadtler, K., Standardization of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling. *medRxiv* **2020**, 2020.05.21.20109280.
<https://www.medrxiv.org/content/medrxiv/early/2020/05/25/2020.05.21.20109280.full.pdf>
213. (U) Konda, A.; Prakash, A.; Moss, G. A.; Schmoltdt, M.; Grant, G. D.; Guha, S., Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. *ACS Nano* **2020**.
<https://www.ncbi.nlm.nih.gov/pubmed/32329337>
214. (U) Kraemer, M. U. G.; Yang, C.-H.; Gutierrez, B.; Wu, C.-H.; Klein, B.; Pigott, D. M.; du Plessis, L.; Faria, N. R.; Li, R.; Hanage, W. P.; Brownstein, J. S.; Layan, M.; Vespignani, A.; Tian, H.; Dye, C.; Pybus, O. G.; Scarpino, S. V., The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science* **2020**, eabb4218.
<https://science.sciencemag.org/content/sci/early/2020/03/25/science.abb4218.full.pdf>
215. (U) Krantz, S. G.; Rao, A. S. S., Level of under-reporting including under-diagnosis before the first peak of COVID-19 in various countries: Preliminary Retrospective Results Based on Wavelets and Deterministic Modeling. *Infection Control & Hospital Epidemiology* **2020**, 1-8.
216. (U) Kratzel, A.; Todt, D.; V'kovski, P.; Steiner, S.; Gultom, M. L.; Thao, T. T. N.; Ebert, N.; Holwerda, M.; Steinmann, J.; Niemeyer, D.; Dijkman, R.; Kampf, G.; Drosten, C.; Steinmann, E.; Thiel, V.; Pfaender, S., Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols. *bioRxiv* **2020**, 2020.03.10.986711.
<https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.10.986711.full.pdf>
217. (U) Krever, M.; Picheta, R., A mink may have infected a human with Covid-19, Dutch authorities believe. *CNN* **2020**. <https://edition.cnn.com/2020/05/20/europe/coronavirus-mink-netherlands-testing-intl/index.html>
218. (U) Kucharski, A. J.; Russell, T. W.; Diamond, C.; Liu, Y.; Edmunds, J.; Funk, S.; Eggo, R. M.; Sun, F.; Jit, M.; Munday, J. D., Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *The lancet infectious diseases* **2020**.
219. (U) Kucirka, L. M.; Lauer, S. A.; Laeyendecker, O.; Boon, D., Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. *Annals of Internal Medicine* **2020**, 0 (0), null. <https://www.acpjournals.org/doi/abs/10.7326/M20-1495>
220. (U) Kupferschmidt, K.; Cohen, J., WHO launches global megatrial of the four most promising coronavirus treatments. *Science* **2020**. <https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments>
221. (U) Lai, M. Y.; Cheng, P. K.; Lim, W. W., Survival of severe acute respiratory syndrome coronavirus. *Clinical Infectious Diseases* **2005**, 41 (7), e67-e71.
<https://academic.oup.com/cid/article/41/7/e67/310340>
222. (U) Lai, S.; Ruktanonchai, N. W.; Zhou, L.; Prosper, O.; Luo, W.; Floyd, J. R.; Wesolowski, A.; Santillana, M.; Zhang, C.; Du, X.; Yu, H.; Tatem, A. J., Effect of non-pharmaceutical interventions to contain COVID-19 in China. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2293-x>
223. (U) Lam, S.; Bordin, N.; Waman, V.; Scholes, H.; Ashford, P.; Sen, N.; van Dorp, L.; Rauer, C.; Dawson, N.; Pang, C.; Abbasian, M.; Sillitoe, I.; Edwards, S.; Fraternali, F.; Lees, J.; Santini, J.; Orengo, C., SARS-CoV-2 spike protein predicted to form stable complexes with host receptor protein orthologues from mammals, but not fish, birds or reptiles. *bioRxiv* **2020**, 2020.05.01.072371.
<https://www.biorxiv.org/content/biorxiv/early/2020/05/01/2020.05.01.072371.full.pdf>
224. (U) Lam, T. T.-Y.; Shum, M. H.-H.; Zhu, H.-C.; Tong, Y.-G.; Ni, X.-B.; Liao, Y.-S.; Wei, W.; Cheung, W. Y.-M.; Li, W.-J.; Li, L.-F.; Leung, G. M.; Holmes, E. C.; Hu, Y.-L.; Guan, Y., Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2169-0>

225. (U) Lan, L.; Xu, D.; Ye, G.; Xia, C.; Wang, S.; Li, Y.; Xu, H., Positive RT-PCR Test Results in Patients Recovered From COVID-19. *Jama* **2020**. <https://jamanetwork.com/journals/jama/fullarticle/2762452>
226. (U) LANL, COVID-19 Confirmed and Forecasted Case Data. <https://covid-19.bsvgateway.org/>.
227. (U) Lasry, A.; Kidder, D.; Hast, M.; Poovey, J.; Sunshine, G.; Zviedrite, N.; Ahmed, F.; Ethier, K. A., Timing of community mitigation and changes in reported COVID-19 and community mobility—four US metropolitan areas, February 26–April 1, 2020. *morbidity and Mortality Weekly Report* **2020**, *69*, 451-457. <https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e2.htm>
228. (U) Lassaunière, R.; Frische, A.; Harboe, Z. B.; Nielsen, A. C.; Fomsgaard, A.; Krogfelt, K. A.; Jørgensen, C. S., Evaluation of nine commercial SARS-CoV-2 immunoassays. *medRxiv* **2020**, 2020.04.09.20056325. <https://www.medrxiv.org/content/medrxiv/early/2020/04/10/2020.04.09.20056325.full.pdf>
229. (U) Lau, S., Coronavirus: WHO official says there's no evidence of 'reinfected' patients in China <https://www.scmp.com/news/china/society/article/3074045/coronavirus-who-official-says-theres-no-evidence-reinfected>.
230. (U) Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A. S.; Reich, N. G.; Lessler, J., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of Internal Medicine* **2020**. <https://doi.org/10.7326/M20-0504>
231. (U) Leung, K.; Wu, J. T.; Liu, D.; Leung, G. M., First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30746-7](https://doi.org/10.1016/S0140-6736(20)30746-7)
232. (U) Leung, N. H. L.; Chu, D. K. W.; Shiu, E. Y. C.; Chan, K.-H.; McDevitt, J. J.; Hau, B. J. P.; Yen, H.-L.; Li, Y.; Ip, D. K. M.; Peiris, J. S. M.; Seto, W.-H.; Leung, G. M.; Milton, D. K.; Cowling, B. J., Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0843-2>
233. (U) Levi, M.; Thachil, J.; Iba, T.; Levy, J. H., Coagulation abnormalities and thrombosis in patients with COVID-19. *The Lancet Haematology* **2020**. [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9)
234. (U) Levine, J., Scientists race to develop vaccine to deadly China coronavirus. <https://nypost.com/2020/01/25/scientists-race-to-develop-vaccine-to-deadly-china-coronavirus/>.
235. (U) Lewis, D., Is the coronavirus airborne? Experts can't agree. *Nature* **2020**. 10.1038/d41586-020-00974-w
236. (U) Li, D.; Jin, M.; Bao, P.; Zhao, W.; Zhang, S., Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. *JAMA Network Open* **2020**, *3* (5), e208292-e208292. <https://doi.org/10.1001/jamanetworkopen.2020.8292>
237. (U) Li, K.; Wohlford-Lenane, C.; Perlman, S.; Zhao, J.; Jewell, A. K.; Reznikov, L. R.; Gibson-Corley, K. N.; Meyerholz, D. K.; McCray, P. B., Jr., Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. *J Infect Dis* **2016**, *213* (5), 712-22. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747621/pdf/jiv499.pdf>
238. (U) Li, L.; Zhang, W.; Hu, Y.; Tong, X.; Zheng, S.; Yang, J.; Kong, Y.; Ren, L.; Wei, Q.; Mei, H.; Hu, C.; Tao, C.; Yang, R.; Wang, J.; Yu, Y.; Guo, Y.; Wu, X.; Xu, Z.; Zeng, L.; Xiong, N.; Chen, L.; Wang, J.; Man, N.; Liu, Y.; Xu, H.; Deng, E.; Zhang, X.; Li, C.; Wang, C.; Su, S.; Zhang, L.; Wang, J.; Wu, Y.; Liu, Z., Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.10044>
239. (U) Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K. S. M.; Lau, E. H. Y.; Wong, J. Y.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Liu, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T. T. Y.; Wu, J. T.; Gao, G. F.; Cowling, B. J.; Yang, B.; Leung, G. M.;

Feng, Z., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2001316>

<https://www.nejm.org/doi/10.1056/NEJMoa2001316>

240. (U) Li, R.; Pei, S.; Chen, B.; Song, Y.; Zhang, T.; Yang, W.; Shaman, J., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* **2020**, eabb3221. <https://science.sciencemag.org/content/sci/early/2020/03/13/science.abb3221.full.pdf>

241. (U) Li, W.; Zhang, B.; Lu, J.; Liu, S.; Chang, Z.; Cao, P.; Liu, X.; Zhang, P.; Ling, Y.; Tao, K.; Chen, J., The characteristics of household transmission of COVID-19. *Clinical Infectious Diseases* **2020**. <https://doi.org/10.1093/cid/ciaa450>

242. (U) Li, X.; Giorgi, E. E.; Marichannegowda, M. H.; Foley, B.; Xiao, C.; Kong, X.-P.; Chen, Y.; Gnanakaran, S.; Korber, B.; Gao, F., Emergence of SARS-CoV-2 through recombination and strong purifying selection. *Science Advances* **2020**, eabb9153. <https://advances.sciencemag.org/content/advances/early/2020/05/28/sciadv.abb9153.full.pdf>

243. (U) Li, X.; Zai, J.; Zhao, Q.; Nie, Q.; Li, Y.; Foley, B. T.; Chaillon, A., Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. *Journal of Medical Virology* **2020**, n/a (n/a). <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25731>

244. (U) Li, Y.; Qian, H.; Hang, J.; Chen, X.; Hong, L.; Liang, P.; Li, J.; Xiao, S.; Wei, J.; Liu, L.; Kang, M., Evidence for probable aerosol transmission of SARS-CoV-2 in a poorly ventilated restaurant. *medRxiv* **2020**, 2020.04.16.20067728. <https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.16.20067728.full.pdf>

245. (U) Li, Y.; Xie, Z.; Lin, W.; Cai, W.; Wen, C.; Guan, Y.; Mo, X.; Wang, J.; Wang, Y.; Peng, P.; Chen, X.; Hong, W.; Xiao, G.; Liu, J.; Zhang, L.; Hu, F.; Li, F.; Zhang, F.; Deng, X.; Li, L., Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. *Med*. <https://doi.org/10.1016/j.medj.2020.04.001>

246. (U) Liu, A., China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data. *Fierce Pharma* **2020**. <https://www.fiercepharma.com/vaccines/china-s-cansino-bio-advances-covid-19-vaccine-into-phase-2-preliminary-safety-data>

247. (U) Liu, P.; Chen, W.; Chen, J.-P., Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (*Manis javanica*). *Viruses* **2019**, *11* (11), 979. <https://www.mdpi.com/1999-4915/11/11/979>

248. (U) Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Li, L.; Zhou, J.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? *PLOS Pathogens* **2020**, *16* (5), e1008421. <https://doi.org/10.1371/journal.ppat.1008421>

249. (U) Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (2019-nCoV) ? *bioRxiv* **2020**, 2020.02.18.954628. <http://biorxiv.org/content/early/2020/02/20/2020.02.18.954628.abstract>

250. (U) Liu, S. T. H.; Lin, H.-M.; Baine, I.; Wajnberg, A.; Gumprecht, J. P.; Rahman, F.; Rodriguez, D.; Tandon, P.; Bassily-Marcus, A.; Bander, J.; Sanky, C.; Dupper, A.; Zheng, A.; Altman, D. R.; Chen, B. K.; Krammer, F.; Mendu, D. R.; Firpo-Betancourt, A.; Levin, M. A.; Bagiella, E.; Casadevall, A.; Cordon-Cardo, C.; Jhang, J. S.; Arinsburg, S. A.; Reich, D. L.; Aberg, J. A.; Bouvier, N. M., Convalescent plasma treatment of severe COVID-19: A matched control study. *medRxiv* **2020**, 2020.05.20.20102236. <https://www.medrxiv.org/content/medrxiv/early/2020/05/22/2020.05.20.20102236.full.pdf>

251. (U) Liu, W.; Zhang, Q.; Chen, J.; Xiang, R.; Song, H.; Shu, S.; Chen, L.; Liang, L.; Zhou, J.; You, L.; Wu, P.; Zhang, B.; Lu, Y.; Xia, L.; Huang, L.; Yang, Y.; Liu, F.; Semple, M. G.; Cowling, B. J.; Lan, K.; Sun, Z.; Yu, H.; Liu, Y., Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2003717>

252. (U) Liu, Y.; Funk, S.; Flasche, S., *The Contribution of Pre-symptomatic Transmission to the COVID-19 Outbreak*; London School of Hygiene and Tropical Medicine: 2020.
<https://cmmid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html>
253. (U) Liu, Y.; Hu, G.; Wang, Y.; Zhao, X.; Ji, F.; Ren, W.; Gong, M.; Ju, X.; Li, C.; Hong, J.; Zhu, Y.; Cai, X.; Wu, J.; Lan, X.; Xie, Y.; Wang, X.; Yuan, Z.; Zhang, R.; Ding, Q., Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2. *bioRxiv* **2020**, 2020.04.22.046565.
<https://www.biorxiv.org/content/biorxiv/early/2020/05/03/2020.04.22.046565.full.pdf>
254. (U) Liu, Y.; Li, T.; Deng, Y.; Liu, S.; Zhang, D.; Li, H.; Wang, X.; Jia, L.; Han, J.; Bei, Z.; Zhou, Y.; Li, L.; Li, J., Stability of SARS-CoV-2 on environmental surfaces and in human excreta. *medRxiv* **2020**, 2020.05.07.20094805.
<https://www.medrxiv.org/content/medrxiv/early/2020/05/12/2020.05.07.20094805.full.pdf>
255. (U) Liu, Y.; Ning, Z.; Chen, Y.; Guo, M.; Liu, Y.; Gali, N. K.; Sun, L.; Duan, Y.; Cai, J.; Westerdahl, D.; Liu, X.; Xu, K.; Ho, K.-f.; Kan, H.; Fu, Q.; Lan, K., Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2271-3>
256. (U) Lokken, E. M.; Walker, C. L.; Delaney, S.; Kachikis, A.; Kretzer, N. M.; Erickson, A.; Resnick, R.; Vanderhoeven, J.; Hwang, J. K.; Barnhart, N.; Rah, J.; McCartney, S. A.; Ma, K. K.; Huebner, E. M.; Thomas, C.; Sheng, J. S.; Paek, B. W.; Retzlaff, K.; Kline, C. R.; Munson, J.; Blain, M.; Lacourse, S. M.; Deutsch, G.; Adams Waldorf, K., Clinical Characteristics of 46 Pregnant Women with a SARS-CoV-2 Infection in Washington State. *Am J Obstet Gynecol* **2020**.
257. (U) Long, Q.-X.; Liu, B.-Z.; Deng, H.-J.; Wu, G.-C.; Deng, K.; Chen, Y.-K.; Liao, P.; Qiu, J.-F.; Lin, Y.; Cai, X.-F.; Wang, D.-Q.; Hu, Y.; Ren, J.-H.; Tang, N.; Xu, Y.-Y.; Yu, L.-H.; Mo, Z.; Gong, F.; Zhang, X.-L.; Tian, W.-G.; Hu, L.; Zhang, X.-X.; Xiang, J.-L.; Du, H.-X.; Liu, H.-W.; Lang, C.-H.; Luo, X.-H.; Wu, S.-B.; Cui, X.-P.; Zhou, Z.; Zhu, M.-M.; Wang, J.; Xue, C.-J.; Li, X.-F.; Wang, L.; Li, Z.-J.; Wang, K.; Niu, C.-C.; Yang, Q.-J.; Tang, X.-J.; Zhang, Y.; Liu, X.-M.; Li, J.-J.; Zhang, D.-C.; Zhang, F.; Liu, P.; Yuan, J.; Li, Q.; Hu, J.-L.; Chen, J.; Huang, A.-L., Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine* **2020**.
<https://doi.org/10.1038/s41591-020-0897-1>
258. (U) Lu, J.; Plessis, L. d.; Liu, Z.; Hill, V.; Kang, M.; Lin, H.; Sun, J.; Francois, S.; Kraemer, M. U. G.; Faria, N. R.; McCrone, J. T.; Peng, J.; Xiong, Q.; Yuan, R.; Zeng, L.; Zhou, P.; Liang, C.; Yi, L.; Liu, J.; Xiao, J.; Hu, J.; Liu, T.; Ma, W.; Li, W.; Su, J.; Zheng, H.; Peng, B.; Fang, S.; Su, W.; Li, K.; Sun, R.; Bai, R.; Tang, X.; Liang, M.; Quick, J.; Song, T.; Rambaut, A.; Loman, N.; Raghwani, J.; Pybus, O.; Ke, C., Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China. *medRxiv* **2020**, 2020.04.01.20047076.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/04/2020.04.01.20047076.full.pdf>
259. (U) Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W. J.; Wang, D.; Xu, W.; Holmes, E. C.; Gao, G. F.; Wu, G.; Chen, W.; Shi, W.; Tan, W., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
260. (U) Lu, S.; Zhao, Y.; Yu, W.; Yang, Y.; Gao, J.; Wang, J.; Kuang, D.; Yang, M.; Yang, J.; Ma, C.; Xu, J.; Qian, X.; Li, H.; Zhao, S.; Li, J.; Wang, H.; Long, H.; Zhou, J.; Luo, F.; Ding, K.; Wu, D.; Zhang, Y.; Dong, Y.; Liu, Y.; Zheng, Y.; Lin, X.; Jiao, L.; Zheng, H.; Dai, Q.; Sun, Q.; Hu, Y.; Ke, C.; Liu, H.; Peng, X., Comparison of SARS-CoV-2 infections among 3 species of non-human primates. *bioRxiv* **2020**, 2020.04.08.031807.
<https://www.biorxiv.org/content/biorxiv/early/2020/04/12/2020.04.08.031807.full.pdf>
261. (U) Lu, X.; Zhang, L.; Du, H.; Zhang, J.; Li, Y. Y.; Qu, J.; Zhang, W.; Wang, Y.; Bao, S.; Li, Y.; Wu, C.; Liu, H.; Liu, D.; Shao, J.; Peng, X.; Yang, Y.; Liu, Z.; Xiang, Y.; Zhang, F.; Silva, R. M.; Pinkerton, K. E.; Shen, K.; Xiao, H.; Xu, S.; Wong, G. W. K., SARS-CoV-2 Infection in Children. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2005073>

262. (U) Lu, Y.; Li, Y.; Deng, W.; Liu, M.; He, Y.; Huang, L.; Lv, M.; Li, J.; Du, H., Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan. *Pediatr Infect Dis J* **2020**.
263. (U) Luo, W.; Majumder, M. S.; Liu, D.; Poirier, C.; Mandl, K. D.; Lipsitch, M.; Santillana, M., The role of absolute humidity on transmission rates of the COVID-19 outbreak. *medRxiv* **2020**, 2020.02.12.20022467.
<https://www.medrxiv.org/content/medrxiv/early/2020/02/17/2020.02.12.20022467.full.pdf>
264. (U) Luo, Y.; Trevathan, E.; Qian, Z.; Li, Y.; Li, J.; Xiao, W.; Tu, N.; Zeng, Z.; Mo, P.; Xiong, Y.; Ye, G., Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China. *Emerging Infectious Disease journal* **2020**, 26 (8). https://wwwnc.cdc.gov/eid/article/26/8/20-1016_article
265. (U) MacLean, O. A.; Orton, R. J.; Singer, J. B.; Robertson, D. L., No evidence for distinct types in the evolution of SARS-CoV-2. *Virus Evolution* **2020**. <https://doi.org/10.1093/ve/veaa034>
266. (U) Magagnoli, J.; Narendran, S.; Pereira, F.; Cummings, T. H.; Hardin, J. W.; Sutton, S. S.; Ambati, J., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. *Med* **2020**. <https://doi.org/10.1016/j.medj.2020.06.001>
267. (U) Mahévas, M.; Tran, V.-T.; Roumier, M.; Chabrol, A.; Paule, R.; Guillaud, C.; Fois, E.; Lepeule, R.; Szwebel, T.-A.; Lescure, F.-X.; Schlemmer, F.; Matignon, M.; Khellaf, M.; Crickx, E.; Terrier, B.; Morbieu, C.; Legendre, P.; Dang, J.; Schoindre, Y.; Pawlotsky, J.-M.; Michel, M.; Perrodeau, E.; Carlier, N.; Roche, N.; de Lastours, V.; Ourghanlian, C.; Kerneis, S.; Ménager, P.; Mouthon, L.; Audureau, E.; Ravaud, P.; Godeau, B.; Gallien, S.; Costedoat-Chalumeau, N., Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. *BMJ* **2020**, 369, m1844. <http://www.bmj.com/content/369/bmj.m1844.abstract>
268. (U) Mahevas, M.; Tran, V.-T.; Roumier, M.; Chabrol, A.; Paule, R.; Guillaud, C.; Gallien, S.; Lepeule, R.; Szwebel, T.-A.; Lescure, X.; Schlemmer, F.; Matignon, M.; Khellaf, M.; Crickx, E.; Terrier, B.; Morbieu, C.; Legendre, P.; Dang, J.; Schoindre, Y.; Pawlotski, J.-M.; Michel, M.; Perrodeau, E.; Carlier, N.; Roche, N.; De Lastours, V.; Mouthon, L.; Audureau, E.; Ravaud, P.; Godeau, B.; Costedoat, N., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. *medRxiv* **2020**, 2020.04.10.20060699.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/14/2020.04.10.20060699.full.pdf>
269. (U) Maier, B. F.; Brockmann, D., Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China. *Science* **2020**, 368 (6492), 742-746.
<https://science.sciencemag.org/content/sci/368/6492/742.full.pdf>
270. (U) Majumder, M.; Mandl, K., Early transmissibility assessment of a novel coronavirus in Wuhan, China. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3524675
271. (U) Mallapaty, S., Coronavirus can infect cats — dogs, not so much. *Nature* **2020**.
<https://www.nature.com/articles/d41586-020-00984-8>
272. (U) Mason, M., Hundreds of thousands in L.A. County may have been infected with coronavirus, study finds. *LA Times* **2020**. <https://www.latimes.com/california/story/2020-04-20/coronavirus-serology-testing-la-county>
273. (U) Matthay, M. A.; Aldrich, J. M.; Gotts, J. E., Treatment for severe acute respiratory distress syndrome from COVID-19. *The Lancet Respiratory Medicine* **2020**. [https://doi.org/10.1016/S2213-2600\(20\)30127-2](https://doi.org/10.1016/S2213-2600(20)30127-2)
274. (U) Medicine, U. S. N. L. o., Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older.
<https://clinicaltrials.gov/ct2/show/NCT04405076?term=mRNA-1273&draw=2&rank=1>.

275. (U) Medicine, U. S. N. L. o., Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. <https://clinicaltrials.gov/ct2/show/NCT04334980>.
276. (U) Medicine, U. S. N. L. o., Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant. <https://clinicaltrials.gov/ct2/show/NCT04368988?term=Novavax&draw=2&rank=23>.
277. (U) Medicine, U. S. N. L. o., Immunity and Safety of Covid-19 Synthetic Minigene Vaccine. ClinicalTrials.gov: 2020. <https://clinicaltrials.gov/ct2/show/NCT04276896>
278. (U) Medicine, U. S. N. L. o., Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Frontline Healthcare Workers and First Responders. <https://clinicaltrials.gov/ct2/show/NCT04386252?term=Aivita+Biomedical&draw=2&rank=1>.
279. (U) Medicine, U. S. N. L. o., Safety and Immunity of Covid-19 aAPC Vaccine. ClinicalTrials.gov: 2020. <https://clinicaltrials.gov/ct2/show/NCT04299724>
280. (U) Medicine, U. S. N. L. o., SCB-2019 as COVID-19 Vaccine. <https://clinicaltrials.gov/ct2/show/NCT04405908?term=SCB-2019&draw=2&rank=1>.
281. (U) Medicine, U. S. N. L. o., Tabled COVID-19 Therapeutic Vaccine (COVID-19). <https://clinicaltrials.gov/ct2/show/NCT04380532?term=immunitor&draw=2&rank=11>.
282. (U) Mehra, M. R.; Ruschitzka, F.; Patel, A. N., Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31324-6](https://doi.org/10.1016/S0140-6736(20)31324-6)
283. (U) Melin, A. D.; Janiak, M. C.; Marrone, F.; Arora, P. S.; Higham, J. P., Comparative ACE2 variation and primate COVID-19 risk. *bioRxiv* **2020**, 2020.04.09.034967. <https://www.biorxiv.org/content/biorxiv/early/2020/04/19/2020.04.09.034967.full.pdf>
284. (U) Menachery, V. D.; Dinnon, K. H.; Yount, B. L.; McAnarney, E. T.; Gralinski, L. E.; Hale, A.; Graham, R. L.; Scobey, T.; Anthony, S. J.; Wang, L.; Graham, B.; Randell, S. H.; Lipkin, W. I.; Baric, R. S., Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. *Journal of Virology* **2020**, *94* (5), e01774-19. <https://jvi.asm.org/content/jvi/94/5/e01774-19.full.pdf>
285. (U) Meng, Y.; Wu, P.; Lu, W.; Liu, K.; Ma, K.; Huang, L.; Cai, J.; Zhang, H.; Qin, Y.; Sun, H.; Ding, W.; Gui, L.; Wu, P., Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients. *PLoS Pathog* **2020**, *16* (4), e1008520.
286. (U) Mercurio, N. J.; Yen, C. F.; Shim, D. J.; Maher, T. R.; McCoy, C. M.; Zimetbaum, P. J.; Gold, H. S., Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.1834>
287. (U) Merow, C.; Urban, M. C., Seasonality and uncertainty in COVID-19 growth rates. *medRxiv* **2020**, 2020.04.19.20071951. <https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.19.20071951.full.pdf>
288. (U) Meyers, L. A., COVID-19 Mortality Projections for US States and Metropolitan Areas. <https://covid-19.tacc.utexas.edu/projections/>.
289. (U) Millett, G. A.; Jones, A. T.; Benkeser, D.; Baral, S.; Mercer, L.; Beyrer, C.; Honermann, B.; Lankiewicz, E.; Mena, L.; Crowley, J. S.; Sherwood, J.; Sullivan, P., Assessing Differential Impacts of COVID-19 on Black Communities. *Annals of Epidemiology* **2020**. <http://www.sciencedirect.com/science/article/pii/S1047279720301769>
290. (U) MIT, DELPHI Epidemiological Case Predictions. <https://www.covidanalytics.io/projections>.
291. (U) Mizumoto, K.; Kagaya, K.; Zarebski, A.; Chowell, G., Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* **2020**, *25* (10), 2000180. <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000180>

292. (U) Moderna, Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. Moderna: 2020. <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine/>
293. (U) Montopoli, M.; Zumerle, S.; Vettor, R.; Ruge, M.; Zorzi, M.; Catapano, C. V.; Carbone, G.; Cavalli, A.; Pagano, F.; Ragazzi, E., Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n= 4532). *Annals of Oncology* **2020**.
294. (U) Moriarty, L. F.; Plucinski, M. M.; Marston, B. J. e. a., Public Health Responses fo COVID-19 Outbreaks on Cruise Ships - Worldwide, February - March 2020. *MMWR* **2020**, (ePub: 23 March 2020). <https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e3.htm>
295. (U) Munster, V. J.; Feldmann, F.; Williamson, B. N.; van Doremalen, N.; Pérez-Pérez, L.; Schulz, J.; Meade-White, K.; Okumura, A.; Callison, J.; Brumbaugh, B.; Avanzato, V. A.; Rosenke, R.; Hanley, P. W.; Saturday, G.; Scott, D.; Fischer, E. R.; de Wit, E., Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. *bioRxiv* **2020**, 2020.03.21.001628. <https://www.biorxiv.org/content/biorxiv/early/2020/03/21/2020.03.21.001628.full.pdf>
296. (U) Muoio, D., Scanwell Health, myLAB Box unveil more at-home COVID-19 testing services. *MobiHealthNews* 20 March, 2020. <https://www.mobihealthnews.com/news/scanwell-health-my-lab-box-unveil-more-home-covid-19-testing-services>
297. (U) Nadi, A., An at-home fingerprick blood test may help detect your exposure to coronavirus. *NBC NEWS* 04 April, 2020. <https://www.nbcnews.com/health/health-news/home-fingerprick-blood-test-may-help-detect-your-exposure-coronavirus-n1176086>
298. (U) Nepogodiev, D.; Glasbey, J. C.; Li, E.; Omar, O. M.; Simoes, J. F. F.; al., e., Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31182-X](https://doi.org/10.1016/S0140-6736(20)31182-X)
299. (U) NIH, *Fact Sheet for Patients And Parent/Caregivers - Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)*; National Institutes of Health: 2020. <https://www.fda.gov/media/137565/download>
300. (U) NIH, NIH clinical trial of remdesivir to treat COVID-19 begins <https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins>.
301. (U) Nishiura, H.; Kobayashi, T.; Miyama, T.; Suzuki, A.; Jung, S.-m.; Hayashi, K.; Kinoshita, R.; Yang, Y.; Yuan, B.; Akhmetzhanov, A. R.; Linton, N. M., Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *International Journal of Infectious Diseases* **2020**, *94*, 154-155. <http://www.sciencedirect.com/science/article/pii/S1201971220301399>
302. (U) Northeastern, Modeling of COVID-19 epidemic in the United States. <https://covid19.gleamproject.org/#icubedproj>.
303. (U) Now, C. A., America's COVID warning system. <https://covidactnow.org/?s=38532>.
304. (U) Offeddu, V.; Yung, C. F.; Low, M. S. F.; Tam, C. C., Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis. *Clin Infect Dis* **2017**, *65* (11), 1934-1942. <https://www.ncbi.nlm.nih.gov/pubmed/29140516>
305. (U) Okba, N.; Müller, M.; Li, W.; Wang, C.; GeurtsvanKessel, C.; Corman, V.; Lamers, M.; Sikkema, R.; de Bruin, E.; Chandler, F., Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerging infectious diseases* **2020**, *26* (7).
306. (U) Olson, D. R.; Huynh, M.; Fine, A.; Baumgartner, J.; Castro, A.; Chan, H. T.; Daskalakis, D.; Devinney, K.; Guerra, K.; Harper, S.; Kennedy, J.; Konty, K.; Li, W.; McGibbon, E.; Shaff, J.; Thompson, C.; Vora, N. M.; Van Wye, G., Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak — New York City, March 11–May 2, 2020. *Morbidity and Mortality Weekly Report* **2020**, (ePub: 11 May 2020). https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e5.htm?s_cid=mm6919e5_w
307. (U) Ong, S. W. X.; Tan, Y. K.; Chia, P. Y.; Lee, T. H.; Ng, O. T.; Wong, M. S. Y.; Marimuthu, K., Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory

Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *Jama* **2020**.

https://jamanetwork.com/journals/jama/articlepdf/2762692/jama_ong_2020_id_200016.pdf

308. (U) Ortega, J. T.; Serrano, M. L.; Pujol, F. H.; Rangel, H. R., Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. *EXCLI journal* **2020**, *19*, 410-417. <https://pubmed.ncbi.nlm.nih.gov/32210742>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081066/>

309. (U) Ou, J.; Zhou, Z.; Dai, R.; Zhang, J.; Lan, W.; Zhao, S.; Wu, J.; Seto, D.; Cui, L.; Zhang, G.; Zhang, Q., Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein. *bioRxiv* **2020**, 2020.03.15.991844.

<https://www.biorxiv.org/content/biorxiv/early/2020/04/20/2020.03.15.991844.full.pdf>

310. (U) Oxford, Oxford COVID-19 vaccine to begin phase II/III human trials. University of Oxford: 2020.

<http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iii-human-trials>

311. (U) Pan, A.; Liu, L.; Wang, C.; Guo, H.; Hao, X.; Wang, Q.; Huang, J.; He, N.; Yu, H.; Lin, X., Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA* **2020**.

312. (U) Pan, D.; Sze, S.; Minhas, J. S.; Bangash, M. N.; Pareek, N.; Divall, P.; Williams, C. M. L.; Oggioni, M. R.; Squire, I. B.; Nellums, L. B.; Hanif, W.; Khunti, K.; Pareek, M., The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. *EClinicalMedicine*.

<https://doi.org/10.1016/j.eclinm.2020.100404>

313. (U) Pan, F.; Ye, T.; Sun, P.; Gui, S.; Liang, B.; Li, L.; Zheng, D.; Wang, J.; Hesketh, R. L.; Yang, L.; Zheng, C., Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology* *0* (0), 200370. <https://pubs.rsna.org/doi/abs/10.1148/radiol.2020200370>

314. (U) Pan, Y.; Zhang, D.; Yang, P.; Poon, L. L.; Wang, Q., Viral load of SARS-CoV-2 in clinical samples. *The Lancet Infectious Diseases* **2020**, *20* (4), 411-412.

315. (U) Paranjpe, I.; Fuster, V.; Lala, A.; Russak, A.; Glicksberg, B. S.; Levin, M. A.; Charney, A. W.; Narula, J.; Fayad, Z. A.; Bagiella, E.; Zhao, S.; Nadkarni, G. N., Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. *Journal of the American College of Cardiology* **2020**, 27327.

<http://www.onlinejacc.org/content/accj/early/2020/05/05/j.jacc.2020.05.001.full.pdf>

316. (U) Paranjpe, I.; Russak, A.; De Freitas, J. K.; Lala, A.; Miotto, R.; Vaid, A.; Johnson, K. W.; Danieleto, M.; Golden, E.; Meyer, D.; Singh, M.; Somani, S.; Manna, S.; Nangia, U.; Kapoor, A.; O'Hagan, R.; O'Reilly, P. F.; Huckins, L. M.; Glowe, P.; Kia, A.; Timsina, P.; Freeman, R. M.; Levin, M. A.; Jhang, J.; Firpo, A.; Kovatch, P.; Finkelstein, J.; Aberg, J. A.; Bagiella, E.; Horowitz, C. R.; Murphy, B.; Fayad, Z. A.; Narula, J.; Nestler, E. J.; Fuster, V.; Cordon-Cardo, C.; Charney, D. S.; Reich, D. L.; Just, A. C.; Bottinger, E. P.; Charney, A. W.; Glicksberg, B. S.; Nadkarni, G., Clinical Characteristics of Hospitalized Covid-19 Patients in New York City. *medRxiv* **2020**, 2020.04.19.20062117.

<https://www.medrxiv.org/content/medrxiv/early/2020/04/26/2020.04.19.20062117.full.pdf>

317. (U) Park, A., An At-Home Coronavirus Test May Be on the Way in the U.S. *TIME* 25 March, 2020.

<https://time.com/5809753/at-home-coronavirus-test/>

318. (U) Park, S. W.; Champredon, D.; Earn, D. J. D.; Li, M.; Weitz, J. S.; Grenfell, B. T.; Dushoff, J., Reconciling early-outbreak preliminary estimates of the basic reproductive number and its uncertainty: a new framework and applications to the novel coronavirus (2019-nCoV) outbreak. **2020**, 1-13.

319. (U) Parri, N.; Lenge, M.; Buonsenso, D., Children with Covid-19 in Pediatric Emergency Departments in Italy. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2007617>

320. (U) Pastorino, B.; Touret, F.; Gilles, M.; de Lamballerie, X.; Charrel, R., Prolonged viability of SARS-CoV-2 in fomites. **2020**.

321. (U) Patolia, H.; Pan, J.; Harb, C.; Marr, L. C.; Baffoe-Bonnie, A., Filtration evaluation and clinical use of expired elastomeric P-100 filter cartridges during the COVID-19 pandemic. *Infection Control & Hospital Epidemiology* **2020**, 1-6. <https://www.cambridge.org/core/article/filtration-evaluation-and-clinical-use-of-expired-elastomeric-p100-filter-cartridges-during-the-covid19-pandemic/D5EFCC5EEF65FEA210E1070149CB9DEF>
322. (U) Perchetti, G. A.; Huang, M.-L.; Peddu, V.; Jerome, K. R.; Greninger, A. L., Stability of SARS-CoV-2 in PBS for Molecular Detection. *Journal of Clinical Microbiology* **2020**.
323. (U) Perkins, A.; Espana, G., NotreDame-FRED COVID-19 forecasts. https://github.com/confunguido/covid19_ND_forecasting/blob/master/README.md.
324. (U) Perrone, F.; Piccirillo, M. C.; Ascierio, P. A.; Salvarani, C.; Parrella, R.; Marata, A. M.; Popoli, P.; Ferraris, L.; Marrocco Trischitta, M. M.; Ripamonti, D.; Binda, F.; Bonfanti, P.; Squillace, N.; Castelli, F.; Muiesan, M. L.; Lichtner, M.; Calzetti, C.; Salerno, N. D.; Atripaldi, L.; Cascella, M.; costantini, m.; Dolci, G.; Facciolongo, N. C.; Fraganza, F.; Massari, M.; Montesarchio, V.; Mussini, C.; Negri, E. A.; Botti, G.; Cardone, C.; Gargiulo, P.; Gravina, A.; Schettino, C.; Arenare, L.; Chiodini, P.; Gallo, C., Tocilizumab for patients with COVID-19 pneumonia. The TOCOVID-19 phase 2 trial. *medRxiv* **2020**, 2020.06.01.20119149. <http://medrxiv.org/content/early/2020/06/05/2020.06.01.20119149.abstract>
325. (U) Pfizer, BIONTECH AND PFIZER ANNOUNCE REGULATORY APPROVAL FROM GERMAN AUTHORITY PAUL-EHRLICH-INSTITUT TO COMMENCE FIRST CLINICAL TRIAL OF COVID-19 VACCINE CANDIDATES. 2020. https://www.pfizer.com/news/press-release/press-release-detail/biontech_and_pfizer_announce_regulatory_approval_from_german_authority_paul_ehrlich_institut_to_commence_first_clinical_trial_of_covid_19_vaccine_candidates
326. (U) Pigoga, J. L.; Friedman, A.; Broccoli, M.; Hirner, S.; Naidoo, A. V.; Singh, S.; Werner, K.; Wallis, L. A., Clinical and historical features associated with severe COVID-19 infection: a systematic review. *medRxiv* **2020**, 2020.04.23.20076653. <https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20076653.full.pdf>
327. (U) Price-Haywood, E. G.; Burton, J.; Fort, D.; Seoane, L., Hospitalization and Mortality among Black Patients and White Patients with Covid-19. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMs2011686>
328. (U) Pyankov, O. V.; Bodnev, S. A.; Pyankova, O. G.; Agranovski, I. E., Survival of aerosolized coronavirus in the ambient air. *Journal of Aerosol Science* **2018**, *115*, 158-163. <http://www.sciencedirect.com/science/article/pii/S0021850217302239>
329. (U) Qiu, H.; Wu, J.; Hong, L.; Luo, Y.; Song, Q.; Chen, D., Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30198-5](https://doi.org/10.1016/S1473-3099(20)30198-5)
330. (U) Rabenau, H.; Kampf, G.; Cinatl, J.; Doerr, H., Efficacy of various disinfectants against SARS coronavirus. *Journal of Hospital Infection* **2005**, *61* (2), 107-111. <https://www.sciencedirect.com/science/article/pii/S0195670105000447>
331. (U) Rabenau, H. F.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Preiser, W.; Doerr, H. W., Stability and inactivation of SARS coronavirus. *Med Microbiol Immunol* **2005**, *194* (1-2), 1-6. <https://link.springer.com/content/pdf/10.1007/s00430-004-0219-0.pdf>
332. (U) Radbel, J.; Narayanan, N.; Bhatt, P. J., Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report. *Chest* **2020**.
333. (U) Rambaut, A., Phylodynamic analysis of nCoV-2019 genomes - 27-Jan-2020. <http://virological.org/t/phylodynamic-analysis-of-ncov-2019-genomes-27-jan-2020/353>.
334. (U) Rapid Expert Consultation, *Rapid Expert Consultation Update on SARS-CoV-2 Surface Stability and Incubation for the COVID-19 Pandemic (March 27, 2020)*. The National Academies Press: Washington, DC, 2020. <https://www.nap.edu/read/25763/chapter/1>

335. (U) Ratnesar-Shumate, S.; Williams, G.; Green, B.; Krause, M.; Holland, B.; Wood, S.; Bohannon, J.; Boydston, J.; Freeburger, D.; Hooper, I.; Beck, K.; Yeager, J.; Altamura, L. A.; Biryukov, J.; Yolitz, J.; Schuit, M.; Wahl, V.; Hevey, M.; Dabisch, P., Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces. *The Journal of Infectious Diseases* **2020**. <https://doi.org/10.1093/infdis/jiaa274>
336. (U) Regalado, A., Blood tests show 14% of people are now immune to covid-19 in one town in Germany. *Technology Review* 2020. <https://www.technologyreview.com/2020/04/09/999015/blood-tests-show-15-of-people-are-now-immune-to-covid-19-in-one-town-in-germany/>
337. (U) Reich, N., Ensemble. <https://reichlab.io/>.
338. (U) Remuzzi, A.; Remuzzi, G., COVID-19 and Italy: what next? *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30627-9](https://doi.org/10.1016/S0140-6736(20)30627-9)
339. (U) Ren, X.; Liu, Y.; Chen, H.; Liu, W.; Guo, Z.; Chen, C.; Zhou, J.; Xiao, Q.; Jiang, G.-M.; Shan, H., Application and Optimization of RT-PCR in Diagnosis of SARS-CoV-2 Infection. *medRxiv* **2020**.
340. (U) Rengasamy, S.; Eimer, B.; Shaffer, R. E., Simple respiratory protection--evaluation of the filtration performance of cloth masks and common fabric materials against 20-1000 nm size particles. *Ann Occup Hyg* **2010**, 54 (7), 789-98. <https://www.ncbi.nlm.nih.gov/pubmed/20584862>
341. (U) Richard, M.; Kok, A.; de Meulder, D.; Bestebroer, T. M.; Lamers, M. M.; Okba, N. M. A.; Fentener van Vlissingen, M.; Rockx, B.; Haagmans, B. L.; Koopmans, M. P. G.; Fouchier, R. A. M.; Herfst, S., SARS-CoV-2 is transmitted via contact and via the air between ferrets. *bioRxiv* **2020**, 2020.04.16.044503. <https://www.biorxiv.org/content/biorxiv/early/2020/04/17/2020.04.16.044503.full.pdf>
342. (U) Richardson, S.; Hirsch, J. S.; Narasimhan, M.; Crawford, J. M.; McGinn, T.; Davidson, K. W.; Consortium, a. t. N. C.-R., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.6775>
343. (U) Richter, W.; Hofacre, K.; Willenberg, Z., *Final Report for the Bioquell Hydrogen Peroxide Vapor (HPV) Decontamination for Reuse of N95 Respirators*; Battelle Memorial Institute: 2016. <http://wayback.archive-it.org/7993/20170113034232/http://www.fda.gov/downloads/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMRegulatoryScience/UCM516998.pdf>
344. (U) Riou, J.; Althaus, C. L., Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance* **2020**, 25 (4), 2000058. <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.4.2000058>
345. (U) Riphagen, S.; Gomez, X.; Gonzalez-Martinez, C.; Wilkinson, N.; Theocharis, P., Hyperinflammatory shock in children during COVID-19 pandemic. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)31094-1](https://doi.org/10.1016/S0140-6736(20)31094-1)
346. (U) Rivers, C.; Martin, E.; Watson, C.; Schoch-Spana, M.; Mullen, L.; Sell, T. K.; Gottlieb, S.; Warmbrod, K. L.; Hosangadi, D.; Kobokovich, A.; Potter, C.; Cicero, A.; Inglesby, T. V., *Public Health Principles for a Phased Reopening During COVID-19: Guidance for Governors*; Johns Hopkins Center for Health Security: 2020. https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/reopening-guidance-governors.pdf
347. (U) Robertson, D., nCoV's relationship to bat coronaviruses & recombination signals (no snakes) **2020**. <http://virological.org/t/ncovs-relationship-to-bat-coronaviruses-recombination-signals-no-snakes/331>
348. (U) Rockx, B.; Kuiken, T.; Herfst, S.; Bestebroer, T.; Lamers, M. M.; Oude Munnink, B. B.; de Meulder, D.; van Amerongen, G.; van den Brand, J.; Okba, N. M. A.; Schipper, D.; van Run, P.; Leijten, L.; Sikkema, R.; Verschoor, E.; Verstrepen, B.; Bogers, W.; Langermans, J.; Drosten, C.; Fentener van Vlissingen, M.; Fouchier, R.; de Swart, R.; Koopmans, M.; Haagmans, B. L., Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. *Science* **2020**, eabb7314. <https://science.sciencemag.org/content/sci/early/2020/04/16/science.abb7314.full.pdf>

349. (U) Rosenberg, E. S.; Dufort, E. M.; Blog, D. S.; Hall, E. W.; Hoefler, D.; Backenson, B. P.; Muse, A. T.; Kirkwood, J. N.; George, K. S.; Holtgrave, D. R.; Hutton, B. J.; Zucker, H. A.; Team, N. Y. S. C. R., COVID-19 Testing, Epidemic Features, Hospital Outcomes, and Household Prevalence, New York State—March 2020. *Clinical Infectious Diseases* **2020**. <https://doi.org/10.1093/cid/ciaa549>
350. (U) Rothe, C.; Schunk, M.; Sothmann, P.; Bretzel, G.; Froeschl, G.; Wallrauch, C.; Zimmer, T.; Thiel, V.; Janke, C.; Guggemos, W.; Seilmaier, M.; Drosten, C.; Vollmar, P.; Zwirgmaier, K.; Zange, S.; Wölfel, R.; Hoelscher, M., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2001468>
- <https://www.nejm.org/doi/10.1056/NEJMc2001468>
351. (U) Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Medicine* **2020**. <https://doi.org/10.1007/s00134-020-05991-x>
352. (U) Rundle, A., Severe COVID-19 Risk Mapping. <https://columbia.maps.arcgis.com/apps/webappviewer/index.html?id=ade6ba85450c4325a12a5b9c09ba796c>.
353. (U) Russell, T. W.; Hellewell, J.; Abbott, S.; Golding, N.; Gibbs, H.; Jarvis, C. I.; van Zandvoort, K.; group, C. n. w.; Flasche, S.; Eggo, R. M.; Edmunds, W. J.; Kucharski, A. J., Using a delay-adjusted case fatality ratio to estimate under-reporting. CMMID: 2020. https://cmmid.github.io/topics/covid19/severity/global_cfr_estimates.html
354. (U) Ryan, K. A.; Bewley, K. R.; Fotheringham, S. A.; Brown, P.; Hall, Y.; Marriott, A. C.; Tree, J. A.; Allen, L.; Aram, M. J.; Brunt, E.; Buttigieg, K. R.; Cavell, B. E.; Carter, D. P.; Cobb, R.; Coombes, N. S.; Godwin, K. J.; Gooch, K. E.; Gouriet, J.; Halkerston, R.; Harris, D. J.; Humphries, H. E.; Hunter, L.; Ho, C. M. K.; Kennard, C. L.; Leung, S.; Ngabo, D.; Osman, K. L.; Paterson, J.; Penn, E. J.; Pullan, S. T.; Rayner, E.; Slack, G. S.; Steeds, K.; Taylor, I.; Tipton, T.; Thomas, S.; Wand, N. I.; Watson, R. J.; Wiblin, N. R.; Charlton, S.; Hallis, B.; Hiscox, J. A.; Funnell, S.; Dennis, M. J.; Whittaker, C. J.; Catton, M. G.; Druce, J.; Salguero, F. J.; Carroll, M. W., Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge. *bioRxiv* **2020**, 2020.05.29.123810. <https://www.biorxiv.org/content/biorxiv/early/2020/05/29/2020.05.29.123810.full.pdf>
355. (U) Sagonowsky, E., Swelling ranks of COVID-19 vaccines in human testing, Inovio doses its first patients. *Fierce Pharma* **2020**. <https://www.fiercepharma.com/vaccines/number-covid-19-vaccines-human-testing-grows-inovio-study-more-expected>
356. (U) Saknimit, M.; Inatsuki, I.; Sugiyama, Y.; Yagami, K., Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals. *Jikken Dobutsu* **1988**, *37* (3), 341-5. https://www.jstage.jst.go.jp/article/expanim1978/37/3/37_3_341/pdf
357. (U) Salazar, E.; Perez, K. K.; Ashraf, M.; Chen, J.; Castillo, B.; Christensen, P. A.; Eubank, T.; Bernard, D. W.; Eagar, T. N.; Long, S. W.; Subedi, S.; Olsen, R. J.; Leveque, C.; Schwartz, M. R.; Dey, M.; Chavez-East, C.; Rogers, J.; Shehabeldin, A.; Joseph, D.; Williams, G.; Thomas, K.; Masud, F.; Talley, C.; Dlouhy, K. G.; Lopez, B. V.; Hampton, C.; Lavinder, J.; Gollihar, J. D.; Maranhao, A. C.; Ippolito, G. C.; Saavedra, M. O.; Cantu, C. C.; Yerramilli, P.; Pruitt, L.; Musser, J. M., Treatment of COVID-19 Patients with Convalescent Plasma. *Am J Pathol* **2020**.
358. (U) Santarpia, J. L.; Rivera, D. N.; Herrera, V.; Morwitzer, M. J.; Creager, H.; Santarpia, G. W.; Crown, K. K.; Brett-Major, D.; Schnaubelt, E.; Broadhurst, M. J.; Lawler, J. V.; Reid, S. P.; Lowe, J. J., Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center. *medRxiv* **2020**, 2020.03.23.20039446. <https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.23.20039446.1.full.pdf>

359. (U) Schnirring, L., New coronavirus infects health workers, spreads to Korea. <http://www.cidrap.umn.edu/news-perspective/2020/01/new-coronavirus-infects-health-workers-spreads-korea>.
360. (U) Schwartz, D. A., An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. *Archives of Pathology & Laboratory Medicine* **2020**.
361. (U) Security, J. C. f. H., 2019-nCoV resources and updates on the emerging novel coronavirus. **2020**. <http://www.centerforhealthsecurity.org/resources/2019-nCoV/>
362. (U) Shekerdemian, L. S.; Mahmood, N. R.; Wolfe, K. K.; Riggs, B. J.; Ross, C. E.; McKiernan, C. A.; Heidemann, S. M.; Kleinman, L. C.; Sen, A. I.; Hall, M. W.; Priestley, M. A.; McGuire, J. K.; Boukas, K.; Sharron, M. P.; Burns, J. P.; Collaborative, f. t. I. C.-P., Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatrics* **2020**. <https://doi.org/10.1001/jamapediatrics.2020.1948>
363. (U) Shen, C.; Wang, Z.; Zhao, F.; Yang, Y.; Li, J.; Yuan, J.; Wang, F.; Li, D.; Yang, M.; Xing, L.; Wei, J.; Xiao, H.; Yang, Y.; Qu, J.; Qing, L.; Chen, L.; Xu, Z.; Peng, L.; Li, Y.; Zheng, H.; Chen, F.; Huang, K.; Jiang, Y.; Liu, D.; Zhang, Z.; Liu, Y.; Liu, L., Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.4783>
364. (U) Sheridan, C., Convalescent serum lines up as first-choice treatment for coronavirus. *Nature Biotechnology* **2020**. <https://www.nature.com/articles/d41587-020-00011-1>
365. (U) Sheridan, C., Coronavirus and the race to distribute reliable diagnostics. <https://www.nature.com/articles/d41587-020-00002-2>.
366. (U) Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; Zhao, Y.; Liu, P.; Liang, L.; Cui, P.; Wang, J.; Zhang, X.; Guan, Y.; Tan, W.; Wu, G.; Chen, H.; Bu, Z., Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. *Science* **2020**, eabb7015. <https://science.sciencemag.org/content/sci/early/2020/04/07/science.abb7015.full.pdf>
367. (U) Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; Huang, H.; Yang, B.; Huang, C., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.0950>
368. (U) Sia, S. F.; Yan, L. M.; Chin, A. W. H.; Fung, K.; Choy, K. T.; Wong, A. Y. L.; Kaewpreedee, P.; Perera, R.; Poon, L. L. M.; Nicholls, J. M.; Peiris, M.; Yen, H. L., Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* **2020**.
369. (U) Sit, T. H. C.; Brackman, C. J.; Ip, S. M.; Tam, K. W. S.; Law, P. Y. T.; To, E. M. W.; Yu, V. Y. T.; Sims, L. D.; Tsang, D. N. C.; Chu, D. K. W.; Perera, R.; Poon, L. L. M.; Peiris, M., Infection of dogs with SARS-CoV-2. *Nature* **2020**.
370. (U) Skalina, K. A.; Goldstein, D. Y.; Sulail, J.; Hahm, E.; Narlieva, M.; Szymczak, W.; Fox, A. S., Extended Storage of SARS-CoV2 Nasopharyngeal Swabs Does Not Negatively Impact Results of Molecular-Based Testing. *medRxiv* **2020**, 2020.05.16.20104158. <https://www.medrxiv.org/content/medrxiv/early/2020/05/20/2020.05.16.20104158.full.pdf>
371. (U) Somers, E. C.; Eschenauer, G. A.; Troost, J. P.; Golob, J. L.; Gandhi, T. N.; Wang, L.; Zhou, N.; Petty, L. A.; Baang, J. H.; Dillman, N. O.; Frame, D.; Gregg, K. S.; Kaul, D. R.; Nagel, J.; Patel, T. S.; Zhou, S.; Luring, A. S.; Hanauer, D. A.; Martin, E. T.; Sharma, P.; Fung, C. M.; Pogue, J. M., Tocilizumab for treatment of mechanically ventilated patients with COVID-19. *medRxiv* **2020**, 2020.05.29.20117358. <http://medrxiv.org/content/early/2020/06/03/2020.05.29.20117358.abstract>
372. (U) Song, J.-Y.; Yun, J.-G.; Noh, J.-Y.; Cheong, H.-J.; Kim, W.-J., Covid-19 in South Korea — Challenges of Subclinical Manifestations. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2001801>

373. (U) Stadnytskyi, V.; Bax, C. E.; Bax, A.; Anfinrud, P., The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. *Proceedings of the National Academy of Sciences* **2020**, 202006874. <https://www.pnas.org/content/pnas/early/2020/05/12/2006874117.full.pdf>
374. (U) Su, H.; Yang, M.; Wan, C.; Yi, L.-X.; Tang, F.; Zhu, H.-Y.; Yi, F.; Yang, H.-C.; Fogo, A. B.; Nie, X.; Zhang, C., Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney International*. <https://doi.org/10.1016/j.kint.2020.04.003>
375. (U) Su, Y. C.; Anderson, D. E.; Young, B. E.; Zhu, F.; Linster, M.; Kalimuddin, S.; Low, J. G.; Yan, Z.; Jayakumar, J.; Sun, L.; Yan, G. Z.; Mendenhall, I. H.; Leo, Y.-S.; Lye, D. C.; Wang, L.-F.; Smith, G. J., Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2. *bioRxiv* **2020**, 2020.03.11.987222. <https://www.biorxiv.org/content/biorxiv/early/2020/03/12/2020.03.11.987222.full.pdf>
376. (U) Sukhyun, R.; Seikh Taslim, A.; Cheolsun, J.; Baekjin, K.; Benjamin, J. C., Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020. *Emerging Infectious Disease Journal* **2020**, 26 (10). https://wwwnc.cdc.gov/eid/article/26/10/20-1886_article
377. (U) Sun, S.; Cai, X.; Wang, H.; He, G.; Lin, Y.; Lu, B.; Chen, C.; Pan, Y.; Hu, X., Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clinica Chimica Acta* **2020**, 507, 174-180. <http://www.sciencedirect.com/science/article/pii/S0009898120301790>
378. (U) Sun, S. H.; Chen, Q.; Gu, H. J.; Yang, G.; Wang, Y. X.; Huang, X. Y.; Liu, S. S.; Zhang, N. N.; Li, X. F.; Xiong, R.; Guo, Y.; Deng, Y. Q.; Huang, W. J.; Liu, Q.; Liu, Q. M.; Shen, Y. L.; Zhou, Y.; Yang, X.; Zhao, T. Y.; Fan, C. F.; Zhou, Y. S.; Qin, C. F.; Wang, Y. C., A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. *Cell Host Microbe* **2020**.
379. (U) Suthar, M. S.; Zimmerman, M. G.; Kauffman, R. C.; Mantus, G.; Linderman, S. L.; Hudson, W. H.; Vanderheiden, A.; Nyhoff, L.; Davis, C. W.; Adekunle, S.; Affer, M.; Sherman, M.; Reynolds, S.; Verkerke, H. P.; Alter, D. N.; Guarner, J.; Bryksin, J.; Horwath, M.; Arthur, C. M.; Saakadze, N.; Smith, G. H.; Edupuganti, S.; Scherer, E. M.; Hellmeister, K.; Cheng, A.; Morales, J. A.; Neish, A. S.; Stowell, S. R.; Frank, F.; Ortlund, E.; Anderson, E.; Menachery, V. D.; Roupael, N.; Mehta, A.; Stephens, D. S.; Ahmed, R.; Roback, J. D.; Wrammert, J., Rapid generation of neutralizing antibody responses in COVID-19 patients. *Cell Reports Medicine* **2020**. <https://doi.org/10.1016/j.xcrm.2020.100040>
380. (U) Tan, W.; Lu, Y.; Zhang, J.; Wang, J.; Dan, Y.; Tan, Z.; He, X.; Qian, C.; Sun, Q.; Hu, Q.; Liu, H.; Ye, S.; Xiang, X.; Zhou, Y.; Zhang, W.; Guo, Y.; Wang, X.-H.; He, W.; Wan, X.; Sun, F.; Wei, Q.; Chen, C.; Pan, G.; Xia, J.; Mao, Q.; Chen, Y.; Deng, G., Viral Kinetics and Antibody Responses in Patients with COVID-19. *medRxiv* **2020**, 2020.03.24.20042382. <https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.24.20042382.full.pdf>
381. (U) Tang, W.; Cao, Z.; Han, M.; Wang, Z.; Chen, J.; Sun, W.; Wu, Y.; Xiao, W.; Liu, S.; Chen, E.; Chen, W.; Wang, X.; Yang, J.; Lin, J.; Zhao, Q.; Yan, Y.; Xie, Z.; Li, D.; Yang, Y.; Liu, L.; Qu, J.; Ning, G.; Shi, G.; Xie, Q., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ* **2020**, 369, m1849. <http://www.bmj.com/content/369/bmj.m1849.abstract>
382. (U) The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T., The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly* **2020**, 2, 1-10. <http://weekly.chinacdc.cn//article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51>
383. (U) Thomas, P. R.; Karriker, L. A.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Crawford, K. K.; Bates, J. L.; Hammen, K. J.; Holtkamp, D. J., Evaluation of time and temperature sufficient to inactivate porcine epidemic diarrhea virus in swine feces on metal surfaces. *Journal of Swine Health and Production* **2015**, 23 (2), 84.

384. (U) Thomas, P. R.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Myers, J. N., Methods for inactivating PEDV in Hog Trailers. *Animal Industry Report* **2015**, 661 (1), 91.
385. (U) To, K. K.-W.; Cheng, V. C.-C.; Cai, J.-P.; Chan, K.-H.; Chen, L.-L.; Wong, L.-H.; Choi, C. Y.-K.; Fong, C. H.-Y.; Ng, A. C.-K.; Lu, L.; Luo, C.-T.; Situ, J.; Chung, T. W.-H.; Wong, S.-C.; Kwan, G. S.-W.; Sridhar, S.; Chan, J. F.-W.; Fan, C. Y.-M.; Chuang, V. W. M.; Kok, K.-H.; Hung, I. F.-N.; Yuen, K.-Y., Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. *The Lancet Microbe* **2020**. [https://doi.org/10.1016/S2666-5247\(20\)30053-7](https://doi.org/10.1016/S2666-5247(20)30053-7)
386. (U) To, K. K.-W.; Tsang, O. T.-Y.; Leung, W.-S.; Tam, A. R.; Wu, T.-C.; Lung, D. C.; Yip, C. C.-Y.; Cai, J.-P.; Chan, J. M.-C.; Chik, T. S.-H., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases* **2020**.
387. (U) Treibel, T. A.; Manisty, C.; Burton, M.; McKnight, Á.; Lambourne, J.; Augusto, J. B.; Couto-Parada, X.; Cutino-Moguel, T.; Noursadeghi, M.; Moon, J. C., COVID-19: PCR screening of asymptomatic health-care workers at London hospital. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)31100-4](https://doi.org/10.1016/S0140-6736(20)31100-4)
388. (U) UCLA, COVID-19 Cases in the United States. <https://covid19.uclaml.org/model.html>.
389. (U) Unwin, H. J. T.; Mishra, S.; Bradley, V. C.; Gandy, A.; Vollmer, M.; Mellan, T.; Coupland, H.; Ainslie, K.; Whittaker, C.; Ish-Horowicz, J., State-level tracking of COVID-19 in the United States. **2020**.
390. (U) van der Sande, M.; Teunis, P.; Sabel, R., Professional and Home-Made Face Masks Reduce Exposure to Respiratory Infections among the General Population. *Plos One* **2008**, 3 (7). <Go to ISI>://WOS:000264065800020
391. (U) van Doremalen, N.; Bushmaker, T.; Morris, D. H.; Holbrook, M. G.; Gamble, A.; Williamson, B. N.; Tamin, A.; Harcourt, J. L.; Thornburg, N. J.; Gerber, S. I.; Lloyd-Smith, J. O.; de Wit, E.; Munster, V. J., Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New England Journal of Medicine* **2020**. <https://doi.org/10.1056/NEJMc2004973>
392. (U) van Doremalen, N.; Bushmaker, T.; Munster, V. J., Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. *Euro Surveill* **2013**, 18 (38).
393. (U) van Doremalen, N.; Lambe, T.; Spencer, A.; Belij-Rammerstorfer, S.; Purushotham, J. N.; Port, J. R.; Avanzato, V.; Bushmaker, T.; Flaxman, A.; Ulaszewska, M.; Feldmann, F.; Allen, E. R.; Sharpe, H.; Schulz, J.; Holbrook, M.; Okumura, A.; Meade-White, K.; Pérez-Pérez, L.; Bissett, C.; Gilbride, C.; Williamson, B. N.; Rosenke, R.; Long, D.; Ishwarbhai, A.; Kailath, R.; Rose, L.; Morris, S.; Powers, C.; Lovaglio, J.; Hanley, P. W.; Scott, D.; Saturday, G.; de Wit, E.; Gilbert, S. C.; Munster, V. J., ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. *bioRxiv* **2020**, 2020.05.13.093195. <https://www.biorxiv.org/content/biorxiv/early/2020/05/13/2020.05.13.093195.full.pdf>
394. (U) van Dorp, L.; Acman, M.; Richard, D.; Shaw, L. P.; Ford, C. E.; Ormond, L.; Owen, C. J.; Pang, J.; Tan, C. C. S.; Boshier, F. A. T.; Ortiz, A. T.; Balloux, F., Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. *Infection, Genetics and Evolution* **2020**, 104351. <http://www.sciencedirect.com/science/article/pii/S1567134820301829>
395. (U) van Dorp, L.; Richard, D.; Tan, C. C.; Shaw, L. P.; Acman, M.; Balloux, F., No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. *bioRxiv* **2020**, 2020.05.21.108506. <https://www.biorxiv.org/content/biorxiv/early/2020/05/21/2020.05.21.108506.full.pdf>
396. (U) Varga, Z.; Flammer, A. J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A. S.; Mehra, M. R.; Schuepbach, R. A.; Ruschitzka, F.; Moch, H., Endothelial cell infection and endotheliitis in COVID-19. *The Lancet* **2020**, 395 (10234), 1417-1418. [https://doi.org/10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5)
397. (U) Verdict, Cepheid to develop automated molecular test for coronavirus. Verdict Medical Devices: **2020**. <https://www.medicaldevice-network.com/news/cepheid-automated-test-coronavirus/>

398. (U) von Weyhern, C. H.; Kaufmann, I.; Neff, F.; Kremer, M., Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31282-4](https://doi.org/10.1016/S0140-6736(20)31282-4)
399. (U) Wambier, C. G.; Vaño-Galván, S.; McCoy, J.; Gomez-Zubiaur, A.; Herrera, S.; Hermosa-Gelbard, Á.; Moreno-Arrones, O. M.; Jiménez-Gómez, N.; González-Cantero, A.; Pascual, P. F.; Segurado-Miravalles, G.; Shapiro, J.; Pérez-García, B.; Goren, A., Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients – the “Gabrin sign”. *Journal of the American Academy of Dermatology*. <https://doi.org/10.1016/j.jaad.2020.05.079>
400. (U) Wan, Y.; Shang, J.; Graham, R.; Baric, R. S.; Li, F., Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *Journal of Virology* **2020**, JVI.00127-20. <https://jvi.asm.org/content/jvi/early/2020/01/23/JVI.00127-20.full.pdf>
401. (U) Wang, B.; Wang, L.; Kong, X.; Geng, J.; Xiao, D.; Ma, C.; Jiang, X. M.; Wang, P. H., Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients. *J Med Virol* **2020**.
402. (U) Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.1585>
- https://jamanetwork.com/journals/jama/articlepdf/2761044/jama_wang_2020_oi_200019.pdf
403. (U) Wang, D.; You, Y.; Zhou, X.; Zong, Z.; Huang, H.; Zhang, H.; Yong, X.; Cheng, Y.; Yang, L.; Guo, Q.; Long, Y.; Liu, Y.; Huang, J.; Du, L., Selection of homemade mask materials for preventing transmission of COVID-19: a laboratory study. *medRxiv* **2020**.
404. (U) Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G.; Tan, W., Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.3786>
405. (U) Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9)
406. (U) Watson, C.; Cicero, A.; Blumenstock, J.; Fraser, M., *A National Plan to Enable Comprehensive COVID-19 Case Finding and Contact*; Johns Hopkins Center for Health Security: 2020. https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/a-national-plan-to-enable-comprehensive-COVID-19-case-finding-and-contact-tracing-in-the-US.pdf
407. (U) WCS, A Tiger at Bronx Zoo Tests Positive for COVID-19; The Tiger and the Zoo's Other Cats Are Doing Well at This Time. <https://newsroom.wcs.org/News-Releases/articleType/ArticleView/articleId/14010/A-Tiger-at-Bronx-Zoo-Tests-Positive-for-COVID-19-The-Tiger-and-the-Zoos-Other-Cats-Are-Doing-Well-at-This-Time.aspx> (accessed April 6, 2020).
408. (U) Wei, W. E.; Li, Z.; Chiew, C. J.; Yong, S. E.; Toh, M. P.; Lee, V. J., Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23 - March 16, 2020. *Morbidity and Mortality Weekly Report* **2020**, ePub (1 April 2020). <https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e1.htm>
409. (U) Weissman, D. N.; de Perio, M. A.; Radonovich, L. J., Jr, COVID-19 and Risks Posed to Personnel During Endotracheal Intubation. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.6627>
410. (U) Wen, W.; Su, W.; Tang, H.; Le, W.; Zhang, X.; Zheng, Y.; Liu, X.; Xie, L.; Li, J.; Ye, J.; Dong, L.; Cui, X.; Miao, Y.; Wang, D.; Dong, J.; Xiao, C.; Chen, W.; Wang, H., Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. *Cell Discov* **2020**, 6, 31.

411. (U) Whitman, J. D.; Hiatt, J.; Mowrey, C. T.; al., e., Test performance evaluation of SARS-CoV-2 serological assays. *Unpublished Preprint* **2020**. https://www.dropbox.com/s/cd1628cau09288a/SARS-CoV-2_Serology_Manuscript.pdf?dl=0
412. (U) WHO, *Advice on the use of masks on the context of COVID-19. Interim Guidance*. 5 June 2020.; World Health Organization: 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks>
413. (U) WHO, *COVID-19 Strategy Update*; World Health Organization: 2020. <https://www.who.int/publications-detail/strategic-preparedness-and-response-plan-for-the-new-coronavirus>
414. (U) WHO, Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR -Protocol and preliminary evaluation as of Jan 13, 2020. https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2 (accessed 01/26/2020).
415. (U) WHO, *"Immunity passports" in the context of COVID-19*; World Health Organization: 2020. <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19>
416. (U) WHO, *Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected*; 2020. [https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)
417. (U) WHO, Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.
418. (U) WHO, *Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations*; World Health Organization: 2020. <https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations>
419. (U) WHO, Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. World Health Organization: 2020. <https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>
420. (U) WHO, Novel Coronavirus (2019-nCoV) Situation Report-5 25 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200125-sitrep-5-2019-ncov.pdf?sfvrsn=429b143d_4.
421. (U) WHO, Novel Coronavirus (2019-nCoV) technical guidance: Laboratory testing for 2019-nCoV in humans. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>.
422. (U) WHO, Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine. World Health Organization: 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine>
423. (U) Wölfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M. A.; Niemeyer, D.; Jones, T. C.; Vollmar, P.; Rothe, C.; Hoelscher, M.; Bleicker, T.; Brünink, S.; Schneider, J.; Ehmann, R.; Zwirgmaier, K.; Drosten, C.; Wendtner, C., Virological assessment of hospitalized patients with COVID-2019. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2196-x>
424. (U) Wolff, M. H.; Sattar, S. A.; Adegbunrin, O.; Tetro, J., Environmental survival and microbicide inactivation of coronaviruses. In *Coronaviruses with special emphasis on first insights concerning SARS*, Springer: 2005; pp 201-212.
425. (U) Wong, M. C.; Javornik Cregeen, S. J.; Ajami, N. J.; Petrosino, J. F., Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. *bioRxiv* **2020**, 2020.02.07.939207. <https://www.biorxiv.org/content/biorxiv/early/2020/02/13/2020.02.07.939207.full.pdf>

426. (U) Woolsey, C. B.; Borisevich, V.; Prasad, A. N.; Agans, K. N.; Deer, D. J.; Dobias, N. S.; Heymann, J. C.; Foster, S. L.; Levine, C. B.; Medina, L.; Melody, K.; Geisbert, J. B.; Fenton, K. A.; Geisbert, T. W.; Cross, R. W., Establishment of an African green monkey model for COVID-19. *bioRxiv* **2020**, 2020.05.17.100289. <http://biorxiv.org/content/early/2020/05/17/2020.05.17.100289.abstract>
427. (U) Worobey, M.; Pekar, J.; Larsen, B. B.; Nelson, M. I.; Hill, V.; Joy, J. B.; Rambaut, A.; Suchard, M. A.; Wertheim, J. O.; Lemey, P., The emergence of SARS-CoV-2 in Europe and the US. *bioRxiv* **2020**, 2020.05.21.109322. <https://www.biorxiv.org/content/biorxiv/early/2020/05/23/2020.05.21.109322.full.pdf>
428. (U) Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S., Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. *bioRxiv* **2020**, 2020.02.11.944462. <https://www.biorxiv.org/content/biorxiv/early/2020/02/15/2020.02.11.944462.full.pdf>
429. (U) Wright, E. S.; Lakdawala, S. S.; Cooper, V. S., SARS-CoV-2 genome evolution exposes early human adaptations. *bioRxiv* **2020**, 2020.05.26.117069. <https://www.biorxiv.org/content/biorxiv/early/2020/05/26/2020.05.26.117069.full.pdf>
430. (U) Wu, F.; Wang, A.; Liu, M.; Wang, Q.; Chen, J.; Xia, S.; Ling, Y.; Zhang, Y.; Xun, J.; Lu, L.; Jiang, S.; Lu, H.; Wen, Y.; Huang, J., Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv* **2020**, 2020.03.30.20047365. <https://www.medrxiv.org/content/medrxiv/early/2020/04/06/2020.03.30.20047365.full.pdf>
431. (U) Wu, H.; Zhu, H.; Yuan, C.; Yao, C.; Luo, W.; Shen, X.; Wang, J.; Shao, J.; Xiang, Y., Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China. *JAMA Network Open* **2020**, 3 (6), e2010895-e2010895. <https://doi.org/10.1001/jamanetworkopen.2020.10895>
432. (U) Wu, J. T.; Leung, K.; Leung, G. M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet* **2020**. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30260-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext)
433. (U) Wu, L.-P.; Wang, N.-C.; Chang, Y.-H.; Tian, X.-Y.; Na, D.-Y.; Zhang, L.-Y.; Zheng, L.; Lan, T.; Wang, L.-F.; Liang, G.-D., Duration of antibody responses after severe acute respiratory syndrome. *Emerging infectious diseases* **2007**, 13 (10), 1562. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851497/pdf/07-0576_finalD.pdf
434. (U) Wu, P.; Duan, F.; Luo, C.; Liu, Q.; Qu, X.; Liang, L.; Wu, K., Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. *JAMA Ophthalmology* **2020**. <https://doi.org/10.1001/jamaophthalmol.2020.1291>
435. (U) Wyllie, A. L.; Fournier, J.; Casanovas-Massana, A.; Campbell, M.; Tokuyama, M.; Vijayakumar, P.; Geng, B.; Muenker, M. C.; Moore, A. J.; Vogels, C. B. F.; Petrone, M. E.; Ott, I. M.; Lu, P.; Lu-Culligan, A.; Klein, J.; Venkataraman, A.; Earnest, R.; Simonov, M.; Datta, R.; Handoko, R.; Naushad, N.; Sewanan, L. R.; Valdez, J.; White, E. B.; Lapidus, S.; Kalinich, C. C.; Jiang, X.; Kim, D. J.; Kudo, E.; Linehan, M.; Mao, T.; Moriyama, M.; Oh, J. E.; Park, A.; Silva, J.; Song, E.; Takahashi, T.; Taura, M.; Weizman, O.-E.; Wong, P.; Yang, Y.; Bermejo, S.; Odio, C.; Omer, S. B.; Dela Cruz, C. S.; Farhadian, S.; Martinello, R. A.; Iwasaki, A.; Grubaugh, N. D.; Ko, A. I., Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. *medRxiv* **2020**, 2020.04.16.20067835. <https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.16.20067835.full.pdf>
436. (U) Xiao, F.; Sun, J.; Xu, Y.; Li, F.; Huang, X.; Li, H.; Zhao, J.; Huang, J.; Zhao, J., Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. *Emerging Infectious Diseases* **2020**, 26. https://wwwnc.cdc.gov/eid/article/26/8/20-0681_article
437. (U) Xiao, K.; Zhai, J.; Feng, Y.; Zhou, N.; Zhang, X.; Zou, J. J.; Li, N.; Guo, Y.; Li, X.; Shen, X.; Zhang, Z.; Shu, F.; Huang, W.; Li, Y.; Zhang, Z.; Chen, R. A.; Wu, Y. J.; Peng, S. M.; Huang, M.; Xie, W. J.; Cai, Q. H.;

- Hou, F. H.; Chen, W.; Xiao, L.; Shen, Y., Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. *Nature* **2020**.
438. (U) Xinhua, China detects large quantity of novel coronavirus at Wuhan seafood market http://www.xinhuanet.com/english/2020-01/27/c_138735677.htm.
439. (U) Xu, X.; Han, M.; Li, T.; Sun, W.; Wang, D.; Fu, B.; Zhou, Y.; Zheng, X.; Yang, Y.; Li, X.; Zhang, X.; Pan, A.; Wei, H., Effective treatment of severe COVID-19 patients with tocilizumab. *Proceedings of the National Academy of Sciences* **2020**, 202005615. <https://www.pnas.org/content/pnas/early/2020/04/27/2005615117.full.pdf>
440. (U) Xu, X.; Sun, J.; Nie, S.; Li, H.; Kong, Y.; Liang, M.; Hou, J.; Huang, X.; Li, D.; Ma, T.; Peng, J.; Gao, S.; Shao, Y.; Zhu, H.; Lau, J. Y.-N.; Wang, G.; Xie, C.; Jiang, L.; Huang, A.; Yang, Z.; Zhang, K.; Hou, F. F., Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0949-6>
441. (U) Xue, K. S.; Bloom, J. D., Reconciling disparate estimates of viral genetic diversity during human influenza infections. *Nature Genetics* **2019**, 51 (9), 1298-1301. <https://doi.org/10.1038/s41588-019-0349-3>
442. (U) Yan, C. H.; Faraji, F.; Prajapati, D. P.; Boone, C. E.; DeConde, A. S., In *Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms*, International Forum of Allergy & Rhinology, Wiley Online Library: 2020.
443. (U) Yan, J.; Guo, J.; Fan, C.; Juan, J.; Yu, X.; Li, J.; Feng, L.; Li, C.; Chen, H.; Qiao, Y.; Lei, D.; Wang, C.; Xiong, G.; Xiao, F.; He, W.; Pang, Q.; Hu, X.; Wang, S.; Chen, D.; Zhang, Y.; Poon, L. C.; Yang, H., Coronavirus disease 2019 (COVID-19) in pregnant women: A report based on 116 cases. *Am J Obstet Gynecol* **2020**.
444. (U) Yang, H.; Wang, C.; Poon, L., Novel coronavirus infection and pregnancy. *Ultrasound in Obstetrics & Gynecology* **2020**.
445. (U) Yang, P.; Qi, J.; Zhang, S.; Bi, G.; Wang, X.; Yang, Y.; Sheng, B.; Mao, X., Feasibility of Controlling COVID-19 Outbreaks in the UK by Rolling Interventions. *medRxiv* **2020**, 2020.04.05.20054429. <https://www.medrxiv.org/content/medrxiv/early/2020/04/07/2020.04.05.20054429.full.pdf>
446. (U) Yu, B.; Li, C.; Chen, P.; Zhou, N.; Wang, L.; Li, J.; Jiang, H.; Wang, D. W., Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. *Sci China Life Sci* **2020**, 1-7.
447. (U) Yu, J.; Tostanoski, L. H.; Peter, L.; Mercado, N. B.; McMahan, K.; Mahrokhian, S. H.; Nkolola, J. P.; Liu, J.; Li, Z.; Chandrashekar, A.; Martinez, D. R.; Loos, C.; Atyeo, C.; Fischinger, S.; Burke, J. S.; Slein, M. D.; Chen, Y.; Zuiani, A.; N. Lelis, F. J.; Travers, M.; Habibi, S.; Pessaint, L.; Van Ry, A.; Blade, K.; Brown, R.; Cook, A.; Finneyfrock, B.; Dodson, A.; Teow, E.; Velasco, J.; Zahn, R.; Wegmann, F.; Bondzie, E. A.; Dagotto, G.; Gebre, M. S.; He, X.; Jacob-Dolan, C.; Kirilova, M.; Kordana, N.; Lin, Z.; Maxfield, L. F.; Nampanya, F.; Nityanandam, R.; Ventura, J. D.; Wan, H.; Cai, Y.; Chen, B.; Schmidt, A. G.; Wesemann, D. R.; Baric, R. S.; Alter, G.; Andersen, H.; Lewis, M. G.; Barouch, D. H., DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* **2020**, eabc6284. <https://science.sciencemag.org/content/sci/early/2020/05/19/science.abc6284.full.pdf>
448. (U) Yu, N.; Li, W.; Kang, Q.; Zeng, W.; Feng, L.; Wu, J., No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30320-0](https://doi.org/10.1016/S1473-3099(20)30320-0)
449. (U) Yu, W.-B.; Tang, G.-D.; Zhang, L.; Corlett, R. T., Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. *ChinaXiv* **2020**. <http://www.chinaxiv.org/abs/202002.00033>
450. (U) Yu, W. B.; Tang, G. D.; Zhang, L.; Corlett, R. T., Decoding the evolution and transmissions of the novel pneumonia coronavirus (SARS-CoV-2 / HCoV-19) using whole genomic data. *Zool Res* **2020**, 41 (3), 247-257.
451. (U) Zachariah, P.; Johnson, C. L.; Halabi, K. C.; Ahn, D.; Sen, A. I.; Fischer, A.; Banker, S. L.; Giordano, M.; Manice, C. S.; Diamond, R.; Sewell, T. B.; Schweickert, A. J.; Babineau, J. R.; Carter, R. C.; Fenster, D.

- B.; Orange, J. S.; McCann, T. A.; Kernie, S. G.; Saiman, L.; Group, f. t. C. P. C.-M., Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York. *JAMA Pediatrics* **2020**, e202430-e202430.
<https://doi.org/10.1001/jamapediatrics.2020.2430>
452. (U) Zaigham, M.; Andersson, O., Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. *Acta Obstet Gynecol Scand* **2020**.
453. (U) Zhang, J.; Litvinova, M.; Liang, Y.; Wang, Y.; Wang, W.; Zhao, S.; Wu, Q.; Merler, S.; Viboud, C.; Vespignani, A.; Ajelli, M.; Yu, H., Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science* **2020**, eabb8001.
<https://science.sciencemag.org/content/sci/early/2020/05/04/science.abb8001.full.pdf>
454. (U) Zhang, J.; Litvinova, M.; Wang, W.; Wang, Y.; Deng, X.; Chen, X.; Li, M.; Zheng, W.; Yi, L.; Chen, X.; Wu, Q.; Liang, Y.; Wang, X.; Yang, J.; Sun, K.; Longini, I. M., Jr.; Halloran, M. E.; Wu, P.; Cowling, B. J.; Merler, S.; Viboud, C.; Vespignani, A.; Ajelli, M.; Yu, H., Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30230-9](https://doi.org/10.1016/S1473-3099(20)30230-9)
455. (U) Zhang, J.; Wu, J.; Sun, X.; Xue, H.; Shao, J.; Cai, W.; Jing, Y.; Yue, M.; Dong, C., Associations of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. *Epidemiology and Infection* **2020**, 1-19. <https://www.cambridge.org/core/article/associations-of-hypertension-with-the-severity-and-fatality-of-sarscov2-infection-a-metaanalysis/4116FAD7D866737099F976E7E7FAEB15>
456. (U) Zhang, Q.; Zhang, H.; Huang, K.; Yang, Y.; Hui, X.; Gao, J.; He, X.; Li, C.; Gong, W.; Zhang, Y.; Peng, C.; Gao, X.; Chen, H.; Zou, Z.; Shi, Z.; Jin, M., SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation. *bioRxiv* **2020**, 2020.04.01.021196.
<http://biorxiv.org/content/early/2020/04/03/2020.04.01.021196.abstract>
457. (U) Zhang, T.; Wu, Q.; Zhang, Z., Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. *Current Biology* **2020**, 30 (7), 1346-1351.e2.
<http://www.sciencedirect.com/science/article/pii/S0960982220303602>
458. (U) Zhang, X.; Tan, Y.; Ling, Y.; Lu, G.; Liu, F.; Yi, Z.; Jia, X.; Wu, M.; Shi, B.; Xu, S.; Chen, J.; Wang, W.; Chen, B.; Jiang, L.; Yu, S.; Lu, J.; Wang, J.; Xu, M.; Yuan, Z.; Zhang, Q.; Zhang, X.; Zhao, G.; Wang, S.; Chen, S.; Lu, H., Viral and host factors related to the clinical outcome of COVID-19. *Nature* **2020**.
<https://doi.org/10.1038/s41586-020-2355-0>
459. (U) Zhao; Musa; Lin; Ran; Yang; Wang; Lou; Yang; Gao; He; Wang, Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. *Journal of Clinical Medicine* **2020**, 9 (2), 388.
460. (U) Zhao, G.; Jiang, Y.; Qiu, H.; Gao, T.; Zeng, Y.; Guo, Y.; Yu, H.; Li, J.; Kou, Z.; Du, L.; Tan, W.; Jiang, S.; Sun, S.; Zhou, Y., Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. *PLoS One* **2015**, 10 (12), e0145561.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689477/pdf/pone.0145561.pdf>
461. (U) Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; Qian, S.; Hong, C.; Wang, F.; Liu, Y.; Wang, Z.; He, Q.; He, B.; Zhang, T.; Ge, S.; Liu, L.; Zhang, J.; Xia, N.; Zhang, Z., Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. *SSRN* **2020**.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546052#
462. (U) Zhen-Dong, T.; An, T.; Ke-Feng, L.; Peng, L.; Hong-Ling, W.; Jing-Ping, Y.; Yong-Li, Z.; Jian-Bo, Y., Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerging Infectious Disease Journal* **2020**, 26 (5). https://wwwnc.cdc.gov/eid/article/26/5/20-0198_article
463. (U) Zhongchu, L., The sixth press conference of "Prevention and Control of New Coronavirus Infected Pneumonia". Hubei Provincial Government: 2020.
http://www.hubei.gov.cn/hbfb/xwfbh/202001/t20200128_2015591.shtml

464. (U) Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
465. (U) Zhou, H.; Chen, X.; Hu, T.; Li, J.; Song, H.; Liu, Y.; Wang, P.; Liu, D.; Yang, J.; Holmes, E. C.; Hughes, A. C.; Bi, Y.; Shi, W., A novel bat coronavirus reveals natural insertions at the S1/S2 cleavage site of the Spike protein and a possible recombinant origin of HCoV-19. *bioRxiv* **2020**, 2020.03.02.974139. <https://www.biorxiv.org/content/biorxiv/early/2020/03/11/2020.03.02.974139.full.pdf>
466. (U) Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.; Shi, Z.-L., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv* **2020**, 2020.01.22.914952. <https://www.biorxiv.org/content/biorxiv/early/2020/01/23/2020.01.22.914952.1.full.pdf>
467. (U) Zhu, F.-C.; Li, Y.-H.; Guan, X.-H.; Hou, L.-H.; Wang, W.-J.; Li, J.-X.; Wu, S.-P.; Wang, B.-S.; Wang, Z.; Wang, L.; Jia, S.-Y.; Jiang, H.-D.; Wang, L.; Jiang, T.; Hu, Y.; Gou, J.-B.; Xu, S.-B.; Xu, J.-J.; Wang, X.-W.; Wang, W.; Chen, W., Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31208-3](https://doi.org/10.1016/S0140-6736(20)31208-3)
468. (U) Zhu, Y.; Chen, Y. Q., On a Statistical Transmission Model in Analysis of the Early Phase of COVID-19 Outbreak. *Statistics in Biosciences* **2020**, 1-17. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113380/>
469. (U) Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H.-L.; Peiris, M.; Wu, J., SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2001737>